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A B S T R A C T
Background
Several options exist for managing overactive bladder (OAB), including electrical stimulation (ES) with non-implanted devices, con-
servative treatment and drugs. Electrical stimulation with non-implanted devices aims to inhibit contractions of the detrusor muscle,
potentially reducing urinary frequency and urgency.
Objectives
To determine the effectiveness of: ES with non-implanted electrodes compared with placebo or any other active treatment for OAB;
ES added to another intervention compared with the other intervention alone; different methods of ES compared with each other.
Search methods
We searched theCochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register
of ControlledTrials (CENTRAL),MEDLINE,MEDLINE In-Process, ClinicalTrials.gov,WHO ICTRP and handsearching of journals
and conference proceedings (searched 10 December 2014). We searched the reference lists of relevant articles and contacted specialists
in the field. We imposed no language restrictions.
Selection criteria
We included randomised or quasi-randomised controlled trials of ESwith non-implanted devices comparedwith any other treatment for
OAB in adults. Eligible trials included adults with OABwith or without urgency urinary incontinence (UUI). Trials whose participants
had stress urinary incontinence (SUI) were excluded.
Data collection and analysis
Two review authors independently screened search results, extracted data from eligible trials and assessed risk of bias, using the Cochrane
Collaboration’s ’Risk of bias’ tool.
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Main results
We identified 51 eligible trials (3443 randomised participants). Thirty-three trials did not report the primary outcomes of subjective
change in OAB symptoms. The majority of trials were deemed to be at low or unclear risk of selection and attrition bias and unclear
risk of performance and detection bias. Lack of clarity with regard to risk of bias was largely due to poor reporting.
Twenty-three trials (1654 participants) compared ES with no active treatment, placebo or sham treatment. Moderate-quality evidence
indicated that OAB symptoms were more likely to improve in people receiving ES than with no active treatment, placebo or sham
treatment (relative risk (RR) for no improvement 0.54, 95% confidence interval (CI) 0.47 to 0.63). Moderate-quality evidence indicated
that similar numbers of people receiving ES and no active treatment, placebo or sham treatment experienced adverse effects.
Eight trials (542 participants) compared ESwith conservative treatment. Very low-quality evidence suggested no evidence of a difference
between ES and PFMT or PFMT plus biofeedback in OAB symptoms (RR for no improvement 0.79, 95% CI 0.51 to 1.21 and 0.97,
95% CI 0.60 to 1.57 respectively). There was no evidence of a difference between ES and conservative treatment with regard to adverse
effects.
Sixteen trials (894 participants) compared ES with drug treatment (probanthine, tolterodine, oxybutynin, propantheline bromide,
solifenacin succinate, terodiline, trospium chloride, terodiline). Moderate-quality evidence indicated that OAB symptoms were more
likely to improve with ES than drug treatment (RR for no improvement 0.66, 95% CI 0.48 to 0.90). Low-quality evidence suggested
a greater risk of adverse effects with oxybutynin (RR 1.26, 95% CI 1.07 to 1.49) and with tolterodine (RR 1.51, 95% CI 1.21 to 1.89)
than with ES. There was insufficient evidence of a difference between ES and trospium hydrochloride (RR 0.73, 95% CI 0.43 to 1.25).
Eight trials (252 participants) compared ES combined with another treatment versus the other treatment alone, two trials (48 partici-
pants) compared ES plus conservative treatment with no active treatment, placebo or sham treatment and six trials (361 participants)
compared different types of ES. None of these comparisons had sufficient evidence to indicate any differences between the treatment
groups in terms of OAB or adverse effects.
Moderate-quality evidence suggested that ES improved OAB-related quality of life more than no active treatment, placebo or sham
treatment. There was insufficient evidence of any difference between ES and any other treatment with regard to quality of life.
There was insufficient evidence to determine if the benefits of ES persisted after the active treatment period stopped.
Authors’ conclusions
Electrical stimulation appeared to bemore effective than both no treatment and drug treatment forOAB. There was insufficient evidence
to determine if ES was more effective than conservative treatment or which type of ES was more effective. This review underlines the
need to conduct well-designed trials in this field measuring subjective outcomes and adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Non-invasive electrical stimulation for overactive bladder in adults
Background
People with overactive bladder (OAB) have a frequent and compelling desire to urinate, which has a significant impact on quality of
life. Many people with OAB also have urinary incontinence. OAB affects around 17% of the world’s population and is particularly
common in elderly people. Treatment for OAB includes pelvic floor muscle training, drug therapy and electrical stimulation.
Non-invasive electrical stimulation works by passing an electrical current through the bladder muscles, via a vaginal or anal probe, or
through a fine needle inserted into the tibial nerve around the ankle. The current is intended to reduce (inhibit) contractions of the
detrusor muscle (the bladder muscle which squeezes out urine); this should reduce the number of times a person will need to urinate.
Invasive electrical stimulation involves implanting electrodes within the body and requires a surgical procedure.
Aim
We investigated whether electrical stimulation was better than no treatment at all or better than any other treatment available for OAB.
We also investigated which type of electrical stimulation was better for OAB and whether or not electrical stimulation was safe.
Results
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We identified 51 studies (3443 people altogether) comparing electrical stimulation versus no treatment or any other available treatment.
We found electrical stimulation was better than no treatment and better than drugs at reducing the main symptoms of OAB. However,
we could not tell if electrical stimulation was better than any of the other treatments available, such as pelvic floor training, because
many of the studies we identified did not report whether or not the treatment improved OAB symptoms. Nor can we tell which type
of electrical stimulation was better. We did not find enough information to know whether or not electrical stimulation was safer than
other treatments, or if one type of electrical stimulation was safer than others. Finally, we could not tell from the evidence whether
or not any benefits of electrical stimulation persisted after the course of electrical stimulation stopped. The evidence in this review is
current up to December 2015.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Electrical stimulation compared to no active treatment, placebo or sham treatment for overactive bladder in adults
Patient or population: overactive bladder in adults
Intervention: Electrical stimulation
Comparison: No active treatment, placebo or sham treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no active treat-
ment, placebo or sham
treatment
Risk with Electrical stim-
ulation
Number of participants
with no improvement in
OAB symptoms
Study population RR 0.54
(0.47 to 0.63)
647
(8 RCTs) MODERATE 1
705 per 1000 381 per 1000
(332 to 444)
Moderate
721 per 1000 389 per 1000
(339 to 454)
Number of participants
with no improvement in
UUI
Study population RR 0.65
(0.55 to 0.77)
324
(4 RCTs) LOW 1
791 per 1000 514 per 1000
(435 to 609)
Moderate
729 per 1000 474 per 1000
(401 to 561)
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QoL due to OAB
assessed with: change in
OAB-Q severity score
ThemeanQoL due to OAB
was 0
ThemeanQoL due to OAB
in the intervention group
was 8.77 lower (14.18
lower to 3.36 lower)
- 240
(2 RCTs) MODERATE 2
Number of participants
with adverse effects
Study population RR 0.96
(0.90 to 1.03)
450
(3 RCTs) MODERATE 1
139 per 1000 133 per 1000
(125 to 143)
Moderate
354 per 1000 340 per 1000
(318 to 364)
Cost-effectiveness - not
reported
see comment see comment not estimable ( studies) -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Unclear risk of selection bias and detection bias. Low risk of performance bias and attrition bias.
2 Low risk of attrition bias. Unclear risk of bias in all other domains.
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B A C K G R O U N D
Description of the condition
Overactive bladder (OAB) is a chronic disorder with an overall
prevalence in the adult population of over 10%, but that may ex-
ceed 40% in elderly groups (Irvin 2006). According to the Inter-
national Continence Society, OAB is characterised by symptoms
of urinary urgency (a strong compelling desire to urinate that is
difficult to overcome), with or without urinary incontinence. If
there is urinary incontinence accompanied by urgency, the leakage
is called urgency urinary incontinence (UUI). Overactive bladder
is usually accompanied by daytime frequency (increased need to
urinate) and nocturia (waking during the night to urinate), but
without urinary infection or other bladder pathologies (Abrams
2003). Overactive bladder with urinary incontinence is known as
’overactive bladder wet’; OAB without incontinence is known as
’overactive bladder dry’.
Urinary incontinence has many psychosocial implications. It ap-
pears that OAB has a greater psychological impact than stress uri-
nary incontinence (SUI), with 60% of patients with OAB report-
ing a history of depression compared with 14% of patients with
SUI (Zorn 1999).
Overactive bladder hasmany potential causes, such as urinary tract
infections, neurogenic diseases and pelvic organ prolapse. Urgency
symptoms are often associated with involuntary contractions of
the detrusor muscle in the bladder: this is termed detrusor overac-
tivity if it is diagnosed using urodynamics. This overactivity can
be related to neurogenic, myogenic, or idiopathic origins (Shaw
2011). However, currently its aetiology is unclear.
Description of the intervention
Conservative management, such as bladder training (Wallace
2004) or pelvic floor muscle training, has been recommended as
a first-line treatment for OAB (Abrams 2003).
The main type of medical treatment for OAB is pharmacotherapy
with anticholinergics, which have proven to be effective in several
randomised controlled trials (RCTs) (Madhuvrata 2012). How-
ever, common side effects such as dry mouth and constipation
limit long-term compliance, with discontinuation rates of 70%
to 90% within one year (D´ Souza 2008). Intravesical botulinum
toxin injections may be an effective and safe option to treat refrac-
tory OAB (Duthie 2011); in the UK, bladder wall injections with
botulinum toxinA are recommended forwomenwithOABcaused
by proven detrusor overactivity if conservative or drug treatments
have failed (NICE 2013). This is considered to be a surgical in-
tervention in this review.
In patients for whom conservative or drug treatment is not suffi-
cient, neuromodulation is an alternative. It is thought that neu-
romodulation with electrical stimulation (ES) can target specific
nerves in the sacral plexus that control pelvic floor function.
Electrical stimulation can be used to treatOAB via different routes,
such as implantable or internal (sacral neuromodulation) and non-
implantable external electrodes. Stimulation with non-implanted
electrodes can be delivered invasively (percutaneous stimulation),
semi-invasively (typically vaginal or anal probes) or non-invasively
(transcutaneous stimulation).
Electrical stimulation can be used on its own or in association with
pelvic floor muscle training, often indicated in SUI and OAB.
There is currently little consensus regarding the optimum treat-
ment regimen, the number and duration of sessions and the pa-
rameters used, such as electrical frequency and pulse width.
This review includes non-implanted electrodes only; implanted
devices are included in another Cochrane systematic review
(Herbison 2009).
Routes of administration
Intravaginal electrical stimulation
Intravaginal electrical stimulation for treating urinary inconti-
nence was first reported in the literature in the 1960s (Cadwell
1963). Subsequently, it has been shown to achieve satisfactory re-
sults with frequencies below 12Hertz (Hz) stimulating the puden-
dal nerve, which is thought to inhibit the detrusor muscle, reduce
involuntary contractions and, consequently, reduce the number of
micturitions (Messelink 1999). Electrical stimulation also works
in a passive way, helping patients become conscious of their per-
ineal (pelvic floor) muscle contractions and this may, in turn, help
to inhibit involuntary detrusor contractions (Amaro 2003).
The contraindications to intravaginal ES are pregnancy, vaginal
infection or lesion, a reduced perception of vaginal sensation,men-
struation, and metallic implants (Richardson 1996).
Rectal (anal) electrical stimulation
Transcutaneous electrical nerve stimulation delivers an electrical
current through an electrode placed in the ischiorectal area. Elec-
trodes inserted in the rectal canal may inhibit detrusor contrac-
tions through contact with the pudendal nerve afferent fibres and
thus may be effective in the treatment of UUI and OAB.
Posterior tibial nerve stimulation
Percutaneous tibial nerve stimulation is a form of neuromodula-
tion that delivers retrograde stimulation to the sacral nerve plexus
via a needle electrode inserted into the ankle, cephalad to the me-
dial malleolus, an anatomical area recognised as the bladder cen-
tre. Transcutaneous tibial nerve stimulation is less invasive than
percutaneous stimulation and can be delivered over the peroneal
region of the ankle through surface electrodes (ICI 2013).
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How the intervention might work
Electrical stimulation is thought to inhibit detrusor contractions,
thus decreasing the number of micturitions and potentially in-
creasing bladder capacity (Wang 2006). Electrodes can be located
in the vaginal or rectal canals in such a way as to obtain direct
contact with a significant quantity of afferent nerve fibres of the
pudendal nerve. This stimulation of the pudendal nerve activates
the skeletal pelvic floor muscles and inhibits detrusor contraction.
Partial or total innervation of the pudendal nerve is necessary so
that nerve stimulation can occur (Messelink 1999). The anal elec-
trode can be used for men to stimulate the pudendal nerve, or in
women where the vaginal approach is contraindicated.
There are two main mechanisms whereby ES is thought to work.
1. Electrical stimulation in the form of neurostimulation aims
to stimulate motor efferent fibres of the pudendal nerve, which
elicits a direct response from the effector organ, for instance a
contraction of the pelvic floor muscles (Fall 1991; Scheepens
2003).
2. Electrical stimulation in the form of neuromodulation aims
to remodel reflex loops, for instance the detrusor inhibition
reflex, by stimulating afferent nerve fibres of the pudendal nerve
that influence these reflex loops via the spinal cord (Vodusek
1986; Weil 2000) .
The different sites for non-implanted ES, for instance direct in-
travaginal stimulation or peripheral transcutaneous tibial nerve
stimulation, may involve different mechanisms and therefore may
have different degrees of effectiveness.
Why it is important to do this review
Numerous treatment options exist forOAB, includingbehavioural
therapies such as pelvic floor muscle rehabilitation, bladder train-
ing, and dietary modification, as well as pharmacological ther-
apy and neuromodulation. Overall, behavioural therapies are con-
sidered the mainstay of treatment for urinary incontinence. It is
known that OAB can be improved through behavioural therapy
or drug treatment, but it is not known whether non-invasive ES
achieves better clinical outcomes. This review aims to present an
overview of current evidence related to ES in the treatment of
OAB.
This systematic review aims to investigate the effects of non-im-
planted ES in patients with OAB with or without urgency incon-
tinence. It also aims to compare specific subgroups to investigate
whether ES might be more beneficial for some populations than
for others.
O B J E C T I V E S
To determine the effectiveness of electrical stimulation (ES) with
non-implanted electrodes in comparisonwith placebo or any other
active treatment in adults with overactive bladder (OAB), with or
without urgency urinary incontinence (UUI).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), quasi-RCTs
(RCTs in which allocation to treatment is based on methods such
as alternate medical records, date of birth, or other predictable
methods) and randomised cross-over trials .
Types of participants
Eligible studies included adults (≥18 years old, or according to
study authors’ definitions of adult) with either of the following:
• symptomatic diagnosis of overactive bladder (OAB),
urgency urinary incontinence (UUI), or mixed urinary
incontinence;
• urodynamic diagnosis of detrusor overactivity in addition
to OAB symptoms (urgency, frequency or episodes of urgency
incontinence).
Studies including participants with stress urinary incontinence
(SUI), with or without OAB symptoms were included if data were
reported separately for SUI and participants with OAB, or if the
majority (> 50%) of the population had OAB/UUI-predominant
symptoms.
Types of interventions
Eligible comparators were any intervention intended to decrease
urinary frequency and included placebo, sham treatment, conser-
vative treatment (including complementary therapies), drugs and
surgery. We also included studies comparing different electrical
stimulation (ES) methods with each other. There were no restric-
tions by type of device, stimulation parameters (such as contin-
uous, interrupted, or duration of stimulation), duration of treat-
ment, route of administration (e.g. vaginal, rectal, skin, pretib-
ial area), or other similar factors. We excluded trials of different
combinations of treatments even if one of those was ES, where
is was not possible to identify the effect of this treatment alone
(e.g. ES plus another treatment versus ES plus other combined
treatments).
We investigated the following comparisons:
1. ES versus no active treatment, placebo or sham treatment;
2. ES versus conservative treatment (e.g. bladder training,
pelvic floor muscle training, biofeedback, magnetic stimulation);
3. ES versus drugs (e.g. anticholinergics);
7Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4. ES versus surgery (including botulinum toxin);
5. ES plus another treatment versus other treatment alone;
6. ES plus another treatment versus no active treatment,
placebo or sham treatment;
7. one type of electrical stimulation versus another.
Types of outcome measures
The following outcomes were considered.
Primary outcomes
• Perception of cure (number of participants with OAB
symptoms; number of participants with self-reported UUI)
• Perception of improvement (number of participants with
no improvement in OAB symptoms; number of participants
with no improvement in self-reported UUI)
• Quality of life measures due to OAB or incontinence
(however defined by authors or by any validated measurement
scales such as the International Consultation on Incontinence
Questionnaire (ICIQ))
Secondary outcomes
• Quantification of symptoms
◦ Number of incontinence episodes (per 24 hours)
◦ Number of urgency episodes (per 24 hours)
◦ Number of micturitions (per 24 hours)
◦ Number of nocturia episodes (per night)
◦ Number of pads used per 24 hours
◦ Pad tests (weights) (e.g. one-hour pad test, 24-hour
pad test)
• Clinicians’ observations
◦ Number of participants with objectively measured
incontinence (such as observation of leakage, leakage observed at
urodynamics study)
◦ Number of participants with detrusor overactivity
observed at urodynamic study
◦ Bladder capacity measured by urodynamic study
• Socioeconomic measures
◦ Costs of interventions
◦ Cost-effectiveness of interventions
◦ Resource implications
• Procedure outcome measures
◦ Duration of procedure
◦ Length of hospital stay
◦ Time to return to normal activity level
• Adverse effects
◦ Skin damage
◦ Pain or discomfort
◦ Vascular, visceral or nerve injury
◦ Voiding dysfunction
◦ Other complications
We also included other outcomes that were not pre-specified but
were deemed important during the course of data analysis.
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) outcomes
We included the following outcomes in ’Summary of findings’
tables:
• number of participants with no improvement in OAB
symptoms or urgency symptoms;
• number of participants with no improvement in self-
reported UUI;
• quality of life measures due to OAB;
• adverse effects (pain or discomfort due to treatment);
• cost-effectiveness of interventions.
Search methods for identification of studies
We did not impose any restrictions, for example language or pub-
lication status, on the searches described below.
Electronic searches
This review drew on the search strategy developed for the
Cochrane Incontinence Group. We identified relevant trials from
the Cochrane Incontinence Group Specialised Trials Register. For
more details of the search methods used to build the Specialised
Register please see the Group’s module in The Cochrane Library.
The Register contains trials identified from the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, MED-
LINE In-Process, ClinicalTrials.gov,WHO International Clinical
Trials Registry Platform (WHO ICTRP), UK Clinical Research
Network Portfolio and handsearching of journals and conference
proceedings. Most of the trials in the Cochrane Incontinence
Group Specialised Register are also contained in CENTRAL. The
date of the last search was: 10 December 2014. The terms used to
search the Incontinence Group Specialised Register are given in
Appendix 1.
Some of the review authors (OLFG, RE, MOG, AK, JLA) also
searched the following databases; the search terms used are given
in Appendix 1:
• PubMed (inception to December 2013) was searched on 12
December 2013;
• CENTRAL (2013, Issue 12 ) was searched on 12
December 2013;
• Embase on OvidSP (covering from 1980 onwards) and the
Latin-American and Caribbean Center on Health Sciencies
Information (LILACS) (on the Virtual Health Library/Bireme)
(covering from 1982 to December 2013) were both searched on
12 December 2013. The highly sensitive Embase and LILACS
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strategies for identification of RCTs (Castro 1997; Castro 1999;
Lefebvre 2011) were combined with search terms relating to the
condition and interventions;
• Information about ongoing clinical trials was sought by
searching the clinical trials registration sites ClinicalTrials.gov
and WHO ICTRP on 12 December 2013.
A further updated search of the Cochrane Incontinence Group
Specialised Trials Register was performed on 10 December 2015,
the results of which were screened and the potentially eligible
studies were added to Studies awaiting classification. These studies
will be fully incorporated into this review at the first update.
Searching other resources
Reference lists
The review authors scrutinised the reference lists of the identified
relevant studies for additional citations.
Personal contact
We consulted clinical specialists and contacted authors of included
trials where appropriate to obtain unpublished data.
Data collection and analysis
Selection of studies
Two review authors independently screened the trials identified by
the literature search.We resolved any disagreements by consulting
a third review author.
Data extraction and management
Two review authors extracted data independently, with discrepan-
cies resolved by discussion. We used a pre-standardised data ex-
traction form to extract data pertaining to study characteristics
(design, methods of randomisation), participants, interventions
and outcomes.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias in included
trials using the Cochrane Collaboration’s tool for assessing risk
of bias (Higgins 2011), considering the following four domains:
random sequence generation, allocation concealment, blinding,
and incomplete outcome data. We resolved any disagreements by
consulting a third review author.
Measures of treatment effect
We analysed included trial data as described in theCochraneHand-
book for Systematic Reviews of Interventions (Higgins 2011).
(a) Binary outcomes
For dichotomous data, we calculated risk ratios (RRs) with 95%
confidence intervals (CIs).
(b) Continuous outcomes
For continuous data, we present mean differences (MDs) with
95% CIs.
Unit of analysis issues
The unit of analysis is each participant recruited into the trials.
We analysed studies with non-standard designs, such as cross-over
trials and cluster-randomised trials, as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We analysed studies with multiple treatment groups by treating
each pair of arms as a separate comparison, as appropriate.
Dealing with missing data
We analysed data on an intention-to-treat (ITT) basis, as far as
possible, whereby all participants must be analysed according to
the groups to which they were randomised. Where participants
were excluded after allocation or withdrew from the trial, we report
any details provided in full. Where data from randomised cross-
over trials were incomplete we included data from the first period
of randomisation only.
We made all reasonable attempts to contact authors for clarifica-
tion of missing data. Where trials reported mean values without
standard deviations (SDs) but with P values or 95% CIs, we used
RevMan’s calculator to estimate the SDs. Where trials reported
mean values only, we assumed the outcome to have a SD equal to
the highest SD from the other trials within the same analysis.
Assessment of heterogeneity
We assessed clinical heterogeneity by examination of the study
details and tested for statistical heterogeneity between trial results
using the Chi2 test and the I2 statistic (Higgins 2011), using the
following I2 values:
• < 30% heterogeneity may not be important;
• 30% to 50% may represent moderate heterogeneity;
• > 50% may represent substantial or considerable
heterogeneity.
Assessment of reporting biases
We intended to assess the likelihood of potential publication bias
using funnel plots but insufficient data were available.
Data synthesis
We used Cochrane’s statistical software, Review Manager 2014,
for data analysis. We used the fixed-effect model to analyse data.
Where significant heterogeneity (for example I2 higher than 50%)
was identified, we computed pooled estimates of the treatment
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effect for each outcome under a random-effects model (with two
or more studies).
Where outcomes were reported which were similar to, but not
precisely the same, as pre-specified ones, we used ’surrogate’ out-
comes to substitute formissing data. For example, if a trial reported
episodes of urinary incontinence without specifying the type of
incontinence, e.g. SUI or UUI, we used the data as a substitute
for UUI. Similarly, we used ’improvement in urgency symptoms’
as a substitute for ’improvement in OAB symptoms’. Finally, if
a subjective outcome (such as OAB symptoms) was reported as
combined with an objective outcome (such as detrusor overactiv-
ity) without reporting them separately, we used that outcome as a
surrogate for the subjective outcome.
Subgroup analysis and investigation of heterogeneity
In the case of substantial heterogeneity (I2 > 50%), we investigated
the causes of heterogeneity and, where data permitted, carried out
the following subgroup analyses:
• participants with idiopathic OAB versus those with
neurogenic OAB;
• approaches of electrodes (transcutaneous (e.g. perineal skin,
sacral, posterior pretibial nerve), endocavitary (vaginal, rectal,
urethral), and percutaneous (posterior pretibial nerve).
Sensitivity analysis
We intended to perform a sensitivity analysis comparing trials with
low risk of selection bias to those with high risk of bias but there
were insufficient numbers of eligible trials.
’Summary of findings’ tables
We applied the principles of the GRADE system to assess the
quality of the body of evidence associated with specific outcomes
(perception of cure, perception of improvement and OAB-related
quality of life) (Guyatt 2008). The GRADE approach appraises
the quality of a body of evidence based on the extent to which one
can be confident that an estimate of effect or association reflects
the item being assessed. The quality of a body of evidence consid-
ers within-study risk of bias (methodological quality), the direct-
ness of the evidence, heterogeneity of the data, precision of effect
estimates, and risk of publication bias.We constructed ’Summary
of findings’ tables using the GRADEpro (GRADEproGDT) soft-
ware (http://www.guidelinedevelopment.org/).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search strategy identified 3770 titles; after removal of dupli-
cate references there was a total of 3336 titles and abstracts to
screen. Following assessment of 209 full-text articles, 72 reports of
51 studies which met the minimal methodological requirements
were considered for inclusion in this review. Figure 1 details the
screening process.
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Figure 1. PRISMA study flow diagram.
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Since the searchwas conducted on 10December 2014, an updated
search of the Cochrane Incontinence Group Specialised Regis-
ter was performed on 10 December 2015. The search produced
92 titles and abstracts which were screened and a further 13 po-
tentially eligible trials (1001 participants) were identified:12 have
been added to Studies awaiting classification and will be fully in-
corporated into the next update of this review (Abdelbary 2015;
Alves 2015; Chen 2015; Eftekhar 2014; Franco 2011a; Gonzalez
2015; Manriquez 2013; Orhan 2015; Phillips 2012; Preyer 2015;
Schreiner 2014; Slovak 2015). One record was a further report of
an already included study andhas been added to that study (Monga
2011). A further 8 studieswere ongoing andhave been added to the
list of Ongoing Studies (NCT02110680 2014; NCT02311634
2014; NCT02377765 2014; NCT02452593 2014;
NCT02456441 2014; NCT02511717 2015; NCT02582151
2015; NCT02583529 2014)
Included studies
The individual trials are described in the Characteristics of
included studies table.
Fifty-one trials (72 reports) met the inclusion criteria and were in-
cluded in this review. A total of 3443 participants were randomised
across the included trials.
Design
All but four of the included studies were reported as RCTs. Two
randomised cross-over trials (Soomro 2001; Vecchioli-Scaldazza
2013) and two quasi-RCTs (Svihra 2002; Wise 1992) were in-
cluded.
Sample size
Thirty-one of the included studies did not report any details re-
lating to sample size calculation. Sample sizes ranged from 22 to
229 (mean 67, median 50).
Setting
The trials took place in a variety of settings:
• 10 trials took place in Brazil (Amaro 2006; Arruda 2008;
Barroso 2002; Boaretto 2011; Bellette 2009; Marques 2008;
Monteiro 2014; Schmidt 2009; Schreiner 2010; Souto 2014);
• eight in the UK (Monga 2011; Oldham 2013; Seth 2014;
Shepherd 1984; Shepherd 1985; Vohra 2002; Wise 1992; Wise
1993);
• eight in the USA (Brubaker 1997; Firra 2013; Kennelly
2011; Lobel 1998; Peters 2009; Peters 2010; Smith 1996; Sotelo
2011);
• three each in Australia (Bower 1998; Lo 2003; Soomro
2001); Taiwan (Wang 2004; Wang 2006; Wang 2009); and
Turkey (Kaya 2011; Ozdedeli 2010; Sancaktar 2010);
• two each in Italy (Finazzi-Agrò 2010; Vecchioli-Scaldazza
2013); Japan (Yamanishi 2000a; Yamanishi 2000b); and The
Netherlands (Berghmans 2002; Spruijt 2003);
• one each in Belgium (Gaspard 2014), Finland (Vahtera
1997), Russia (Kosilov 2013), Slovakia (Svihra 2002) and
Sweden (Franzén 2010).
Five studies did not report where they took place.
Participants
The trials included a variety of participant groups.
Sex
Eleven trials included male and female participants (Booth 2013;
Gaspard 2014; ; Kennelly 2011; Monga 2011; Peters 2009; Peters
2010; Soomro2001;Vahtera 1997;Walsh 2001;Yamanishi 2000a;
Yamanishi 2000b), one included onlymale participants (Monteiro
2014), and three did not report the participants’ sex (Seth 2014;
Sotelo 2011; Vohra 2002). All other trials included women only.
Age
All trials included adults only. One trial included only participants
over 65 years (Booth 2013); the mean age reported in this trial
was 84 years. Nine trials did not report participants’ age (Lima
2011; Marques 2008; Monga 2011; Seth 2014; Shepherd 1984;
Shepherd 1985; Wang 2006; Wise 1992; Wise 1993). Across the
remaining trials, the mean age of participants in the trials ranged
from 46 to 70 years
Diagnosis
The participants had a variety of diagnoses of the causes of their
overactive bladder (OAB).
• Fifteen trials based their inclusion criteria on urodynamic
diagnosis (Aaronson 1995; Arruda 2008; Berghmans 2002;
Bower 1998; Brubaker 1997; Finazzi-Agrò 2010; Kaya 2011;
Lobel 1998; Shepherd 1985; Smith 1996; Walsh 2001; Wise
1992; Wise 1993; Yamanishi 2000a; Yamanishi 2000b).
• Four trials included only participants with neurogenic OAB
(Gaspard 2014; Monteiro 2014; Seth 2014; Vahtera 1997).
• All other trials reported inclusion criteria based on
symptomatic diagnosis of OAB, urgency urinary incontinence
(UUI), or any kind of incontinence or bladder dysfunction.
The participants had two main types of OAB.
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• Participants with OAB and UUI only (Aaronson 1995;
Amaro 2006; Arruda 2008; Bellette 2009; Berghmans 2002;
Boaretto 2011; Bower 1998; Finazzi-Agrò 2010; Franzén 2010;
Gaspard 2014; Kaya 2011; Kennelly 2011; Kosilov 2013; Lima
2011; Lobel 1998; Marques 2008; Monga 2011; Monteiro 2014;
Ozdedeli 2010; Peters 2009; Peters 2010; Preyer 2007; Sancaktar
2010; Schreiner 2010; Seth 2014; Soomro 2001; Sotelo 2011;
Souto 2014; Svihra 2002; Vecchioli-Scaldazza 2013; Vohra
2002; Walsh 2001; Wang 2004; Wang 2006; Wang 2009; Wise
1992; Wise 1993; Yamanishi 2000a; Yamanishi 2000b
• Participants with mixed urinary incontinence (UUI and
stress urinary incontinence (SUI)) (Barroso 2002; Booth 2013;
Brubaker 1997; Firra 2013; Lo 2003; Oldham 2013; Schmidt
2009; Shepherd 1984; Shepherd 1985; Smith 1996; Spruijt
2003)
Duration of trials
Treatment duration ranged from a single one-off session to four
months. Fourteen trials followed up participants beyond the end
of the treatment period (Amaro 2006; Arruda 2008; Barroso
2002; Gaspard 2014; Kosilov 2013; Lobel 1998; Monteiro 2014;
Ozdedeli 2010; Peters 2010 Schmidt 2009; Schreiner 2010; Souto
2014; Vahtera 1997; Vecchioli-Scaldazza 2013). The duration of
post-treatment follow-up ranged one month to two years. Four
trials did not report treatment duration or follow-up.
Types of interventions
The parameters and components of the active electrical stimula-
tion (ES) interventions varied widely and are summarised in Table
1.
Control/comparator interventions included.
• No active treatment (Berghmans 2002; Marques 2008;
Monteiro 2014; Oldham 2013; Svihra 2002; Vahtera 1997)
• Sham ES (Amaro 2006; Barroso 2002; Bellette 2009;
Booth 2013; Bower 1998; Brubaker 1997; Finazzi-Agrò 2010;
Kennelly 2011; Marques 2008; Peters 2010; Shepherd 1984;
Shepherd 1985; Vohra 2002; Walsh 2001; Yamanishi 2000a)
• Placebo (Kosilov 2013; Wang 2006; Wang 2009)
• Pelvic floor muscle training (PFMT) (Arruda 2008;
Berghmans 2002; Boaretto 2011; Firra 2013; Gaspard 2014;
Lima 2011; Lo 2003; Schmidt 2009; Schreiner 2010; Spruijt
2003; Wang 2004)
• PFMT plus biofeedback (Gaspard 2014; Schmidt 2009;
Wang 2004)
• Laseropuncture (Kosilov 2013)
• Functional magnetic stimulation (Yamanishi 2000b)
• Drug treatment (oxybutynin, tolterodine, probanthine,
trospium plus solifenacin, propantheline bromide, solifenacin
succinate, terodiline) (Arruda 2008; Boaretto 2011; Franzén
2010; ; Kaya 2011; Kosilov 2013; Ozdedeli 2010; Peters 2009;
Preyer 2007; Sancaktar 2010; Smith 1996; Soomro 2001; Souto
2014; Svihra 2002; Vecchioli-Scaldazza 2013; Wang 2006)
• ES plus PFMT plus drug treatment (Kaya 2011)
• Different ES regimens (Lobel 1998; Monga 2011; Seth
2014; Sotelo 2011).
Types of outcomes
Eighteen trials reported the primary outcomes of perception of
cure or improvement of OAB symptoms (Aaronson 1995; Bellette
2009; Booth 2013; Kennelly 2011; Monteiro 2014; Peters 2010;
Shepherd 1985; Vohra 2002; Wang 2006; Wang 2009; Spruijt
2003; Wang 2004; Peters 2009; Smith 1996; Soomro 2001; Lo
2003; Schmidt 2009; Lobel 1998).
A validated measure of quality of life (QoL) was reported in 16
trials (Bellette 2009; Finazzi-Agrò 2010; Firra 2013; Gaspard
2014; Kaya 2011; Oldham 2013; Peters 2010; Sancaktar 2010;
Schmidt 2009; Schreiner 2010; Seth 2014; Souto 2014; Svihra
2002; Vecchioli-Scaldazza 2013; Wang 2004; Wang 2009). One
further trial reported QoL, but did not state the instrument used
(Preyer 2007), and another trial used an in-house QoL instrument
(Yamanishi 2000a).
Nine trials did not report any of the primary outcomes (Berghmans
2002; Bower 1998;; Kosilov 2013; Monga 2011; Sancaktar 2010;
Sotelo 2011; Vahtera 1997; Wise 1993; Yamanishi 2000b).
Five trials reported urodynamic outcomes only (Berghmans 2002;
Bower 1998; Vahtera 1997; Walsh 2001; Yamanishi 2000b).
None of the trials reported any socioeconomic or cost-effectiveness
outcomes.
Excluded studies
After full-text screening, we excluded 126 studies from the review.
The main reasons for exclusion were ineligible study design (non-
RCTs), ineligible population (participants did not have OAB or
UUI), and ineligible interventions such as sacral neuromodulation
with implanted devices or magnetic stimulation.
See the table ’Characteristics of excluded studies’ for full details of
the excluded studies.
Studies awaiting classification
Two studies are awaiting translation (Lin 2004; Zhao 2000).
Since the searchwas conducted on 10December 2014, an updated
search of the Cochrane Incontinence Group Specialised Register
was performed on 10 December 2015. The search produced 92
titles and abstracts which were screened and a further 21 poten-
tially eligible reports of trials were identified.
Twelve of these have been added to Studies awaiting classification
and will be fully incorporated into the next update of this review
(Abdelbary 2015; Alves 2015; Chen 2015; Eftekhar 2014; Franco
2011a; Gonzalez 2015; Manriquez 2013; Orhan 2015; Phillips
2012; Preyer 2015; Schreiner 2014; Slovak 2015).
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Ongoing studies
Five ongoing trials were identified that met our inclusion criteria
(Characteristics of ongoing studies).
The following comparisons are being investigated in the ongoing
trials.
• ES versus sham ES (NCT01464372 2011)
• ES versus conservative treatment (Biemans 2010)
• Different types of ES (NCT01783392 2013;
NCT01912885 2012; NCT01940367 2013)
Since the search was conducted on 10 December 2014, an up-
dated search of theCochrane IncontinenceGroupSpecialisedReg-
ister was performed on 10 December 2015. A further 8 studies
were ongoing and have been added to the list of Ongoing Stud-
ies (NCT02110680 2014;NCT02311634 2014;NCT02377765
2014; NCT02452593 2014; NCT02456441 2014;
NCT02511717 2015; NCT02582151 2015; NCT02583529
2014)
Risk of bias in included studies
See Figure 2; Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Two trials were judged to be at high risk of bias for random se-
quence generation (Monteiro 2014; Svihra 2002) because their
methods of sequence generation did not appear to be truly ran-
dom. Thirty trials did not report their methods in sufficient de-
tail to judge whether allocation to groups was fully randomised
and therefore were at unclear risk of bias (Aaronson 1995; Amaro
2006; Boaretto 2011; Bower 1998;Gaspard 2014; Kennelly 2011;
Kosilov 2013; Lima 2011; Lo 2003; Lobel 1998; Marques 2008;
Monga 2011; Peters 2010; Preyer 2007; Schmidt 2009; Seth
2014; Shepherd 1984; Shepherd 1985; Smith 1996; Soomro
2001; Sotelo 2011; Vahtera 1997; Vecchioli-Scaldazza 2013;
Walsh 2001; Wang 2004; Wang 2006; Wise 1992; Wise 1993;
Yamanishi 2000a; Yamanishi 2000b). Nineteen trials were judged
to be at low risk of bias for randomisation (Arruda 2008; Barroso
2002; Bellette 2009; Berghmans 2002; Booth 2013; Brubaker
1997; Finazzi-Agrò 2010; Firra 2013; Franzén 2010; Kaya 2011;
Oldham 2013; Ozdedeli 2010; Peters 2009; Sancaktar 2010;
Schreiner 2010; Souto 2014; Spruijt 2003; Vohra 2002; Wang
2009).
Allocation concealment
Eight trials reported adequate methods of allocation concealment
of allocation and so were at low risk of bias (Berghmans 2002;
Firra 2013; Franzén 2010; Ozdedeli 2010; Shepherd 1984; Wang
2004; Wang 2006), none were judged to be at high risk and the
remainder did not report sufficient detail regarding their methods
of allocation concealment and were therefore judged to be at un-
clear risk of bias.
Blinding
Blinding of participants and personnel (performance bias)
Two trials (Arruda 2008; Bellette 2009) were judged to be at high
risk of performance bias because treatment was carried out by
personnel who were aware of treatment group allocation, which
may have influenced their treatment methods.
Thirteen trials were judged to be at low risk of performance bias (
Amaro 2006; Barroso 2002; Berghmans 2002; Booth 2013; Bower
1998; Brubaker 1997; Finazzi-Agrò 2010; Kennelly 2011; Peters
2010; Shepherd1985;Wang 2006;Wang 2009; Yamanishi 2000a)
and the remainder (38 trials) were unclear.
For some comparisons, blinding of participants would not be pos-
sible, for instance ES versus drug treatment, versus surgery or ver-
sus conservative treatment. Trials investigating those comparisons
were judged to be at unclear risk of performance bias because
knowledge of the treatment received may have had an influence
on self-reported outcomes but there was no means of avoiding it.
Blinding of outcome assessment (detection bias)
One trial (Firra 2013) was at high risk of detection bias because, al-
though it was impossible to blind participants due to the nature of
the interventions (electrical stimulation versus conservative treat-
ment), the authors reported in a personal communication that the
outcome assessors were not blinded to group allocation.
Seventeen trials were judged to be at low risk of detection bias
(Amaro 2006; Arruda 2008; Barroso 2002; Berghmans 2002;
Brubaker 1997; Finazzi-Agrò 2010; Gaspard 2014; Kaya 2011;
Kennelly 2011; Lo 2003; Oldham 2013; Ozdedeli 2010; Schmidt
2009; Shepherd 1984; Vecchioli-Scaldazza 2013; Wang 2004;
Wang 2006) and the remainder (33 trials) were unclear.
Incomplete outcome data
One trial was at high risk of attrition bias (Seth 2014) because it
reported differential attrition with no adequate explanation and
did not report whether the analysis included all participants who
were randomised. The Wise 1993 study experienced differential
withdrawal for reasons attributable to the comparator and was
therefore judged to be a high risk of attrition bias.
Twenty-four trials were judged to be at low risk of attrition bias
(Arruda 2008; Bellette 2009; Berghmans 2002; Booth 2013;
Finazzi-Agrò 2010; Franzén 2010; Gaspard 2014; Kaya 2011;
Kennelly 2011; Lobel 1998; Monteiro 2014; Peters 2009; Peters
2010; Preyer 2007; Schmidt 2009; Schreiner 2010; Spruijt 2003;
Vecchioli-Scaldazza 2013; Vohra 2002; Walsh 2001; Wang 2004;
Wang 2009; Yamanishi 2000a; Yamanishi 2000b) and the remain-
der (25 trials) were unclear.
Effects of interventions
See: Summary of findings for the main comparison Electrical
stimulation compared to no active treatment, placebo or sham
treatment for overactive bladder in adults; Summary of findings
2 Electrical stimulation compared to conservative treatment for
overactive bladder in adults; Summary of findings 3 Electrical
stimulation compared to drug treatment for overactive bladder in
adults; Summary of findings 4Electrical stimulation plus another
treatment compared to other treatment alone for overactive
bladder in adults
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1. Electrical stimulation versus no active treatment,
placebo, or sham treatment
Twenty-three trials with 1654 participants compared ES with no
active treatment, placeboor sham treatment (Amaro2006; Barroso
2002; Bellette 2009; Berghmans 2002; Booth 2013; Bower 1998;
Brubaker 1997; Finazzi-Agrò 2010; Kennelly 2011; Kosilov 2013;
Marques 2008; Monteiro 2014; Oldham 2013; Peters 2010;
Shepherd 1984; Shepherd 1985; Svihra 2002; Vahtera 1997;
Vohra 2002; Walsh 2001; Wang 2006; Wang 2009; Yamanishi
2000a).
Primary outcomes
OAB symptoms (number of participants with OAB
symptoms; number of participants with no improvement in
OAB symptoms)
Two small trials reported on the number of people with persistent
OAB symptoms (Bellette 2009;Monteiro 2014). Based on 61 par-
ticipants, there was no statistically significant difference between
ES and sham, placebo or no active treatment (risk ratio (RR) 0.68,
95% confidence interval (CI) 0.43 to 1.06, n=61) (Analysis 1.1).
Overall, there was moderate-quality evidence supporting the use
of ES in terms of improvement in OAB symptoms, compared
to no active treatment, placebo or sham treatment (Summary of
findings for the main comparison), with more people reporting
improvement in symptoms with ES (RR for no improvement:
0.54, 95% CI 0.47 to 0.63; n = 647) (Analysis 1.2) (Monteiro
2014; Oldham 2013; Booth 2013; Kennelly 2011; Peters 2010;
Vohra 2002; Wang 2006; Wang 2009). However, heterogeneity
was high (I2 = 55%) due to differences in participant population.
One of the studies included onlymale participants who had neuro-
genic bladder (Monteiro 2014); all other studies had similar pop-
ulations of mostly female middle-aged participants, all with idio-
pathic OAB. Removing this study in a sensitivity analysis changed
the RR only slightly (0.57, 95% CI 0.49 to 0.67, n = 595) and
reduced heterogeneity to I2 = 51%. Using a random-effects model
did not alter the findings in that the result remained statistically
significant with relatively narrow confidence intervals (RR 0.51,
95% CI 0.38 to 0.67).
Additionally, with regard to improvement in OAB symptoms,
a subgroup analysis of neurogenic OAB versus idiopathic OAB
found that ES was more beneficial than no active treatment,
placebo or sham treatment for those with idiopathic OAB
(Analysis 1.3). The one trial that included participants with neu-
rogenic bladder (Monteiro 2014) was small (24 people) but the
findings were consistent in showing that ES was better than the
control intervention (Analysis 1.3).
A further subgroup analysis found the following routes of ES to be
more effective thanno active treatment, placeboor sham treatment
(Analysis 1.4).
• Percutaneous tibial nerve stimulation (RR for no
improvement 0.52, 95% CI 0.42, 0.65; n = 269, three studies)
• Posterior tibial nerve stimulation with surface electrodes
(RR for no improvement 0.05 95% CI 0.00 to 0.81; n = 24, one
study)
• intravaginal (RR for no improvement 0.45, 95% CI 0.33 to
0.62; n = 191, three studies)
However, one trial of ES delivered through surface electrode
patches, compared to sham patches, found a difference which was
not statistically significant (RR for no improvement 0.83, 95%CI
0.62 to 1.13; n = 163) (Kennelly 2011).
More people reported improvement in urgency symptoms in the
ES groups than in those receiving no active treatment, sham or
placebo (RR for no improvement: 0.62, 95% CI 0.52 to 0.73;
n = 330) (Analysis 1.5) (Booth 2013; Peters 2009; Wang 2006;
Wang 2009), but again, heterogeneity was high (I2 = 63%) due
to differences in participant population (Booth 2013). Again, the
sensitivity analysis changed the result slightly (RR 0.64, 95% CI
0.53 to 0.76).
More people reported improvement in urinary frequency in those
receiving ES than in the groups receiving no active treatment,
placebo or sham treatment (RR for no improvement 0.66, 95%CI
0.53 to 0.81, n = 236) (Analysis 1.6) (Booth 2013; Peters 2009).
There was no evidence of heterogeneity.
A further two small trials reported greater satisfaction in the ES
groups than in those receiving no active treatment, placebo or
sham (RR for number not satisfied 0.61 95% CI 0.38 to 0.97; n
= 98) (Analysis 1.7) (Amaro 2006; Yamanishi 2000a).
Urinary incontinence (number of participants with self-
reported urgency urinary incontinence (UUI); number of
participants with no improvement in self-reported UUI)
Based on 122 participants, fewer people had persistent UUI in
the ES groups than in the groups receiving no active treatment, or
placebo sham treatment (RR 0.78, 95% CI 0.62 to 0.99, n = 122)
(Analysis 1.8) (Monteiro 2014; Amaro 2006; Yamanishi 2000a).
A more reliable result was found for the number of people with
no improvement in UUI (fixed-effect analysis) (RR 0.65, 95% CI
0.55 to 0.77, n = 324) (Analysis 1.9) (Booth 2013; Finazzi-Agrò
2010; Peters 2010; Yamanishi 2000a), but the quality of evi-
dence was deemed to be low (Summary of findings for the main
comparison). However, heterogeneity was high (I2 = 75%), which
may be partly explained by differences in participant population,
whereby Booth 2013 included only elderly patients. Nevertheless,
removing this trial in a sensitivity analysis made very little differ-
ence to the result (RR 0.65, 95% CI 0.54, 0.78). Using random-
effects meta-analysis instead of fixed-effect showed a slightly lower
risk of no improvement (RR 0.52, 95% CI 0.32 to 0.86), but the
result remains statistically significantly in favour of ES.
A subgroup analysis found that ES delivered through percutaneous
tibial nerve stimulation and through intravaginal electrodes was
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more effective thanno active treatment, placeboor sham treatment
in improving UUI (RR for no improvement 0.59, 95% CI 0.36
to 0.97, n = 270, three studies and 0.34 95% CI 0.16 to 0.72, n
= 54, one study, respectively) (Analysis 1.10).
Quality of life (QoL) due to OAB symptoms
Seven trials reported a measure of QoL related to OAB or in-
continence. One trial used an instrument that was not validated
(Yamanishi 2000a); the other instruments used were:
• International Consultation on Incontinence Questionnaire
- Urinary Incontinence (ICIQ-UI) (Oldham 2013);
• Overactive Bladder Questionnaire (OAB-Q) (Bellette 2009;
Peters 2010);
• Incontinence Quality of Life (I-QOL) (Finazzi-Agrò 2010;
Svihra 2002);
• King’s Health Questionnaire (Wang 2009).
There was moderate-quality evidence that OAB-related QoL was
improved to a greater extent with ES than with no active treat-
ment, placebo or sham treatment (Summary of findings for the
main comparison). Almost all of the trials reported that ES was
better than no active treatment or sham treatment (Analysis 1.12;
Analysis 1.13; Analysis 1.14; Analysis 1.16; Analysis 1.17). Data
from two trials (n = 240) reporting OAB-Q severity scores were
pooled; themeandifference (MD) for change in scorewas in favour
of ES (-8.77, 95% CI -14.18 to -3.36) (Analysis 1.15) (Bellette
2009; Peters 2010).
Additionally, one trial (Peters 2010) reported a change in SF-36
scores, a generic measure of QoL, which favoured ES (MD -13.60,
95% CI -19.30 to -7.90; n = 208) (Analysis 1.18).
Secondary outcomes
Quantification of symptoms
A variety of differentmeasures of quantification of symptoms were
reported. For the following outcomes, ES was found to be more
effective than no active treatment, placebo or sham treatment.
• Incontinence episodes per 24 hours: ES versus sham ES:
MD -1.70 (95% CI -2.35 to -1.05) (n = 36) (Analysis 1.19)
(Barroso 2002).
• Incontinence episodes per 24 hours: ES versus placebo:
MD -1.10 (95% CI -1.82 to -0.38) (n = 107) (Analysis 1.19)
(Kosilov 2013)
• Micturitions per 24 hours: MD -1.09, 95% CI -1.70 to -
0.47. (n = 285) (Analysis 1.20) (Amaro 2006; Peters 2010;
Bellette 2009) (Estimated SDs used for Bellette 2009 - see
Characteristics of included studies)
People receiving ES had fewer nocturia episodes than those re-
ceiving sham treatment (MD -0.37, 95% CI -0.73 to -0.02; n =
245) (Analysis 1.21) (Bellette 2009; Peters 2010). However, het-
erogeneity was high (I2 = 65%), possibly attributable to the dif-
ferent sample sizes in the trials as there was little other evidence to
indicate clinical heterogeneity.
No significant differenceswere found in terms of pads per day (MD
-0.30, 95% CI -1.10 to 0.50; n = 68) (Analysis 1.22) (Yamanishi
2000a) or number of participants with nocturnal enuresis (RR
0.17, 95% CI 0.02 to 1.18 Analysis 1.32).
In addition, one small trial reported that ES was better than sham
treatment in terms of improvement in: nocturia (Analysis 1.23);
incomplete bladder emptying (Analysis 1.24); weakurinary stream
(Analysis 1.25); intermittency (Analysis 1.26); urinary straining
(Analysis 1.27); urine leakage (Analysis 1.28); interference in ev-
eryday life (Analysis 1.29) (Booth 2013, n = 28),
None of the trials reported pad tests.
Two trials reported outcomes at two different time points (Kosilov
2013;Monteiro 2014).Generally, outcomeswereworse after treat-
ment stopped but the result still favoured ES.
Study Outcome End of treatment End of follow-up (12 months
after baseline)
Kosilov 2013
Six months’ treatment
Urinary incontinence episodes
per 24 hours (mean, SD, N)
ES 2.2 (0.9), 51.
Placebo 2.7 (1.1), 56
ES 3.7 (1.3), 51.
Placebo: 4.8 (2.4), 56.
Monteiro 2014
45 days’ treatment
Participants with urinary ur-
gency
ES: 7/12
Control: 10/12
ES: 6/12
Control: 9/12
Participants with urgency uri-
nary incontinence (UUI)
ES: 8/12
Control: 7/12
ES: 9/12
Control: 8/12
Participants with nocturnal
enuresis
ES: 0/12
Control: 0/12
ES: 2/12
Control: 2/12
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(Continued)
Participants with nocturia ES: 5/12
Control: 1/12
ES: 9/12
Control: 6/12
Participants with increased day-
time frequency
ES: 3/12
Control: 0/12
ES: 11/12
Control: 9/12
Clinicians’ observations
No trials reported objectively measured incontinence. Numerous
urodynamic and objective measures of OAB were reported.
The number of people with persistent detrusor overactivity was
lower in the ES groups than in those receiving no active treatment,
sham or placebo (RR 0.68, 95% CI 0.54 to 0.85; n = 118) (
Analysis 1.30) (Brubaker 1997; Yamanishi 2000a). Heterogeneity
was high (I2 = 72%); however there was little evidence of clinical
heterogeneity but in a random-effects meta-analysis, the estimate
of effect no longer reached statistical significance (RR 0.68, 95%
CI 0.43 to 1.07).
More ES participants reported improvement in detrusor overac-
tivity (RR for no improvement 0.19, 95% CI 0.07 to 0.50; n =
58) (Analysis 1.31) (Yamanishi 2000a).
One small trial (n = 31) reported results in favour of ES for De-
trusor Activity Index Score (Analysis 1.33) (Berghmans 2002).
Bladder capacity measured by urodynamics was greater in people
having ES (MD -87.44 mL, 95% CI -95.37 to -79.50, n = 251)
(Analysis 1.34) (Bower 1998; Walsh 2001; Yamanishi 2000a).
A small number of trials with few participants reported other ob-
jective measures which favoured ES.
• Maximum bladder pressure (MD -7.00 cmH2O, 95% CI -
8.95 to -5.05; n = 107) (Analysis 1.35) (Kosilov 2013).
• Volume at first desire to void (MD -16.55 mL, 95% CI -
27.22 to -2.55; n = 154) (Analysis 1.37) (Bower 1998; Kosilov
2013).
There was no evidence of a difference between ES and no active
treatment, sham or placebo for the following outcomes.
• Volume voided per 24 hours (MD -10.4 mL, 95% CI -
33.25 to 12.45; n = 205) (Analysis 1.36) (Peters 2010)
• Pelvic floor muscle strength (MD 7.00 cmH2O, 95% CI -
2.82 to 16.82; n = 40) (Analysis 1.38) (Amaro 2006).
The Kosilov 2013 trial reported various cystometric measures two
time points: at the end of six months’ treatment and after a further
six months. The data indicated an increase in severity at the second
time point for both groups but the result was still in favour of ES.
Outcome End of 6 months’ treatment 12 months after baseline
Volume at first desire to void (mL) (mean,
SD, N)
ES: 297.0 (45.3), 51
Placebo: 279.7 (54.8), 56
ES: 210.9 (28.7), 51
Placebo: 192.9 (28.9), 56
Volume at maximal desire to urinate (mL)
(mean, SD, N)
ES: 334.8 (38.3), 51
Placebo: 311.5 (51.7), 56
ES: 251.9 (42.9), 51
Placebo: 206.3 (SD missing), 56
Maximum bladder pressure (cmH2O)
(mean, SD, N)
ES: 35.4 (9.3), 51
Placebo: 31.0 (7.9), 56
ES: 30.9 (4.9), 51
Placebo: 23.9 (5.4), 56
Socioeconomic measures
None of the trials comparing ES with no active treatment, placebo
or sham treatment reported socioeconomic measures or cost-ef-
fectiveness outcomes.
Adverse effects
Three trials reported a variety of adverse events in both active
ES and sham treatment groups (Kennelly 2011; Peters 2010;
Yamanishi 2000ac). They included skin irritation, urinary tract
infection, vaginal pain, discomfort and tingling. Overall, similar
numbers of people reported that they had experienced these effects
(RR 0.96, 95% CI 0.90 to 1.03; n = 450) (Analysis 1.39), which
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was supported by evidence deemed to be of moderate quality (
Summary of findings for the main comparison).
Other outcomes
FIve trials reported data relating to a variety of other outcomes,
which could not be included in a meta-analysis. The following
outcomes all favoured ES (Analysis 1.40) (Amaro 2006; Bellette
2009; Kennelly 2011; Oldham 2013).
• Reduction in analogue discomfort sensation
• Reduction in analogue wetness sensation
• Absolute change in UUI episodes
• Daytime frequency
• Nocturia
• Per cent change in frequency and urgency
• ICI-Q score
However, the Kennelly 2011 trial also reported that active ES was
less effective than shamES in terms of change in frequency, change
in OAB-Q score and change in volume per void. Additionally,
exactly the same result was reported in both arms of the trial for
change in urgency episodes (Analysis 1.40).
2. Electrical stimulation versus conservative
treatment
Eight trials with 542 participants compared ES to conserva-
tive treatment (Arruda 2008; Berghmans 2002; Boaretto 2011;
Kosilov 2013; Lima 2011; Spruijt 2003; Wang 2004; Yamanishi
2000b).
Primary outcome
OAB symptoms (number of participants with OAB
symptoms; number of participants with no improvement in
OAB symptoms)
One small trial reported the number of participants with persistent
OAB symptoms and found no significant difference between ES
and conservative treatment (pelvic floor muscle training (PFMT))
(RR 1.11, 95% CI 0.57 to 2.17; n = 42) Analysis 2.1) (Arruda
2008).
There was very low-quality evidence for the effectiveness of
ES compared to conservative treatment for improving OAB
(Summary of findings 2). One small trial (Wang 2004; n = 69),
reported no statistically significant difference between ES and
PFMT, or between ES and PFMT plus biofeedback in the number
of participants with no improvement in OAB symptoms (RR for
ES versus PFMT 0.79, 95% CI 0.51 to 1.21; RR for ES versus
PFMT plus biofeedback 0.97, 95% CI 0.60 to 1.57) (Analysis
2.2). Similarly, there was no significant difference for numbers of
participants with UUI (RR for ES versus PFMT 0.79, 95% CI
0.51 to 1.21; RR for ES versus PFMT plus biofeedback 0.97, 95%
CI 0.60 to 1.57) (Analysis 2.3).
More participants were dissatisfied after receiving ES than those
receiving PFMT (RR 2.39, 95% CI 1.21 to 4.75; n = 124) (
Analysis 2.4) (Arruda 2008; Boaretto 2011).
No trials comparing ES versus conservative treatment reported
subjective measures of UUI.
Quality of life (QoL) due to OAB symptoms
One trial reported greater QoL in people receiving PFMT than
ES, based on theKing’sHealthQuestionnaire scores (MD129.81,
95% CI 47.83 to 211.79; n = 79) (Analysis 2.5). The same trial
found no evidence of a difference between ES and PFMT plus
biofeedback in terms of QoLmeasured by theKing’sHealthQues-
tionnaire (MD -5.78, 95% CI -88.99 to 77.43, n = 69) (Analysis
2.5) (Wang 2004).
Secondary outcomes
Quantification of symptoms
A variety of different measures of quantification of symptoms was
reported.
Based ondata fromone trial (n =42) (Arruda 2008), therewas little
evidence of a difference between ES and PFMT in the following
outcomes.
• Daily micturitions (MD 0.80, 95% CI -0.53 to 2.13)
(Analysis 2.6)
• Nocturia episodes (MD 0.20, 95% CI -0.53 to 0.93)
(Analysis 2.7)
• Pads used per day (MD 0.10, 95% CI -0.82 to 1.02)
(Analysis 2.9).
Electrical stimulation was found to be more effective than con-
servative treatment in terms of incontinence episodes (MD -1.79,
95% CI -2.29 to -1.30; n = 156) (Analysis 2.8) Arruda 2008;
Kosilov 2013).
The Kosilov 2013 trial reported the number of incontinence
episodes at two time points; after six months and after nine
months. The data indicated an increase in incontinence at the sec-
ond time point for both groups but the result was still in favour
of ES.
None of the trials reported outcomes relating to urgency or pad
tests.
Clinicians’ observations
No trials reported objectively measured incontinence. Numerous
urodynamic and objective measures of OAB were reported. No
statistically significant differenceswere foundbetweenES and con-
servative treatment for the following outcomes.
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• OAB according to urodynamic evaluation: RR 0.90, 95%
CI 0.46 to 1.75 (n = 42) (Analysis 2.10) (Arruda 2008)
• Detrusor overactivity: RR 1.24, 95% CI 0.95 to 1.63 (n =
32) (Analysis 2.11) (Yamanishi 2000b)
• Detrusor Activity Index Score: MD -0.05, 95% CI -0.27 to
0.17 (n = 35) (Analysis 2.12) (Berghmans 2002)
• Maximum cystometric capacity: MD 38.76 mL, 95% CI -
32.06 to 109.58 (n = 74) (Analysis 2.13) (Arruda 2008;
Yamanishi 2000b)
• Post micturition residual volume: MD 1.00 mL, 95% CI -
0.84 to 2.84 (n = 42) (Analysis 2.14) (Arruda 2008)
• Bladder capacity at first desire to void: MD -8.45 mL, 95%
CI -21.96 to 5.7 (n = 188) (Analysis 2.15) (Arruda 2008;
Kosilov 2013; Yamanishi 2000b)
• Maximum bladder pressure: MD -1.10 cmH2O, 95% CI -
3.16 to 0.96 (n = 114) (Analysis 2.17) (Kosilov 2013)
• Involuntary detrusor contraction volume: MD -41.00 mL,
95% CI -122.61 to 40.61 (n = 42) (Analysis 2.18) (Arruda 2008)
• Involuntary detrusor contraction maximal pressure: MD
5.20 cmH2O, 95% CI -6.07 to 16.47 (n = 42) (Analysis 2.19)
(Arruda 2008)
One statistically significant result, in favour of ES, was reported
for volume at maximum desire to void: MD -73.00 mL, 95% CI
-86.78 to -59.22 (n = 114) (Analysis 2.16) (Kosilov 2013). XX
The Kosilov 2013 trial reported various cystometric measures at
two time points; at the end of six months’ treatment and after a
further six months. The data indicated an increase in severity at
the second time point for both groups but the result still favoured
ES.
Outcome End of 6 months’ treatment 12 months after baseline
Volume at first desire to void (mL) (mean,
SD, N)
ES: 297.0 (45.3), 51
Laseropuncture: 254.5 (49.1), 63
ES: 210.9 (28.7), 51
Laseropuncture: 199.3 (49.4), 63
Volume at maximal desire to urinate (mL)
(mean, SD, N)
ES: 334.8 (38.3), 51
Laseropuncture: 286.0 (36.6), 63
ES: 251.9 (42.9), 51
Laseropuncture: 178.9 (29.0), 63
Maximum bladder pressure (cmH2O)
(mean, SD, N)
ES: 35.4 (9.3), 51
Laseropuncture: 38.9 (7.8), 63
ES: 30.9 (4.9), 51
Laseropuncture: 29.8 (6.3), 63
Socioeconomic measures
None of the trials comparing ES to conservative treatment re-
ported socioeconomic measures or cost-effectiveness outcomes.
Adverse effects
One trial (n = 32) reported no adverse effects in either treatment
group (Analysis 2.20) (Yamanishi 2000b). No other trials com-
paring ES to conservative treatment reported adverse effects data.
3. Electrical stimulation versus drug treatment
Sixteen trials with 894 participants compared ES to the following
drug treatments:
• probanthine (Aaronson 1995)
• trospium and solifenacin (Kosilov 2013)
• extended release tolterodine (Peters 2009)
• tolterodine (not reported if extended or immediate release
(Franzén 2010; Preyer 2007)
• probantheline bromide (Smith 1996)
• immediate release oxybutynin (Arruda 2008; Boaretto
2011)
• oxybutynin (not reported if extended or immediate release
(Soomro 2001; Souto 2014; Svihra 2002; Wang 2006; Wang
2009; Wise 1993)
• solifenacin succinate (Vecchioli-Scaldazza 2013)
• terodiline (Wise 1992)
• trospium hydrochloride (Ozdedeli 2010)
Primary outcome
OAB symptoms (number of participants with OAB
symptoms; number of participants with no improvement in
OAB symptoms)
Data from two trials were pooled and showed that fewer partici-
pants still had OAB symptoms after ES than after treatment with
tolterodine (RR 0.58, 95% CI 0.36 to 0.93, n = 150) (Analysis
3.1). However, when pooled with ES versus oxybutynin there was
no significant difference betweenES and drug treatment (RR0.72,
95% CI 0.49 to 1.07, n = 193) (Analysis 3.1) (Arruda 2008;
Franzén 2010; Peters 2010).
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Overall, there was moderate-quality evidence that more people
had symptomatic improvement in the ES groups than in the drug
treatment groups (RR for no improvement 0.66, 95% CI 0.48
to 0.90; n = 265) (Analysis 3.2) (Boaretto 2011; Franzén 2010;
Smith 1996; Wang 2006; Wang 2009) (Summary of findings 4).
With regard to improvement inOAB symptoms, a subgroup analy-
sis found that ES delivered through intravaginal or transanal routes
was more effective than drug treatment (RR for no improvement
in OAB symptoms 0.69, 95% CI 0.49 to 0.99; n = 201), but
one small trial found no statistically significant difference between
transcutaneous posterior tibial nerve stimulation and drug treat-
ment (RR 0.51, 95% CI 0.23 to 1.13; n = 64) (Analysis 3.3).
No statistically significant difference was found in the number of
people not satisfied with ES or drug treatment (RR 1.05, 95%
CI 0.62 to 1.77; n = 138) (Analysis 3.4) (Arruda 2008; Boaretto
2011; Ozdedeli 2010).
Urinary incontinence (number of participants with self-
reported urgency urinary incontinence (UUI); number of
participants with no improvement in self-reported UUI)
Two trials reported different outcomes relating to self-reported
urinary incontinence but found insufficient evidence to detect a
difference between ES and drug treatment for the following.
• Number of people with persistent urinary incontinence (RR
0.53, 95% CI 0.15 to 1.80; n = 37) (Analysis 3.5) (Souto 2014)
• Number of people with no improvement in UUI (RR 0.94,
95% CI 0.43 to 2.06; n = 64) (Analysis 3.6) (Franzén 2010)
The Souto 2014 trial reported data at two time points; 12 weeks
and 24weeks. The data indicated an increase in numbers of people
with persistent urinary incontinence in the ES group at the second
time point, but the result was still not statistically significant (
Analysis 3.5).
The quality of evidence for improvement in UUI was deemed to
be low (Summary of findings 3).
Quality of life (QoL) due to OAB symptoms
One trial reported various QoLmeasures but found little evidence
of a difference between ES and drug treatment according to the
following instruments, where a higher score equates to greater
severity (n = 30) (Vecchioli-Scaldazza 2013).
• OABq-SF score: (MD -0.20, 95% CI -0.99 to 0.59)
(Analysis 3.7)
• Patient Global Impression of Improvement (PGI-I) score
(MD -0.60, 95% -1.27 to 0.07) (Analysis 3.8)
• Patient Perception of Intensity of Urgency Score (PPIUS)
(MD -0.50, 95% -1.33 to 0.33) (Analysis 3.9)
The Ozdedeli 2010 trial reported QoL measured at two different
time points; at the end of six weeks’ treatment and 18 weeks after
baseline measurements. The data indicated that drug therapy re-
sulted in better QoL initially but that after the end of treatment
the effect was reversed.
Outcome End of treatment End of follow-up
IIQ-7 score (lower score indicates higher
satisfaction) (median, range, N)
ES: 28.5 (0-76.1), 16.
Trospium hydrochloride: 23.8 (0-100), 15
ES: 4.8 (0-57.8), 16.
Trospium hydrochloride: 51.2 (4.8-68.1),
15
There was insufficient information reported in the included trials
to rate the quality of evidence for OAB-related QoL.
Secondary outcomes
Quantification of symptoms
There were more episodes of incontinence in people undergoing
ES than in those receiving drug treatment (MD1.68, 95%CI 1.30
to 2.07; n = 237). However, heterogeneity was high (I2 = 94%)
and the result was no longer statistically significant in a random-
effects model (MD 0.84, 95% CI -1.71 to 3.39) (Analysis 3.10)
(Arruda 2008; Kosilov 2013; Peters 2009).
There was insufficient evidence of a difference between ES and
drug treatment for the following outcomes.
• Change (i.e. reduction) in incontinence episodes from
baseline: MD 0.80, 95% CI -0.40 to 2.00; n = 115 (Analysis
3.11) (Peters 2009; Preyer 2007)
• Urgency episodes: MD -0.60, 95% CI -1.98 to 0.78; n =
84 (Analysis 3.12) (Peters 2009)
• Change in urgency episodes: MD 0.60, 95% CI -1.14 to
2.35; n = 115 Analysis 3.13 (Peters 2009; Preyer 2007)
• UUI episodes: MD -0.90, 95% CI -2.01 to 0.21; n = 30
(Analysis 3.14) (Vecchioli-Scaldazza 2013)
• Number of micturitions per 24 hours: MD 0.24, 95% CI -
0.49 to 0.98; n = 194 (Analysis 3.15) (Arruda 2008; Peters 2009;
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Souto 2014; Vecchioli-Scaldazza 2013) (Estimated SD for Souto
2014)
• Change in number of micturitions per 24 hours: MD 0.34,
95% CI -0.49 to 1.16; n = 176 (Analysis 3.16) (Franzén 2010;
Peters 2009; Preyer 2007) (Estimated SD used for Franzén 2010)
• Nocturia episodes: MD -0.02, 95% CI -0.41 to 0.37; n =
157 (Analysis 3.17) (Arruda 2008; Peters 2009;
Vecchioli-Scaldazza 2013)
• Change in number of nocturia episodes: MD -0.10, 95%
CI -0.69 to 0.49 n = 84 (Analysis 3.18) (Peters 2009)
• Number of people with nocturia: RR 0.70, 95% CI 0.13 to
3.73; n = 37 (Analysis 3.19) (Souto 2014)
• Pads used per day: MD 0.00, 95% CI -0.96 to 0.96; n = 43
(Analysis 3.20) (Arruda 2008)
The Ozdedeli 2010 trial reported various symptoms measured at
two different time points; at the end of six weeks’ treatment and
18 weeks after baseline measurements. The ES group had fewer
urgency and incontinence episodes at the end of treatment, but
this trend was maintained only for urgency episodes at the end
of 18 weeks’ follow-up. Conversely, the group treated with drug
therapy had fewer daily micturitions and less severe urgency at the
end of treatment, but both of these trends were reversed at the end
of 18 weeks’ follow-up.
Outcome End of treatment End of follow-up
Urgency episodes per 24 hours (median,
range, N)
ES: 1.7 (0-13.0), 16
Trospium hydrochloride: 2.7 (0-8.0), 15
ES: 3.0 (0-7.0), 16
Trospium hydrochloride: 4.4 (0-6.0), 15
Incontinence episodes per 24 hours (me-
dian, range, N)
ES: 0.3 (0-9), 16
Trospium hydrochloride: 1 (0-5), 15
ES: 2.4 (0-5), 15
Trospium hydrochloride: 0 (0-2), 16
Number of micturitions per 24 hours (me-
dian, range, N)
ES: 7.0 (0.6-15.4), 16
Trospium hydrochloride: 6.0 (3.3-14.7),
15
ES: 6.5 (5.3-11.3), 16
Trospium hydrochloride: 8.2 (5.7-14.1),
15
Severity of urgency (VAS: higher score =
greater severity) (median, range, N)
ES: 31.5 (0-73), 16
Trospium hydrochloride: 23.0 (1-84), 15
ES: 15.0 (1-58), 16
Trospium hydrochloride: 35.5 (11-86), 15
Clinicians’ observations
No trials reported objectively measured incontinence. Numerous
urodynamic and objective measures of OAB were reported. No
statistically significant differenceswere foundbetweenES anddrug
treatment for the following outcomes.
• OAB according to urodynamic evaluation: RR 0.67, 95%
CI 0.37 to 1.21; n = 43 (Analysis 3.21) (Arruda 2008)
• Maximum cystometric capacity: MD 80.60 mL, 95% CI -
31.12 to 191.32; n = 43 (Analysis 3.22) (Arruda 2008)
• Volume voided per 24 hours: MD -11.61 mL, 95% CI -
27.18 to 3.95; n = 114 (Analysis 3.23) (Peters 2009;
Vecchioli-Scaldazza 2013)
• Change in volume voided per 24 hours: MD -8.92 mL,
95% CI -28.97 to 11.13; n = 145 (Analysis 3.24) (Franzén 2010;
Peters 2009)
• Maximum bladder pressure: MD 2.10 cmH2O, 95% CI
0.30 to 3.90; n = 110 (Analysis 3.27) (Kosilov 2013)
• Post micturition residual volume: MD -3.70 mL, 95% CI -
7.77 to 0.37; n = 43 (Analysis 3.28) (Arruda 2008)
• Involuntary detrusor contraction volume: MD -115.30
cmH2O, 95% CI -239.03 to 8.43; n = 22 (Analysis 3.29)
(Arruda 2008)
• Involuntary detrusor contraction maximal pressure: MD
2.80, 95% CI -6.38 to 11.98; n = 43 (Analysis 3.30) (Arruda
2008)
Drug treatment was better than ES for the following outcomes.
• Volume at first desire to void: MD 44.33 mL, 95% Ci
31.34 to 57.33; n = 153) (Analysis 3.25) (Arruda 2008; Kosilov
2013)
• Volume at maximum desire to void: MD 28.00 mL, 95%
CI 13.41 to 42.59; n = 110 (Analysis 3.25) (Kosilov 2013)
Two trials reported various cystometric outcomes measured at two
time points; at the end of treatment and after a further follow-
up period (Kosilov 2013; Ozdedeli 2010). The data were incon-
clusive, with some outcomes favouring the same intervention at
both time points and others showing a result opposite to the initial
measurement.
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Study Outcome End of treatment End of follow-up
Kosilov 2013 6 months’ treat-
ment, 12 months’ follow-up
Volume at first desire to void
(mL) (mean, SD, N)
ES: 297.0 (45.3), 51
Trospium + solifenacin: 289.3
(37.6), 59
ES: 210.9 (28.7), 51
Trospium + solifenacin: 257.5
(28.9), 59
Volume at maximal desire to
urinate (mL) (mean, SD, N)
ES: 334.8 (38.3), 51
Trospium + solifenacin: 313.7
(47.1), 59
ES: 251.9 (42.9), 51
Trospium + solifenacin: 279.9
(33.8), 59
Maximum bladder pressure
(cmH2O) (mean, SD, N)
ES: 35.4 (9.3), 51
Trospium+ solifenacin: 32.8 (6.
0), 59
ES: 30.9 (4.9), 51
Trospium+ solifenacin: 28.8 (4.
7), 59
Ozdedeli 2010 6 weeks’ treat-
ment, 18 weeks’ follow-up
Maximal detrusor pressure (me-
dian, range, N)
ES: 12 (2-56), 16
Trospiumhydrochloride: 22 (4-
49), 15
ES: 19 (3-48), 16
Trospiumhydrochloride: 28 (3-
48), 15
Maximal cystometric capacity
(median, range, N)
ES: 442.0 (62-550), 16
Trospium hydrochloride: 405.0
(195-550), 15
ES: 500.0 (125-540), 16
Trospium hydrochloride: 378.0
(94-450), 15
Volume at first desire to void
(median, range, N)
ES: 204.0 (60-410), 16
Trospium hydrochloride: 209
(116-295), 15
ES: 150.0 (72-234), 16
Trospium hydrochloride: 149.5
(65-250), 15
Socioeconomic measures
None of the trials comparing ES to drug treatment reported so-
cioeconomic measures or cost-effectiveness outcomes.
Adverse effects
There was low-quality evidence regarding the number of adverse
effects associated with ES compared to drug treatment (Summary
of findings 4). Both oxybutynin and tolterodine had more adverse
effects than ES (oxybutynin RR 1.26 95% CI 1.07 to 1.49; n
= 79 (Svihra 2002; Wise 1993); tolterodine RR 1.51, 95% CI
1.21 to 1.89; n = 94 (Franzén 2010; Preyer 2007)). However,
there was no statistically significant different between participants
treated with trospium hydrochloride and those with ES (RR 0.73,
95% CI 0.43 to 1.25; n = 35) (Ozdedeli 2010). The reported
adverse effects included dry mouth, constipation, headache, skin
irritation, blurred vision, muscular pain, indigestion, nausea and
dizziness. Due to the variety of adverse effects associated with
different drugs, the data were not pooled to obtain one overall
estimate effect, as this may have led to a misleading result (Analysis
3.31).
4. Electrical stimulation versus surgery
No studies were identified that compared ES with surgery.
5. Electrical stimulation plus another treatment
versus another treatment alone
Eight trials with 252 participants compared ES plus another treat-
ment versus the other treatment alone (Berghmans 2002; Firra
2013; Gaspard 2014; Kaya 2011; Lo 2003; Sancaktar 2010;
Schmidt 2009; Schreiner 2010). The other treatments included:
• pelvic floor muscle training (Berghmans 2002; Firra 2013;
Gaspard 2014; Lo 2003; Schmidt 2009; Schreiner 2010);
• drug therapy: trospium chloride (Kaya 2011); tolterodine
(Sancaktar 2010).
Primary outcome
OAB symptoms (number of participants with OAB
symptoms; number of participants with no improvement in
OAB symptoms)
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None of the trials comparing ES plus another treatment versus
another treatment alone reported numbers of participants with
OAB symptoms or with no improvement in OAB symptoms.
There was very low-quality evidence with regard to partici-
pants’ satisfaction with ES plus PFMT compared to PFMT alone
(Summary of findings 4). Data from two trials showed no evi-
dence of a difference between the groups in terms of satisfaction
(RR for not satisfied 0.70, 95% CI 0.39 to 1.24; n = 82) (Analysis
4.1) (Gaspard 2014; Schreiner 2010). Heterogeneity was high (I2
= 76%), which may be partly explained by clinical heterogeneity
whereby the trial by Gaspard and colleagues included only par-
ticipants with multiple sclerosis but Schreiner and colleagues in-
cluded any participants aged over 60 with UUI. A random-effects
meta-analysis showed an even more inconclusive result (RR 1.16,
95% CI 0.13 to 10.04).
Urinary incontinence (number of participants with self-
reported urgency urinary incontinence (UUI); number of
participants with no improvement in self-reported UUI)
One trial (Schreiner 2010) found that ES plus PFMT was better
than PFMT alone for UUI.
• RR for persistent UUI: 0.57, (95% CI 0.35 to 0.93; n = 51
(Analysis 4.2)
• RR for number of participants with less than 50% reduction
in UUI: 0.33, 95% CI 0.16, 0.69; n = 51) (Analysis 4.3)
No other outcomes relating to improvement inUUIwere reported
by the trials comparing ES plus another treatment versus another
treatment alone.
Quality of life (QoL) due to OAB symptoms
One trial reported better QoL in people receiving ES plus drug
treatment compared to drug treatment alone, measured by the
Incontinence Impact Questionnire (IIQ) (MD -2.20, 95% CI -
3.50 to 0.90; n = 38) (Analysis 4.4) (Sancaktar 2010). Similarly,
one trial using the International Consultation on Incontinence
Questionnaire (ICI-Q) reported greater QoL in people receiving
ES plus PFMT compared to PFMT alone (MD -2.70, 95% CI -
5.14 to -0.26; n = 51) (Analysis 4.5) (Schreiner 2010).
There was no evidence of a difference in QoL between ES plus
conservative treatment compared to conservative treatment alone
according to the following instruments.
• SF-Qualiveen: MD -0.18, 95% CI -0.77 to 0.41; n = 31
(Analysis 4.7) (Gaspard 2014)
• York Incontinence Perception Scale: MD 5.80, 95% CI -
3.47 to 15.07; n = 12 (Analysis 4.8) (Firra 2013)
The Gaspard 2014 trial measured QoL at the end of nine weeks’
treatment and after six months; the data suggested that QoL de-
creased for both groups after treatment ended but there was still
no significant difference between the groups.
There was insufficient information reported in the included trials
to rate the quality of evidence for OAB-related QoL.
Secondary outcomes
Quantification of symptoms
Data from one trial showed better results for participants receiving
ES plus drugs than in those receiving drug treatment alone for the
following outcomes.
• Incontinence episodes: MD -0.90, 95% CI -1.06 to -0.74;
n = 38 (Analysis 4.9) (Sancaktar 2010)
• Urgency episodes: MD -1.90, 95% CI -2.39 to -1.41; n =
38 (Analysis 4.10) (Sancaktar 2010)
ES plus PFMT was better than PFMT alone for the following
outcomes:
• Urgency episodes: MD -2.80, 95% CI -4.57 to -1.03; n =
51 (Analysis 4.10) (Schreiner 2010)
• Incontinence episodes: MD -0.83, 95% CI -1.47 to -0.19;
n = 119) (Analysis 4.9) (Firra 2013; Gaspard 2014)
• Change in nocturia episodes: MD -1.20, 95% CI -1.80 to -
0.60; n = 51 (Analysis 4.11) (Schreiner 2010)
There was no evidence of a difference between ES plus PFMT and
PFMT alone for the nocturia episodes (MD -1.10, 95% CI -1.87
to 0.33; n = 51) (Analysis 4.14) (Schreiner 2010)
Norwas there evidence of a difference in urgency episodes between
ES plus PFMT with biofeedback compared to those receiving
PFMT with biofeedback without ES (MD 0.58, 95% CI -0.91
to 2.07; n = 51) (Analysis 4.10) (Gaspard 2014). The Gaspard
2014 trial measured the number of urgency episodes at the end
of nine weeks’ treatment and after six months; the data indicated
an increase in episodes for both groups after treatment ended, but
there was still no significant difference between the groups.
For number of micturitions per 24 hours, ES plus PFMT with
drug treatment was more effective than drug treatment alone (MD
-2.00, 95%CI -3.84 to -0.16; n = 31) (Analysis 4.12) (Kaya 2011),
but there was no evidence of a difference in number micturitions
between ES plus PFMT and PFMT alone (MD -0.75, 95% CI -
1.62 to 0.12; n = 63) (Analysis 4.12) (Firra 2013; Schreiner 2010),
nor between ES plus drug treatment and drug treatment alone
(MD -1.40, 95% CI -4.18 to 1.38; n = 40) (Analysis 4.12) (Souto
2014). Similarly, there was no evidence of a difference between ES
plus PFMT and PFMT alone in terms of change from baseline in
number of micturitions (MD -0.60, 95% CI -1.46 to 0.26; n =
51) (Analysis 4.13) (Schreiner 2010).
Clinicians’ observations
No trials reported objectively measured incontinence. Numerous
urodynamic measures of OAB were reported. Detrusor Activity
Index scores were worse in people undergoingES plus conservative
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treatment than conservative treatment alone (MD 0.22, 95% CI
0.03 to 0.41; n = 37) (Analysis 4.15) (Berghmans 2002).
There was no evidence of a difference between ES plus conserva-
tive treatment and conservative treatment alone for the following
outcomes.
• Bladder hyperactivity score: MD -0.08, 95% CI -2.67 to
2.51; n = 31 (Analysis 4.16) (Gaspard 2014)
• Pelvic floor muscle strength: MD 20.20 cmH2O, 95% CI -
2.02 to 42.42; n = 12 (Analysis 4.17) (Firra 2013)
The Gaspard 2014 trial measured bladder hyperactivity scores at
the end of nine weeks’ treatment and after six months; the data
indicated an increase in bladder hyperactivity for both groups af-
ter treatment ended but there was still no significant difference
between the groups.
Socioeconomic measures
None of the trials comparing ES ES plus another treatment to
another treatment alone reported socioeconomicmeasures or cost-
effectiveness outcomes
Adverse effects
One trial, comparing ES plus conservative treatment with conser-
vative treatment alone, reported no adverse effects in either group
(n = 51) (Schreiner 2010). There was no evidence of a difference
in adverse effects in the trial comparing ES plus drug treatment
versus drug treatment alone (RR 0.45, 95% CI 0.04 to 4.55; n
= 38) (Sancaktar 2010) and comparing ES plus PFMT plus drug
treatment versus drug treatment alone (RR 0.31, 95% CI 0.01
to 7.15) (Kaya 2011) (Analysis 4.18). The quality of evidence for
adverse effects was deemed to be very low (Summary of findings
4). The reported adverse effects were constipation, dry mouth,
headache, skin irritation.
Other outcomes
One trial reported data relating to a variety of other outcomes,
which could not be included in ameta-analysis. Percentage change
in frequency was in favour of ES plus PFMT compared to PFMT
alone (Firra 2013).
A further three outcomes were in favour of PFMT alone compared
to ES plus PFMT (Firra 2013):
• per cent change in incontinence episodes (Analysis 4.19);
• per cent change in YIPS score (Analysis 4.19);
• per cent change in pelvic floor muscle strength (Analysis
4.19).
6. Electrical stimulation plus another treatment
versus no active treatment, placebo, or sham
treatment
Two trials with 48 participants compared ES plus pelvic floormus-
cle training versus no active treatment, placebo or sham treatment
(Berghmans 2002; Firra 2013).
Primary outcome
OAB symptoms (number of participants with OAB
symptoms; number of participants with no improvement in
OAB symptoms)
None of the identified trials comparing ES plus conservative treat-
ment with no active treatment, placebo or sham reported out-
comes relating to numbers of people withOAB symptoms orUUI,
nor were there any outcomes reported relating to improvement in
symptoms or in UUI.
Quality of life (QoL) due to OAB symptoms
One trial reported no evidence of a difference in York Inconti-
nence Perception Scale scores between the groups receiving ES
plus PFMT and the groups receiving no active treatment (MD
-12.40, 95% CI -20.89 to -3.91; n = 12) (Analysis 5.1) (Firra
2013). No other outcomes relating to QoL were reported in any
of the identified trials.
Secondary outcomes
Quantification of symptoms
One trial was too small to detect a difference in incontinence
episodes (MD -1.60, 95% CI -3.57 to 0.37; n = 12) (Analysis 5.2)
or daily micturitions (MD 0.50, 95% CI -3.24 to 4.24; n = 12)
(Analysis 5.3) (Firra 2013).
No other outcomes relating to quantification of symptoms were
reported.
Clinicians’ observations
None of the trials reported objectively measured incontinence or
bladder capacity.
The trials comparing ES plus conservative treatment versus no
active treatment reported results in favour of no active treatment
for pelvic floor muscle strength (MD 7.30 cmH2O, 95% CI -
16.79. to, 31.39; n = 12) (Analysis 5.5) (Firra 2013) and for De-
trusor Activity Index score (MD 0.04, 95% CI -0.14, 0.22; n =
33) (Analysis 5.4) (Berghmans 2002).
Adverse effects
None of the trials comparing ES plus another treatment to no
active treatment reported adverse effects data.
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7. One type of electrical stimulation versus another
type of electrical stimulation
Six trials with 361 participants compared one type of ES with
another (Boaretto 2011; Bower 1998; Lobel 1998; Monga 2011;
Seth 2014; Sotelo 2011).
Primary outcome
OAB symptoms (number of participants with OAB
symptoms; number of participants with no improvement in
OAB symptoms)
One trial, comparing two different pulse widths, reported similar
satisfaction in both groups (RR for number of people not satisfied:
0.73, 95%CI 0.25 to 2.10; n = 38) (Analysis 6.1) (Boaretto 2011).
Another trial (n = 37; Lobel 1998), comparing ES once a week ver-
sus ES twice a week, reported that all participants were improved
after five weeks of treatment and that 24% (9/37) were satisfied
enough to request no further treatment. However, these data were
not reported separately for the two treatment groups.
No other primary outcomes were reported in any of the identified
trials comparing one type of ES with another.
Quality of life (QoL) due to OAB symptoms
One trial (n = 48; Seth 2014), comparing daily ES with weekly
ES, reported change in ICIQ-OAB and ICIQLUTS-QOL scores,
but did not present the data according to treatment group.
None of the other identified trials reported QoL outcomes.
Secondary outcomes
Quantification of symptoms
One trial (n = 74; Monga 2011), comparing ES patches placed
by investigators versus patches placed by participants, reported
various outcomes relating to quantification of symptoms but did
not separate the data according to treatment group.
No other outcomes relating to quantification of symptoms were
reported by any of the identified trials.
Clinicians’ observations
One trial (n = 32; Bower 1998), comparing two different ES fre-
quencies, found little evidence of a difference in maximum cysto-
metric capacity (MD -46.00, 95% CI -146.48 to 54.84) (Analysis
6.2) or volume at first desire to void (MD-54.50, 95%CI -125.75,
16.75) (Analysis 6.3).
No other clinicians’ observations were reported by any of the iden-
tified trials.
Adverse effects
One trial (n = 37; Lobel 1998), comparing ES once a week versus
ES twice a week, reported the following adverse effects across all
participants but not separated by treatment group.
• Discomfort: 16% (6/37)
• Leg tremor: 8% (3/37)
• Urinarytrct infection: 8% (3/37)
Another trial (n = 50; Sotelo 2011), comparing different ES patch
placements, reported one participant experiencing adverse effects
but did not report to which treatment group the participant be-
longed.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Electrical stimulation compared to conservative treatment for overactive bladder in adults
Patient or population: overactive bladder in adults
Intervention: Electrical stimulation
Comparison: Conservative treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with conservative
treatment
Risk with Electrical stim-
ulation
Number of participants
with no improvement in
OAB symptoms - ES ver-
sus PFMT + biofeedback
Study population RR 0.79
(0.51 to 1.21)
69
(1 RCT) VERY LOW 12
500 per 1000 395 per 1000
(255 to 605)
Moderate
559 per 1000 441 per 1000
(285 to 676)
Number of participants
with no improvement in
OAB symptoms - ES ver-
sus PFMT
Study population RR 0.97
(0.60 to 1.57)
69
(1 RCT) VERY LOW 12
618 per 1000 599 per 1000
(371 to 970)
Moderate
618 per 1000 599 per 1000
(371 to 970)
Number of participants
with adverse effects
Study population not estimable 32
(1 RCT) LOW 34
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0 per 1000 0 per 1000
(0 to 0)
Number of participants
with no improvement in
UUI - not reported
see comment see comment not estimable ( studies) -
QoL due to OAB
assessed with: King’s
Health Questionnaire
ThemeanQoL due to OAB
was 0
The mean QoL due to
OAB in the intervention
group was 129.81 unde-
fined higher (47.83 higher
to 211.79 higher)
- 69
(1 RCT) LOW 1
Cost-effectiveness - not
reported
see comment see comment not estimable ( studies) -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Small sample size, wide 95% CIs
2 Unclear risk of selection bias and performance bias. Low risk of detection bias and attrition bias.
3 Small sample size with zero events
4 Low risk of attrition bias. Unclear risk of bias in all other domains
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Electrical stimulation compared to drug treatment for overactive bladder in adults
Patient or population: overactive bladder in adults
Setting:
Intervention: Electrical stimulation
Comparison: Drug treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with drug treatment Risk with Electrical stim-
ulation
Number of participants
with no improvement in
OAB symptoms
Study population RR 0.66
(0.48 to 0.90)
265
(5 RCTs)
⊕⊕⊕©
MODERATE
444 per 1000 293 per 1000
(213 to 399)
Moderate
442 per 1000 292 per 1000
(212 to 398)
Number of participants
with no improvement in
UUI
Study population RR 0.94
(0.43 to 2.06)
64
(1 RCT)
⊕⊕©©
LOW 12
290 per 1000 273 per 1000
(125 to 598)
Moderate
290 per 1000 273 per 1000
(125 to 598)
Number of participants
with adverse effects
Study population not pooled 208
(5 RCTs)
⊕⊕©©
LOW 134
not pooled not pooled
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Moderate
not pooled not pooled
QoL due to OAB - not re-
ported
ThemeanQoL due to OAB
was 0
ThemeanQoL due to OAB
in the intervention group
was 0 undefined (0 to 0 )
- 35
(1 RCT)
-
Cost-effectiveness - not
reported
see comment see comment not estimable ( studies) -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Small sample size with wide 95% confidence intervals
2 Unclear risk of performance and detection bias
3 Trials used different drugs which might have different mechanism of action and therefore different side effects
4 Unclear risk of selection, performance, detection and attrition bias
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Electrical stimulation plus another treatment compared to other treatment alone for overactive bladder in adults
Patient or population: overactive bladder in adults
Intervention: Electrical stimulation plus another treatment
Comparison: other treatment alone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with other treat-
ment alone
Risk with Electrical stim-
ulation plus another
treatment
Number of participants
with adverse effects
Study population not pooled 120
(3 RCTs) VERY LOW 12
not pooled not pooled
Moderate
not pooled not pooled
Number of participants
with no improvement in
UUI - not reported
see comment see comment not estimable ( studies) -
QoL due to OAB - not re-
ported
see comment see comment not estimable ( studies) -
Cost-effectiveness - not
reported
see comment see comment not estimable ( studies) -
Number of participants
with no improvement in
OAB symptoms assessed
with: number of partici-
pants not satisfied
Study population RR 0.70
(0.39 to 1.24)
82
(2 RCTs) VERY LOW 134
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429 per 1000 300 per 1000
(167 to 531)
Moderate
358 per 1000 251 per 1000
(140 to 444)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Small sample sizes and wide 95% CI
2 Low risk of selection bias due to randomisation and low risk of attrition bias. Unclear risk of selection bias due to allocation concealment.
Unclear risk of performance, and detection bias.
3 Estimates of treatment effect are in different directions
4 Unclear risk of selection, performance and detection bias. Low risk of attrition bias.
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D I S C U S S I O N
Summary of main results
To the best of our knowledge, this is the first systematic review
to synthesise all available data from randomised controlled trials
(RCTs) relating to the effectiveness of electrical stimulation (ES)
with non-implanted devices compared with any other treatment
for overactive bladder (OAB). The results of the review suggest
that ES shows promise in treating OAB.
There is moderate-quality evidence that ES is more effective than
no active treatment, placebo or sham in the improvement of OAB,
urgency urinary incontinence (UUI) and quality of life (QoL)
(Summary of findings for the main comparison). This is largely
supported by evidence from secondary outcomes, such as incon-
tinence episodes, frequency and detrusor overactivity. However,
there was insufficient evidence to identify whether one type of ES
is more effective than any other in improving OAB, UUI or QoL,
or whether one type of ES is associated with fewer adverse effects
than any other.
ES appears to be more effective than drug treatment in improving
OAB symptoms (with moderate-quality evidence, Summary of
findings 4), but there was no evidence of a difference between ES
and drugs in improving UUI or other secondary outcomes. Fur-
thermore, ES administered in addition to drug treatment may be
more effective in improving OAB symptoms than ES alone, sug-
gesting that drug treatment may have an enhancing effect on ES,
although the quality of evidence is very low (Summary of findings
4). In general, the trials comparing ES to drug treatment were not
sufficiently powered to lead to robust conclusions regarding the
primary outcome of improvement of OAB or UUI. However, ES
appears to be associated with fewer adverse effects than drug treat-
ment, although again, the quality of evidence is low (Summary of
findings 4).
There was little evidence to suggest any difference in effectiveness
between ES and conservative treatment, or that the addition of ES
to conservative treatment was better than conservative treatment
alone in improving OAB symptoms. Furthermore, the quality of
the evidence identified was very low (Summary of findings 2),
therefore no conclusions can be drawn.
Similarly, there was insufficient evidence to estimate the effect of
ES plus another treatment versus no active treatment, placebo or
sham; this is based on two small trials of lowmethodological qual-
ity. Given the effectiveness of ES alone compared to no active treat-
ment, it is likely that the true effect of ES plus another treatment
is at least equivalent to ES alone.
Based on the small number of trials reporting outcomes at the end
of treatment as well as after a longer follow-up period, it appears
that the effect of ES diminishes after the end of treatment. How-
ever, this was also the case for most other interventions and is likely
to be due to the nature of the condition. Where ES was found to
be more effective than a comparator intervention at the first mea-
surement point. this trend was generally found to be maintained
at the longer-term follow-up. Nonetheless, this evidence should
be considered in the context that the outcomes measured at mul-
tiple time points in this small set of trials tended to be objective
measures rather than the more reliable and meaningful subjective
report of symptoms.
None of the trials reported any socioeconomic or cost-effective-
ness outcomes. It is important to consider cost-effectiveness in
any intervention to assist policymakers, healthcare providers and
patients in decision-making with regard to treatment. Future tri-
als should include a measure of costs from both the provider and
patient perspective.
Overall completeness and applicability of
evidence
The comprehensive search strategy, contact with clinical experts
and the inclusion of unpublished data obtained from trial au-
thors mean that the body of evidence presented here is as com-
plete as possible, notwithstanding the limitations of bibliographic
databases, whereby it is possible that not all potentially eligible
trials are identifiable due to inadequate indexing.
However, the included studies do not address all of the objec-
tives of the review because many of them did not report data in
a usable way or did not measure the primary outcomes, i.e. sub-
jective report of symptoms. Five trials reported urodynamic out-
comes only (Berghmans 2002; Bower 1998; Vahtera 1997; Walsh
2001; Yamanishi 2000b), which is of limited use because sub-
jective, patient-reported cure or improvement should take prece-
dence over objective, clinician-observed outcomes; for instance, a
patient may still have OAB according to objective measurements
but if their subjective assessment is that of no bothersome symp-
toms then usually no further treatment will be required. Future
trials should ensure appropriate subjective outcomes are measured
and reported.
Another key outcome, QoL associated with OABor incontinence,
was inadequately addressed by the included studies. While 16 of
the 51 trials incorporated a validated measure of QoL it was dif-
ficult to discern a clear picture regarding clinically meaningful re-
sults. Two trials included definitions of clinical significance relat-
ing to the QoL instruments used (Oldham 2013; Svihra 2002);
the QoL findings of those trials were not clinically meaning-
ful. The remaining trials that measured QoL were unclear about
the clinical significance of their QoL instruments (Bellette 2009;
Finazzi-Agrò 2010; Firra 2013; Gaspard 2014; Kaya 2011; Peters
2010; Sancaktar 2010; Schmidt 2009; Schreiner 2010; Seth 2014;
Souto 2014; Vecchioli-Scaldazza 2013; Wang 2009; Wang 2004).
It is therefore difficult to form any conclusions regarding the po-
tential for ES to improve QoL in relation to OAB.
The paucity of adverse effects data in the included trials meant that
there was insufficient evidence to identify a difference in adverse
effects between ES and no active treatment, placebo or sham, or
between ES plus another treatment and the other treatment alone.
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Adverse effects were not reported at all in the following compar-
isons: ES versus conservative treatment; ES plus another treatment
versus no active treatment/sham/placebo. Given that the included
trials do not provide evidence of a difference in effectiveness be-
tween conservative treatment, which is often the first-line treat-
ment for OAB, and ES, it would be useful to be informed about
possible adverse effects.
Quality of the evidence
Despite the large number of identified trials (51), the amount
and quality of evidence is insufficient to reach a robust conclu-
sion regarding the effectiveness of ES compared to other active
treatments. The total number of participants was relatively low
(3443) due to the small sample sizes of individual trials, which led
to downgrading the quality of evidence in some instances because
underpowered trials are likely to have a greater degree of impreci-
sion. Small sample sizes in individual trials can also lead to under-
powered meta-analyses, which then give inconclusive overall esti-
mates of effect. Another key methodological limitation of many of
the included trials was the use of objective rather than subjective
assessment of symptoms. Given that we have identified a further
14 eligible trials, with 1001 participants, to be included in the
first update of this review, it may be that the overall quality of
the evidence will be higher when data from these trials are meta-
analysed.
Assessing the risk of bias and methodological quality of the in-
cluded trials was limited by the extent to which adequate details
were provided in reports of trials. Future trials should adhere to
CONSORTguidelines to ensure clarity and reproducibility in the
reporting of methods. Risk of selection bias through randomisa-
tion and allocation concealment was generally unclear because of
insufficient reporting. The risk of performance bias was also rela-
tively unclear because of a lack of information to judge whether or
not participants, healthcare providers and outcome assessor were
adequately blinded. In many trials, it would not be possible to
blind participants; however, an element of risk of bias remains
where participants are not blinded because self-reported, subjec-
tive outcomes could be affected by participants’ perception of the
intervention received, which leads to uncertainty regarding the
extent to which the estimate of effect is truly attributable to the
intervention.
Potential biases in the review process
Every attempt was made to reduce the risk of bias in the review
process, with broad inclusion criteria and a comprehensive search
strategy to identify eligible trials. There were no language restric-
tions and translations of non-English trials were obtained wher-
ever possible. The risk of bias was furtherminimised by two review
authors undertaking independent screening of search results and
independent data extraction.
However, unclear reporting of trial methods and data, and subse-
quent problems obtaining clarifications from trial authors limited
the extent to which all relevant data from the identified trials could
be compared meaningfully.
Agreements and disagreements with other
studies or reviews
To the best of our knowledge, this is the first systematic review of
RCTs to investigate the effectiveness of ES with non-implanted
devices compared to any other treatment for OAB. A systematic
review focusing on ES of the pelvic floor found evidence in favour
of ES for urinary incontinence, with or without OAB symptoms
(Jerez-Roig 2013). Similarly, a systematic review investigating ES
for any kind of urinary incontinence in women (Schreiner 2013)
found evidence suggesting that ES was more effective than other
treatments for UUI, but that the evidence for stress urinary incon-
tinence (SUI) or mixed urinary incontinence (MUI) was much
less clear. As UUI is one of the key symptoms of OAB, our find-
ings with regard to OAB can be taken together with the reviews by
Scheiner and colleagues and Jerez-Roig and colleagues to indicate
that ES is effective in treating OAB symptoms. Additionally, our
findings are in accord with those of Berghmans and colleagues
(Berghmans 2013), whose systematic review of ES for any kind
of urinary incontinence in men found limited evidence that ES
was more effective than sham treatment and that ES enhanced the
effectiveness of pelvic floor muscle training (PFMT) in the short
term.
Schreiner and colleagues’ findings regarding different types of ES
were similar to ours in that the heterogeneity of ES interventions in
the identified trials was such that no conclusions could be drawn.
The findings of our review lend further weight to another sys-
tematic review (Rai 2012) comparing drug treatment with other
active treatments for OAB, which found limited evidence that
ES more effective than drugs in improving OAB symptoms and
that there were fewer adverse effects associated with ES than with
drug treatment. Our review identified eight additional trials not
included by Rai and colleagues; consequently, the conclusions of
our review add strength to the evidence base for ES compared to
drug treatment.
The review by Rai and colleagues also found that drugs were more
effective than conservative treatment; therefore the evidence iden-
tified in our review in favour of ES compared to drug treatment
suggests that, in turn, ES may also be more effective than conser-
vative treatment.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
In conducting this review we have attempted to answer several
clinical questions.
• Is electrical stimulation (ES) with non-implanted devices
better than no active treatment, placebo or sham treatment?
Moderate-quality evidence suggests that ES is more effective than
no active treatment, placebo or sham treatment in improving over-
active bladder (OAB) symptoms, urgency urinary incontinence
(UUI) and OAB-related QoL.
• Is one type of ES with non-implanted devices better than
another?
No clear evidence was identified to suggest that one type of ES
was more effective than others. There was substantial heterogene-
ity in the types of ES interventions in the included studies. The
variety of aspects of treatment such as duration and frequency,
duty cycle, current, route of administration (e.g. vaginal, rectal)
and approaches of electrodes (e.g. transcutaneous, percutaneous)
could produce different effects through their different mecha-
nisms, which means that there are many variables to take into ac-
count when considering the effectiveness of one type of ES com-
pared to another and no conclusions could be drawn based on the
identified evidence.
• Is ES with non-implanted devices better than conservative
treatment?
No evidence was identified to indicate any difference in effective-
ness between ES and conservative treatment in terms of improving
OAB symptoms, improving QoL or in terms of adverse effects.
• Is ES with non-implanted devices better than drug
treatment?
Moderate-quality evidence suggests that ES is more effective than
drug treatment in improving OAB symptoms, but for improv-
ing UUI and OAB-related QoL there was no evidence to suggest
a difference. Low-quality evidence suggests that ES incurs fewer
adverse effects than oxybutynin and tolterodine but there was no
evidence of a difference between ES and trospium hydrochloride.
• Is ES with non-implanted devices combined with other
treatments better than other treatments alone?
There was insufficient evidence to indicate any difference in effec-
tiveness of ES combined with other treatments compared to other
treatments alone.
Implications for research
This review highlights the urgent need to conduct well-designed
trials in this field. It is important that future trials should be ade-
quately powered and should measure th following.
• Subjective perception of symptomatic improvement
• Head-to-head comparisons of different types of ES
• Cost-effectiveness of ES compared to other active
treatments
• Clinically meaningful measurement of OAB-related QoL
• Adverse effects data
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaronson 1995
Methods Study design: RCT.
Multicentre or single-centre: not reported.
Setting: not reported.
Period: October 1992 to January 1994
Sample size: Not reported.
Follow-up: unclear
Participants N: 47 randomised and analysed.
Age: 24-82 years.
Sex: women.
Inclusion criteria: genuine stress urinary incontinence (GSUI) or detrusor instability
(DI)
Exclusion criteria: not reported.
Interventions For detrusor overactivity incontinence women only (DI)
A (n = X): Probanthine
B (n = X): electrical stimulation (ES)
2nd RCT in patients with GSUI
C (?): PFMT
D (?): ES
Outcomes Cure - defined as cessation of incontinence. A: NR. B:NR.
Improvement defined as reduction in frequency of voids per 24 hours by ≥ 50%, or ≤
10 voids per 24 hours, or decrease number of pads per 24 hours by ≥ 50%
Cured or improved: A (n = X): unclear (50% ‘responded well’), B (n = X) 69% C (n =
X) (44%), D (n = X) (66%)
Notes No useable data.
Authors contacted for further data.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
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Aaronson 1995 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported.
Amaro 2006
Methods Study design: RCT.
Multicentre or single-centre: single-centre.
Setting: Botucatu Medical School, Unesp - Univ Estadual Paulista
Period: January 2001 to February 2002.
Sample size: “Based on outcome measurements with no numerical variable…the statis-
tical test sample size had previously been established as at least 40 women.”
Follow-up: 7-week treatment period, follow-up appointments one month after end of
treatment
Participants N: 40 randomised
Mean age:
A: 49.0 (range 41 to 79)
B: 47.0 (range 40 to 78)
Sex: women
Inclusion criteria: symptoms of predominant urge incontinence
Exclusion criteria: vaginal prolapse greater than grade II (Baden), retention complaint or
obstruction diagnosis during USD, urinary infection, changes in cutaneous sensitivity,
metal implants, and neurological complaints
Interventions A (n = 20): electrostimulation. Three 20 minute sessions per week on alternate days over
a 7-week period, performed using Dualpex Uro996. Frequency at 4 Hz, a 2-to 4-s work
rest cycle and a 0.1us pulse width. The bipolar square wave cold be delivered over a range
of 0 -100mA. Intensity was controlled according to patient discomfort level feedback
B (n = 20): sham. Same type of vaginal probe with wires disconnected so no electrical
energy was supplied
Outcomes Number of micturitions per 24 hours (mean, SD*, N): A: 7.0 (1.78), 20 B: 7.5 (1.78),
20. P = 0.38
1 hour PAD test (g): A: 1.05 B: 1.13
Number of participants with urgency urinary incontinence: A: 3/20 (15%), B: 6/20 (31.
5%)
Number of participants ‘satisfied’: A: 16/20 (80%), B: 13/20 (65%)
Reduction in ‘analog wetness sensation’: A: 31.5%. B: 26.9%
Reduction in ‘analog discomfort sensation’: A: 39.7%
B: 24.5%
Pelvic floor muscle strength measured with portable perineometer (Dynamed) (cmH2O)
(mean, SD, N): A: 53.8 (18.6), 20. B: 46.8 (12.5), 20
Vaginal cone weight test (g) (mean, SD, N): A: 4.0 (1.3), 20. B: 2.0 (1.1), 20
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Amaro 2006 (Continued)
Notes No SDs reported (except for 2 outcomes).
*SD calculated by FS using means and P value.
No evidence of source of data in review
Information received from study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “In the Randomization the participants in
each groups were raffled” (from correspon-
dence with author)
Allocation concealment (selection bias) Unclear risk “the allocations were concealed because a
nurse, at each session, was responsible for
carrying out the random assignment of pa-
tients” (from correspondence with author)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded. ES sessions carried
out by physiotherapist and outcome as-
sessment carried out by different personnel
(from correspondence with author)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ES sessions carried out by physiotherapist
and outcome assessment carried out by
different personnel (from correspondence
with author)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported, % given with-
out denominators, unclear if all partici-
pants present for follow-up
Arruda 2008
Methods Study design: RCT
Multicentre or single-centre: single-centre.
Setting: Department of Uroginecology, Federal University of São Paulo
Period: August 2001 to September 2005
Sample size: justified (a power calculation was performed based upon a predicted min-
imum difference of eight episodes of urinary leakage, with a significance level of 0.05,
yielding a power estimate of 90% for a sample size of 20 women per each group)
Follow-up: 12 weeks’ treatment, 1-year follow-up
Participants N: 77 randomised, 64 analysed.
Mean age (SD): A 51.9 (13,4). B 51.5 (11.4). C 54.1 (11.6).
Sex: women.
Inclusion criteria: OAB and DO
Exclusion criteria: persistent urinary tract infection, inability to comply with regular
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Arruda 2008 (Continued)
follow-up visits, current pregnancy, postvoid residual volume greater than 100 mL,
contraindications to anticholinergic therapy, cardiac pacemaker, type III stress urinary
incontinence, uncontrolled metabolic conditions or indwelling catheterisation, using
medications including anticholinergic drugs, calcium antagonists, β agonists, dopamine
agonists, striated muscle relaxants, or oestrogens
Interventions A (n = 26): oxybutynin immediate release 5 mg twice daily for 12 weeks
B (n = 25): electrical stimulation (FES). Ambulatory stimulation applied vaginally by a
physiotherapist, twice a week, for 20 minutes at each session using 1 ms of intermittent
biphasic waves, frequency 10Hz. Current intensity ranged from10 to 100mA, according
to participant tolerance to the procedure
C (n = 26): exercises (PFT), performed twice a week in orthostatic, sitting, and supine
positions. Each session had a total duration of 45 minutes. A total of 40 last (2 and 5
s) and 20 sustained (10s) contractions with an equal period of relaxation between them
were administered by a physiotherapist in the outpatient setting
Outcomes Participants with urgency symptoms (subjective):
A 8/22. B 10/21. C 9/21
Participants not satisfied (subjective):
12 weeks: A 5/22. B 10/21. C 5/21.
1 year: A 12/22. B 17/21. C 12/21
Participants not cured (objective evaluation: urodynamics):
A 14/22. B 9/21. C 10/21.
Number of leakage episodes per 24 hours (mean, SD, N):
A 7 (10.6), 22. B 7.9 (13.7), 21. C 7.8 (15.3), 21.
Number of micturitions per 24 hours (mean, SD, N):
A 6.4 (1.6), 22. B 7.9 (2.63), 21. C 7.1 (2.1), 21.
Number of nocturia episodes per night (mean, SD, N):
A 0.9 (0.8), 22. B 1.2 (1.3), 21. C 1.0 (1.1), 21.
Number of pads used per 24 hours (mean, SD, N)
A 0.9 (1.5), 22. B 0.9 (1.7), 21. C 0.8 (1.3), 21.
Post micturition residual volume, mL (mean, SD, N):
A 4.8 (9.4), 22. B 1.1 (2.5), 21. C 2.1 (3.5), 21.
Maximum cystometric capacity, mL (mean, SD, N):
A 517.3 (191.7), 22. B 436.7 (178.7), 21. C 489.0 (141.3), 21
Volume at FDV (mean, SD, N):
A 157.3 (63.8), 22. B 123.8 (59.0), 21. C 137.6 (76.7), 21.
*Involuntary detrusor contraction volume, mL (mean, SD, N):
A 188.6 (183.2), 22. B 173.3 (112.4), 21. C 114.3 (154.2), 21
Involuntary detrusor contraction maximal pressure, mmH2O (mean, SD, N):
A 19.6 (20.9), 22. B 22.4 (6.6), 21. C 17.2 (25.5), 21.
Adverse effects:
Dry mouth: A 16/22. B, C NR
Difficulty on micturition: A 2/22. B, C NR
Dizziness: A 1/22. B, C NR
Blurred vision: A 1/22. B, C NR
Constipation: A 1/22. B, C NR
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Notes *Value for group B reported in paper as 73.3; queried with author and correct value is
173.3
We contacted the main author to clarify methodological aspects of the study and request
further information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “blindly randomized to one of the three
treatment groups”
Additional information from author corre-
spondence: ‘Patients were randomised us-
ing a table of random numbers generated
by a statistical program on a computer’
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Additional information from author corre-
spondence: “patients and researchers knew
to which group the patients belonged”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Additional information from author corre-
spondence:“‘Data were analysed by a statis-
tician who did not know which group the
patients belonged to.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential withdrawal. Adequate ex-
planation for withdrawals
Barroso 2002
Methods Study design: RCT.
Single-centre: not reported.
Setting:Department ofGynecology andObstetricsHospital dasClínicas de PortoAlegre,
Rio Grande do Sul, Brazil
Period: March 2000 to August 2001.
Sample size: 36 participants for a power of 80% and a 2:1 ratio
Follow-up: 6 months
Participants N: 36
Sex: women.
Mean (SD) age:
A: 54 (9.5)
B: 56 (12.2)
Inclusion criteria: SUI, UUI or MUI, understanding and signing a letter of informed
consent
Exclusion criteria: prolapse or first degree urogenital prolapse, intrinsic sphincter defi-
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ciency, cardiac pacemaker, pregnancy or in the puerperal period, post-menopausal cli-
macteric’s symptoms and signs of urogenital atrophy, genitourinary surgery during the
previous 6 months, previous ES of the pelvic floor, medication chronically known to
possibly change voiding function, change in the dose or if they had begun to use a new
medication in the last 3 months, or during treatment with ES, reflex urinary inconti-
nence, paradoxical urinary incontinence, urinary incontinence of intravesical obstruc-
tive factor, urinary incontinence caused by overflow, characterised by the presence of a
large urinary residual volume, urgency incontinence who had with medication treatment
with medication during last three months, or during treatment with ES; reflex urinary
incontinence (clear presence of neurological lesions); paradoxical urinary incontinence
(presence of intravesical obstructive factor); urinary incontinence caused by the presence
of a large urinary residual volume; patients with urge incontinence who had treatment
with medication during last three months
Interventions A: transvaginal electrical stimulation (n = 24). Battery-powered, portable device, 20 or
50 Hz, a pulse width of 300 ms, with asymmetrical biphasic pulses, an adjustable current
intensity (0-100 mA), a 1s rise time, sustained for 5 s and resting for 5 s. A time of-use
counter allowed a check on patient compliance with treatment, because it stored in the
microcontroller memory the total time of use, corresponding to the time during which
current actually circulated through the electrodes. Two 20-minute sessions per day while
recumbent, for 12 weeks
UUI or MUI: equipment programmed for 20 Hz
Stress urinary incontinence: equipment programmed for 50 Hz.
UUI or MUI: equipment programmed for 20 Hz
SUI: equipment programmed for 50 Hz.
B: sham (n = 12). Identical equipment and regimen but without electrical stimulus
All participants requested to complete 3-day voiding diary at beginning of study and
again at 12 weeks’ follow-up
Outcomes Number of participants cured/improved at 12 weeks:
A: 21 (88%) B: NR
Number of voids per 24 hours (mean (SD) N):
A: 7.5 (2.0) 24. B: 10.5 (2.8) 12
Number of nocturia episodes (mean, SD, N):
A: 1.1 (0.5), 24. B: 2.3 (0.9), 12.
Number of incontinence episodes per 24 hours (mean, SD): A: 1.3 (1.0) 24. B: 3.0 (0.
9) 12
Number of uninhibited contractions per 24 hours (mean, SD): A: 2 (8), 24. B: 4 (NR)
Maximum bladder capacity (mean, SD, N):
A: 425.0 mL (97.8), 24. B: 316.7 mL (71.8), 12.
Notes Compliance: 60 hours of equipment use was expected.
A: 46 hours
B: 40 hours
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The participants were randomized before
the study by drawing lots”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The participants were randomized before
the study by drawing lots, with no partic-
ipation by the examiner who, at the start
of the treatment of each patient, was al-
ready receiving the group determined by
randomization (study or control). Likewise
the patients did not know intowhich group
they had been placed (active or placebo)
. The patients in the control group were
evaluated at different times from the study
group, to avoid any exchange of informa-
tion among them”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Urodynamic evaluations carried out by ex-
aminer unaware of the study. Participants
also unaware of intervention allocated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported
Bellette 2009
Methods Study design: RCT.
Multicentre or single-centre: single-centre.
Setting: Female Urology Clinic of the Hospital das Clínicas at Campinas (HC/UNI-
CAMP)
Period: not reported.
Sample size: not reported.
Follow-up: 4 weeks
Participants N: 37 randomised and analysed.
Mean age: 47.73 (10.90)
Sex: women.
Inclusion criteria: 18 to 85 years, symptoms of OAB for > six months, voiding frequency
> eight micturitions daily, episodes of nocturia and/or urgency
Exclusion criteria: pregnancy, neurological problems, accentuated dystopias (stages II
and III in the definitions of ICS), urinary tract infection and urinary stress incontinence
Interventions A (n = 21): ES. Transcutaneous posterior tibial nerve stimulation. 8 sessionswithDualpex
device 961, 30 minutes twice a week
B (n = 16) sham. Electrodes placed without electricity.
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Outcomes Participants with urgency:
A 9/21. B 10/16.
Frequency of micturitions (mean, N)*:
A 8.29, 21 B 10.55, 16
Decrease in frequency and urgency:
A 62.5%. B 42.8% (P < 0.05)
OAB-q severity score:
A 31.72 (18.25), 21. B 51.21 (32.11), 16.
OAB-q total score:
A 83.99 (16.99), 21. B 66.63 (25.06), 16.
Nocturia episodes:
A 1.14 (1), 21. B 2.06 (1.2), 16.
Notes *Contacted author to ask for SDs, no reply. Estimated SD used in meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ‘The randomization process was made by
the FCM’s statistics department’
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ‘The evaluations were carried out by the in-
vestigator or the physiotherapist, and treat-
ment was performed by the same person
who evaluated the patient, thus creating a
bond with the physiotherapist.’
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ‘The evaluations were carried out by the in-
vestigator or the physiotherapist, and treat-
ment was performed by the same person
who evaluated the patient, thus creating a
bond with the physiotherapist.’
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in
analysis. ‘All women were submitted to
eight sessions of therapy, all the question-
naires were completed and none of the
women failed to attend the sessions more
than 3 times. The reasons for missing ses-
sions were very variable, but did not alter
the results of the study.’
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Berghmans 2002
Methods Study design: RCT.
Single-centre.
Setting: Hospital and private clinic (University Hospital Maastricht, Department of
Urology)
Period: not reported.
Sample size: a level of significance of 95%, a power of 80%, an expected dropout rate of
10%, and an expected improvement of bladder overactivity status of treatment groups
in comparison with non treatment group, expressed as a decrease of approximately 30%
in the Detrusor Activity Index (DAI), 20 patients in each of the four groups had to be
recruited. Therefore, the intended sample size was set on 80 persons
Follow-up: unclear (9 weeks?)
Participants N: 80 randomised, 68 participated and analysed
(12 excluded as randomised ‘erroneously’)
Mean (SD) age:
A: 50.5 (11.8)
B: 55.6 (14.8)
C: 61.9 (13.5)
D: 52.3 (15.4)
Sex: women.
Inclusion criteria: Detrusor Activity Index > 0.5; > 18 years, female, drug-free interval
of at least four weeks before start of the study for the following drugs and; anticholinergic,
beta sympathicomimetic, alpha-blocker and psychopharmacological agents
Exclusion criteria: mechanical intravesical obstruction, urinary calculus, repetitive symp-
tomatic UTI (>3X per year), colpitis, clinical evidence of disordered action of heart
(Lown III), pacemaker, pregnancy of lactating period, inability to comply with follow-
up, treatment with physical therapies within three months before start of therapy, neu-
rogenic or congenital disorders resulting in urinary incontinence (e.g spina bifida), psy-
chological disorders, irritation of the vagina (consult with the general practitioner and
patient), poor adjustable diabetes mellitus: last HbA1C > 10, contra-indication for the
use of an intravaginal or anal electrode, not able to understand Dutch, not able to travel
Interventions A: controls (n = 14)
B: Lower Urinary Tract Exercises (LUTE) (n = 18). One session per week for nine
weeks. Patient information and education; bladder training; specific Pelvic Floor Muscle
Exercises (PFME) aiming at detrusor inhibition reflex (DIR); toilet behaviour aiming at
the aspects of the micturition process itself
C: functional electrical stimulation (n = 17). FES was applied vaginally through plug
mounted electrodes. The maximum level of the electrical stimulation was 100 mA (Ieff =
6mA), patient was instructed to use themaximal characteristics were (frequency modula-
tion of 0.1 s trains of rectangular biphasic 200 µs long pulses which varied stochastically
between 4 and 10 Hz). Duration of treatment unclear
D: FES + LUTE group (n = 19). Same LUTE program plus an additional weekly FES
session (for 9 weeks)
Dropouts: A ?0, B 5, C 3, D 2
Outcomes Detrusor Activity Index (DAI): urodynamic variables of ambulatory cystometry com-
bined with data from micturition diary (i.e. condition-specific measure; 0 to 1 scale
where higher = worse) (mean, SD):
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A 0.80 (0.26) 14, B 0.62 (0.33) 18, C 0.57 (0.33) 17, D 0.84 (0.27) 19
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”‘Randomization was done in blocks of
four using opaque and sealed envelopes“
Allocation concealment (selection bias) Low risk ”Randomization was done in blocks of four
using opaque and sealed envelopes“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Besides the patient and the physical thera-
pist all others, involved in randomisation,
registration and evaluationwere blinded for
group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Besides the patient and the physical thera-
pist all others, involved in randomisation,
registration and evaluationwere blinded for
group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout.
A total number of 10 women dropped out
of the trial. One woman stopped before
start oftherapy, because she considered the
burden of investigation to high.During the
treatment period, five women stopped be-
cause illness (two in group II and two in
group III or allegedly reasons of too much
burden felt (one in group IV)
‘’Missing data in the set of post-treatment
DAI-scores were substituted by post-treat-
ment means of the empirical data accord-
ing to the intention-to-treat principle.”
Boaretto 2011
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: Brazil
Period: August 2008 to 2010
Details of sample size calculation: NR
Follow-up: 4 weeks
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Participants N: 73 randomised, unclear how many included in analysis.
Mean (SD) age: 61.3 (NR)
Sex: women
Inclusion criteria: women with OAB
Exclusion criteria: NR
Interventions A (n = 22) PFMT. 12 sessions. Group exercises performed in sitting, standing and supine
positions with 20 contractions of 2s, 10 contractions of 5s and 5 contractions every 10s
B (n = 22) electrical stimulation, pulse width 200 microseconds. Posterior tibial nerve
stimulation transcutaneous (TPTNS). Frequency 10 Hz.12 30-minute sessions
C (n = 16) functional electrical stimulation with vaginal electrode, pulse width 500
microseconds. Frequency 10 Hz.12 30-minute sessions
D (n = 13) oxybutynin. 5 mg immediate release twice daily for 12 weeks
Outcomes Satisfaction:
A 91% (20/22). B 77% (17/22). C 69% (11/16). D 61.5% (8/13)
[not satisfied: A 2/22. B 5/22. C 5/16. D 5/13.]
Notes Data presented for urinary frequency, nocturia, urgency and urgency incontinence but
not usable
Unable to find contact details for authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized into four treatment groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported. Outcome data
presented without denominators or SDs
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Methods Study design: RCT.
Multicentre or single-centre: not reported.
Setting: UK.
Period: not reported.
Sample size: not reported.
Follow-up: six weeks.
Participants N: 30 randomised, 28 analysed
Sex: men and women
Mean age: 84.2 (10.0)
Inclusion criteria: men and women > 65 in residential care home settings or sheltered
accommodation with bothersome LUTS, urinary incontinence, faecal incontinence, or
constipation; capacity to provide ongoing informed consent to participate
Exclusion criteria: pacemaker in situ, leg ulcers or broken skin on lower limb, periph-
eral vascular disease, reduced/absent sensation at the electrode sites, moderate or severe
cognitive impairment or learning difficulties, UTI on assessment, or clinical diagnosis
of only SUI
Interventions A (n = 15) Percutaneous tibial nerve stimulation (PTNS). Two 30-minute sessions per
week for six weeks. Frequency 10 Hz and pulse width 200 ms in continuous mode. The
intensity level of the stimulation current range (0-50 mA)
B (n = 13) Sham. Same procedure with stimulation current reduced to 2 mA
Outcomes Number of participants with no improvement in incomplete bladder emptying:
A 7/15, B 12/13
Number of participants with no improvement in voiding frequency:
A 4/15, B 7/13
Number of participants with no improvement in urgency:
A 4/15, B 9/13
Number of participants with no improvement in nocturia:
A 8/15, B 10/13
Number of participants with no improvement in weak urinary stream:
A 6/15, B 12/13
Number of participants with no improvement in intermittency:
A 10/15, B 11/13
Number of participants with no improvement in urinary straining:
A 9/15, B 12/13
Number of participants with no improvement in frequency of UI episodes:
A 8/15. B 11/13.
Number of participants with no improvement in amount of urine leaked:
A 7/15. B 11/13.
Number of participants with no improvement in interference with everyday life:
A 6/15. B 7/13.
Number of participants with no improvement in constipation:
A 14/15, B 6/13
Number of participants with no improvement in bowel urgency:
A 11/15, B 12/13
Number of participants with no improvement in faecal leakage:
A 8/15, B 10/13
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Reduction in American Urological Association Symptom Index (AUASI) score (median,
IQR, N):
A -7 (-8 to -3), 15. B 1 (-1 to 4), 13. (P < 0.001, Mann-Whitney U 16.5000, Z -3.742)
Reduction in International Consultation on Incontinence Questionnaire Urinary In-
continence Short Form (ICIQ-SF) score (median, IQR, N):
A 2 (0 to -6), 15. B 0 (-3 to 3), 13. (P = 0.132)
Number of participants with no improvement in ICIQ-SF score:
A 5/15. B 7/13
Notes Two participants had predominantly faecal incontinence.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “online randomization service”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded. “Staff were blind to
the group allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Fidelity to the protocol was high and 28 of
the 30 participants completed the 12 ses-
sion course, with two discontinued at ses-
sion five because they developed infections”
Bower 1998
Methods Study design: RCT
Multicentre or single-centre: single
Setting: Australia
Period: January 1996 - February 1997
Details of sample size calculation: 40% volume increase and 35% decrease in maximum
detrusor pressure 16 participants would be required per group for an 80% chance of
detecting significant change
Follow-up: immediately following single ES session
Participants N:
DO group: 48 randomised
Urgency group: 31 randomised
Mean (SD) age: overall 55.4 (16.8). DO group: 56.5 (16.8). Urgency group: 56.3 (16.
9)
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Sex: women
Inclusion criteria: DO or urgency
Exclusion criteria: UTI, pregnancy, cardiac pacemaker, impaired cognition, neurogenic
bladder dysfunction or cystocele beyond the introitus
Interventions DO group
A1 (n = 16) transcutaneous electrical nerve stimulation - suprapubic placement. Fre-
quency 150 Hz, 200 microsecond pulse width
B1 (n = 16) transcutaneous electrical nerve stimulation - sacral placement. Frequency
10 Hz, 200 microsecond pulse width
C1 (n = 15) sham electrical stimulation.
Urgency group:
A2 (n = ?) transcutaneous electrical nerve stimulation - suprapubic placement. Frequency
150 Hz, 200 microsecond pulse width
B2 (n = ?) transcutaneous electrical nerve stimulation - sacral placement. Frequency
10Hz, 200 microsecond pulse width
C3 (n = ?) sham electrical stimulation.
Outcomes Vol. at FDV (mean, SD, N):
A1 208.5 (132), 16. B1 154 (61), 16. C1 186 (77), 15.
A2 180 (51). B2 111 (37). C2 138 (51). (n not reported)
Max. cystometric capacity (mean, SD, N):
A1 352 (144), 16. B1 305 (146), 16. C 313.5 (81), 15.
A2 291 (51). B2 241 (53). C2 285 (45). (n not reported)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized to 3 groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both the supervising urogynaecologist
and the patient were blind to group alloca-
tion”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data for urgency group not presented with
numbers of participants, unclear howmany
in urgency group were randomised to each
intervention
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Brubaker 1997
Methods Study design: RCT.
Multicentre or single-centre: 4 centres.
Setting: Rush-Presbyterian-St.Luke´ sMedical Center, Chicago;MethodistHospital, In-
dianopolis; Greater Baltimore Medical Center; and the Oregon Health Science Univer-
sity, Portland
Period: not reported.
Sample size: not reported.
Follow-up: 8 weeks.
Participants N: 148 enrolled, 121 randomised and analysed.
Mean (SD) age for all participants (not stratified by GSUI/DO):
A 56 (11.9)
B 57.7 (12.4)
Sex: women.
Inclusion criteria: women with symptoms or urodynamic evidence of genuine stress
incontinence or detrusor instability
Exclusion criteria: urinary incontinence other than genuine stress incontinence, detrusor
instability, ormixed incontinence. Age <25 years, leakage episodes≤ 3/weeks, inadequate
cognitive ability investigator judgment), infected urine, anatomic defect that precluded
use of device, postvoid residual > 100 mL, implanted electric device, genitourinary
surgery < 6 months previously, medication alteration≤ 3 months previously, anticipated
geographic relocation during study
Interventions For DO and mixed women only (n = 61):
A (n=33) transvaginal electric stimulation.Device: InCareMicrogyn II. 20Hz frequency,
2-second 4-second work-rest cycle, pulse width 0.1-us. Bipolar square wave could be
delivered over a range of 0 to 100mA. 20 minutes daily
B (n = 28) sham. Identical device with disconnected wire so no electricity supplied. 20
minutes daily
Outcomes Definition of cure: absence of abnormality as measured objectively by urodynamics
Number of participants with DO:
A 14/32, B 23/28
UI frequency 2.2
No improvement 2.3
Compliance 2.4
Notes We contacted the main author of the study to request further information about further
three publications of the same study. The authors replied with information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers,
and used for stratified randomisation
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Allocation concealment (selection bias) Unclear risk The study nurse at each site was responsible
for carrying out the random assignment of
patients in accordance with the randomi-
sation scheme
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study nurse at each sitewas aware of the
difference in probes, however the physician
investigators were masked as to the type of
vaginal probe provided to each participant
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data sent to centralised data manager
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “A total of 148 women were enrolled, 18%
of whom withdrew from the study, leaving
of a total 121 participants who completed
the study. There was no statistically sig-
nificant difference between the treatment
groups with respect to withdrawal rates :
21% for the sham group and 14% for the
stimulation group.”
No explanation reported for withdrawals.
Finazzi-Agrò 2010
Methods Study design: RCT.
Multicentre or single-centre: single-centre.
Setting: Tor Vergata University Hospital in Rome,Italy.
Period: February 2007 to February 2009.
Sample size: with a sample size of 15 in each group this study had a power of 82,3% to
yield a statistically significant result assuming that the difference in proportions was 0,45
(specifically 0.05 vs 0.50). This effect was selected because the magnitude is reasonable
according to previously published findings. To account for a dropout rate of 10% the
number of patients to be recruited was set at 17 for each group, 34 total
Follow-up: 4 weeks.
Participants N: 35 randomised, 32 analysed
Mean age (no SD reported):
A 44.9
B 45.5
Sex: women.
Inclusion criteria: female, urgency incontinence and urodynamically diagnosed detru-
sor overactivity incontinence, unresponsive to behavioural and rehabilitation therapy or
antimuscarinics, able to give written, informed consent,18 years of age or older, men-
tally competent and able to understand all study requirements, able to understand the
procedures, advantages and possible side effects, willing and able to complete a 3-day
voiding diary and I-QoL questionnaire, bladder capacity 100 mL or greater, no signs of
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neurologic abnormalities at objective examination; no history of neurologic pathology,
no pharmacological treatment or pharmacological treatment unchanged for 30 days be-
fore beginning the study
Exclusion criteria: pregnancy or intention to become pregnant during the study, active
UTI or recurrent UTI (more than 4 per year), presence of urinary fistula, bladder or
kidney stones, interstitial cystitis, cystoscopic abnormalities that could be malignant,
diabetes mellitus, cardiac pacemaker or implanted defibrillator
Interventions A (n = 18) Percutaneous tibial nerve stimulation (PTNS). 12 sessions, 30 minutes, 3
times aweek for 4 weeks. 34-gauge needle inserted percutaneously approx. 5 cm cephalad
to the medial malleolus of right or left ankle; surface electrode placed on medial aspect
of ipsilateral calcaneous. Stimulation current (0 to 10 mA) with a fixed frequency of 20
Hz and a pulse width of 200 msec was increased until flexion of the big toe or fanning
of all toes became noticeable. The current was set at the highest level that was tolerable
to the patient
B (n = 17) sham. Same schedule as PTNS group with stimulator briefly activated for
approximately 30 seconds so the patient felt a minor electrical sensation in the skin
Outcomes Number of participants with < 50% reduction in urgency incontinence episodes:
A 5/17. B 18/18.
Number of incontinence episodes per 24 hours(mean, range, N):
A 1.8 (1.2-2.2), 17. B 3.8 (3.0-4.5), 15.
Number of micturitions per 24 hours (mean, range, N):
A 9.5 (8.4-10.7), 17. B 13.9 (11.3-16.5), 15
Voided volume mL (mean, range, N):
A 150.5 (126.8-174.3) 17. B 150.4 (125.8-175.1), 15.
I-QoL score (mean, range, N):
A 69.9 (65.8-73.3), 17. B 70.6 (62.2-79.1), 15
Notes Contacted author asking for SDs 27-11-14
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomization list.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To verify patient blindness with respect to
the assigned treatment after 3 sessions pa-
tients were asked which procedure they be-
lieved they received
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The results of the 2 groups were collected
by 2 physicians, and analysed by a third
physician and a statistician, both of whom
were blinded regarding the procedure use
67Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Finazzi-Agrò 2010 (Continued)
in any single patient
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the PTNS group 1 patient and in the
placebo group 2 did not complete the study
for personal reasons not related to the used
technique. There were left 17 patients in
the PTNS group and 15 in the placebo
group.There was a loss of less than 20%
have considered at low risk of bias
Firra 2013
Methods Study design: RCT
Multicentre or single-centre: single
Setting: USA
Period: NR
Details of sample size calculation: ‘to achieve a power of 0.80 with an estimated conven-
tional large effect size (f = 0.40), we sought a sample size of 66 women (33 with urge UI
and 33 with stress UI) with 11 participants per treatment by diagnosis group.’
Follow-up: 8 weeks
Participants N: 63 randomised, 48 analysed.
Mean (SD) age:
UUI overall 61.0 (12.4), A 57.3 (12.5) B 66.5 (12.4) C 63.0 (14.5)
SUI overall 55.1 (14.4), A 52.7 (15.0) B 63.6 (13.3) C 48.2 (16.2)
Sex: women
Inclusion criteria: SUI or UUI diagnosed by urodynamics or Medical, Epidemiological
and Social Aspects of Aging (MESA) questionnaire, parous or nulliparous women 21
years or older, manual dexterity to dial the Liberty Electrical Stimulation Unit, fluent
English,≥ 3 incontinent episodes in 3 days.Women onHRT tomaintain same oestrogen
intake throughout study, women not taking hormones were asked not start an oestrogen
regimen during study
Exclusion criteria: zero score on Oxford pelvic floor muscle strength scale, denervation
injury to the sphincters, anti-incontinence surgery, vaginal extent to extent that middle
finger could not be inserted into vagina, BMI > 50, stage III/IV prolapse, pregnancy,
neurologic conditions, any potentially confounding prescriptions drugs,
Interventions UUI
A (n = 7) intravaginal electrical stimulation plus PFMT. 14 sessions of 60 minutes
PFMT exercises, then 30 minutes (12.5Hz) at highest tolerable intensity. Tampon-
shaped Liberty ES device
B (n = 8) PFMT alone. 60 minutes twice a week for 8 weeks.
C (n = 7) no active treatment
SUI
D (n = 14) as per group A
E (n = 15) as per group B
F (n = 12) as per group C
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Outcomes York Incontinence Perception Scale (YIPS) score (higher score is better) (mean, SD, N):
UUI: A 41.2 (10.2), 6. B 47.0 (5.5), 6. C 28.8 (2.9), 6.
SUI: D 46.4 (7.2), 9. E SUI 44.8 (6.3), 12. F 29.9 (2.2), 9.
% change in YIPS score (mean, N):
UUI: A 38.7%, 6. B 78.7%, 6. C -2.4%, 6.
SUI: D 57.8%, 9. E SUI 37.0%, 12. F 2.0%, 9.
Pelvic floor muscle strength, cm H2O (mean, SD, N):
UUI: A 27.0 (16.0), 6. B 47.2 (22.7), 6. C 34.3 (25.5), 6.
SUI: D 36.7 (14.1), 9. E 32.5 (18.5), 12. F 26.1 (18.6), 9.
% change in pelvic floor muscle strength, cm H2O:
UUI: A 8.9%, 6. B 155.1%, 6. C 1.2%, 6.
SUI: D 119.8%, 9. E 49.8%, 12. F 5.2%, 9.
Incontinence episodes in 3 days (mean, SD, N):
UUI: A 3.0 (4.4), 6. B 2.3 (2.9), 6. C 7.8 (5.9), 6.
SUI: D 1.4 (1.6), 9. E 4.1 (4.2), 12. F 8.0 (5.6), 9.
*incontinence episodes per day (mean, SD, N):
A 1.0 (1.47), 6. B 0.8 (0.97), 6. C 2.6 (1.97), 6.
D 0.5 (0.53), 9. E 1.4 (1.4), 12. F 2.7 (1.87), 9.
% change in incontinence episodes in 3 days (mean, N):
UUI: A -78.1%, 6. B -70.5%, 6. C -4.0%, 6.
SUI: D SUI -83.7%, 9. E SUI -66.9%, 12. F SUI 50.9%, 9.
Frequency of micturitions in 3 days (mean, SD, N):
UUI: A 25.7 (9.4), 6. B 23.5 (5.9), 6. C 24.2 (10.4), 6.
SUI: D 24.1 (10.4), 9. E 22.8 (8.3), 12. F 24.6 (8.9), 9.
*frequency of micturitions per day (mean, SD, N):
A 8.6 (3.13), 6. B 7.8 (1.97), 6. C 8.1 (3.47), 6.
D 8.0 (3.47), 9. E 7.6 (2.77), 12. F 8.2 (2.97), 9.
% change in frequency of micturitions in 3 days (mean, N):
A -19.2%, 6. B -16.7%, 6. C 27.4%, 6.
D -6.6%, 9. E -8.8%, 12. F -14.9%, 9.
Notes Different numbers of participants reported in thesis and journal article
*Mean (SD) per day calculated from 3-day data: mean and SD divided by 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “2 containers were prepared representing
diagnosis groups (urge or stress inconti-
nence). Each container held 33 slips of pa-
per with 11 reading “e-stim,” 11 reading
“therapeutic exercise” and 11 reading “con-
trol.” The office assistant offered the cor-
rect diagnostic container to the participant
on the second visit.”
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Allocation concealment (selection bias) Low risk ”2 containers were prepared representing
diagnosis groups (urge or stress inconti-
nence). Each container held 33 slips of pa-
per with 11 reading “e-stim,” 11 reading
“therapeutic exercise” and 11 reading “con-
trol.” The office assistant offered the cor-
rect diagnostic container to the participant
on the second visit.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The primary researcher performed the
outcome measures and administered the
exercise programs. She was blinded to the
participants’ diagnosis as determinedby the
MESA but was not blinded to group allo-
cation.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “The primary researcher performed the
outcome measures and administered the
exercise programs. She was blinded to the
participants’ diagnosis as determinedby the
MESA but was not blinded to group allo-
cation.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some differential attrition: “of those who
dropped out after randomizationmost (11/
16) were in the exercise and stimulation
group...there was no indication that dis-
comfort was a factor.”
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Methods Study design: RCT.
Multicentre or single-centre: 3 centres in Sweden.
Period: September 2001 and December 2005.
Sample size: The power analysis was calculated on the basis of the primary outcome mea-
sure, reduction of micturitions per 24 hours. The minimal patient-perceivable improve-
ment has been found to be a mean reduction of micturitions per 24 hours equivalent
to 20%. A reduction smaller than 20% would thereby not be of any significant clinical
importance. There is a large uncertainty regarding the efficacy that can be expected for
both ES treatment and drug treatment being 30% to 50%.Under the assumption that
ES treatment would give a 70% reduction of symptoms and drug treatment (tolterodine)
a 50% reduction and thereby give a difference between treatments of 20%, a Chi-square
test with a two-sided significance level of 5 % yielded a power of 80% for a sample size
of 103 patients in each group. If the assumption was even bigger difference in efficacy,
70% for ES treatment vs. 40% for tolterodine, the sample size with an additional 10%
to compensate for dropouts would be 55 patients in each group
Follow-up: 24 months
Participants N: 72 randomised and 61 analysed at 6 months, 52 analysed at 12 months, 46 at 24
months
Sex: Women.
Mean (SD) age:
A 55 (11)
B 61 (12)
Inclusion criteria: urgency incontinence symptoms for≥ 3 months, increased frequency
of micturition (≥ 8 micturitions per 24 hours), mean volume of urine voided per mic-
turition ≤ 200 mL, total urine volume per 24 hours of less < 3,000 mL during a 48-
hour bladder diary
Exclusion criteria: Persistent UTI, post-void volume greater than 150 mL, history of
neurological disease or dementia, pregnancy, contraindications to anticholinergic ther-
apy, and a cardiac pacemaker. Participants were also excluded if they had used tolterodine
or any other anticholinergic drugs in order to treat urgency/urge incontinence during
the last 2 months or had received ES treatment within the last 3 years
Interventions A (n = 33). ES vaginally and/or transanally with the MS-310 Device, MIC Rehab AB.
Over 5-7 weeks, 10 stimulation treatments one to two times per week for 20 minutes
with a frequency of 5-10 Hz. The maximum ES was done with maximum tolerable
intensity, which was adjusted up to the level of tolerable discomfort
B (n =31) Tolterodine SR 4 mg orally once daily for 6 months, with dose reduction
allowed to tolterodine SR 2 mg daily if intolerable side effects occurred
Outcomes Number of participants with moderate or severe urgency symptoms:
A 10/33, B 12/31
Number of participants with no improvement in urgency symptoms:
A 9/33, B 9/31
Change in frequency of micturition (mean, 95%CI [SD]*, N):
6 months:
A -2.8 (-3.6 to -2.2 [1.96]), 30. B −3.2 (−4.1 to −2.4 [2.41]), 31
12 months:
A −3.1 (95% CI, −4.0 to −2.1 [2.65]), n = 30. B −3.1 (95% CI, −4.3 to −1.9 [3.
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41]) n = 31
24 months:
A −3.4 (−4.6 to −2.2 [3.35), n = 30. B −3.7 (−4.8 to −2.6 [3.12]), n = 31
Change in mean urine volume (mL) (mean, 95%CI [SD]*,, N):
A 54 (28 to 80 [72.66]), 30. B 55 (36 to 74 [53.97]), 31
Side effects:
A 0/33
B** 9/30 dry mouth, 1/30 muscular pain
King’s Health Questionnaire: see Table 3. Various outcomes reported
Notes *SD calculated by FS, using 95%CI.
**based on information received from author.
6-month data used in analysis because treatment is given for 6 months. Most other
included studies provide data for end of treatment period
N per treatment group at 12 and 24 months not given, assume same as 6 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization sequence was developed
centrally, using a computer random num-
ber generator.”
Allocation concealment (selection bias) Low risk “Assignment was enclosed in sequentially
numbered opaque sealed envelopes by a
person not involved in the study. Patients
were included into the study and allocated
to treatment group by the clinical staff re-
sponsible for the study at each participat-
ing center, by opening the lowest numbered
envelope”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Blinding of study personnel and partici-
pants to treatment assignment for the du-
ration of the study was not possible due to
the nature of the interventions.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. Adequate expla-
nation for withdrawals
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Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: Belgium
Period: November 2010 - November 2012
Details of sample size calculation: 15 per group required for 80% power to detect be-
tween-group difference
Follow-up: 9 weeks’ treatment, 6 months’ follow-up
Participants N: 31 randomised and analysed.
Mean (SD) age: A 43.5 (14.0). B 40.5 (9.5)
Sex: women and men
Inclusion criteria: EDSS score < 7 and, urgency symptoms, nocturia, urgency inconti-
nence, urinary retention and/or weak stream, post-voiding symptoms such as incomplete
bladder emptying sensation
Exclusion criteria: acute MS episodes during the study, UTI, pelvic-perineal treatment
in the past 6 months, pregnancy
Interventions A (n = 16) PFME with biofeedback. One 30-minute session per week for 8 weeks
B (n = 15) ES + PFME. As per group A plus transcutaneous posterior tibial nerve
stimulation. Frequency 10 Hz, 220 µs pulse width. One 30-minute session per week for
9 weeks. Rectangular biphasic pulse. An external electrode was located 5 cm above the
medial malleolus and 1 cm behind the tibia. The other electrode was positioned on the
dorsum of the foot. 20s on - 4s off
Outcomes Number of participants not satisfied:
A 1/16. B 4/15
SF-Qualiveen total score (higher score = greater severity) (median, IQR, N):
9 weeks: A 1.000 (0.656, 1.719), 16. B 1.375 (0.625, 2.188), 15
6 months: A 1.313 (0.687, 1.625), 16. B 1.500 (0.344, 2.094), 15
*mean, SD, N
9 weeks: A 1.07 (0.65), 16. B 1.51 (0.83), 15.
6 months: A 1.21 (0.74), 16. B 1.39 (0.91), 15.
Bladder hyperactivity score (median, IQR, N):
9 weeks: 5.00 (1.50, 8.00), 16. B 6.00 (2.5, 9.25), 15.
6 months: 7.00 (3.50, 9.50), 16. B 5.00 (4.25, 7.75), 15.
*mean, SD, N
9 weeks: A 5.4 (3.67), 16. B 6.75 (3.91), 15.
6 months: A 6.42 (3.9), 16. B 6.5 (3.45), 15.
Daily urgency episodes (median, IQR, N):
9 weeks: 1.2 (0.3, 5.0), 16. B 0.7 (0.2, 4.3), 15.
6 months: 2.0 (0.3, 2.7), 15. 1.4 (0.0, 2.0), 15.
*mean, SD, N
9 weeks: A 2.69 (3.02), 16. B 2.63 (3.08), 15.
6 months: A 2.25 (2.53), 16. B 1.67 (1.64), 15.
Adverse effects: A 0/16 B 0/15
Notes Subcategories of Qualiveen scores available in paper.
Emailed authors asking for means (SDs) 2 April 2015. Replied with data marked *
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were randomised”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not possible.
Other blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Data analysis was blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential withdrawal. Adequate ex-
planations for withdrawal not reported. In-
tention-to-treat analysis carried out
Kaya 2011
Methods Study design: RCT.
Multicentre or single-centre: single centre.
Setting: Departments of Physiotherapy and Rehabilitation and Obstetrics and Gynae-
cology, Hacettepe University, Turkey
Period: January 2007 and June 2008
Sample size: Not reported.
Follow-up: 8 weeks.
Participants N: 46 randomised, 45 analysed
Sex: Women.
Mean (SD) age:
A 45.1 (8.6)
B 47.4 (5.5)
C 48.5 (6.3)
Inclusion criteria: patients with OAB symptoms and diagnosed with urodynamic DO
Exclusion criteria: accompanying neurological disorder, neoplasm, second degree or
greater pelvic organ prolapse(Baden Walker), type III SUI, pregnancy, any mental dis-
order interfering the patient´ s co-operation during the treatment, use of a pacemaker
or an intrauterine device, or previous medical, surgical treatment or physiotherapy for
DO. In addition, contraindications to trospium chloride were reasons for exclusion
Interventions A (n = 15). Pharmacotherapy: 15 mg trospium chloride 3 times per day
B (n = 15) Physiotherapy (ES): interferential current therapy; 20-minute sessions (0-10
Hz 10 minutes; 0-100 Hz 10 minutes) of ES 5 times per week for 8 weeks using an
electrotherapy device with vacuum electrodes. Two vacuum electrodes were placed in
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the suprapubic region and the other two were placed cross-wise on the medial side of the
ischial tuberosity. Pelvic floor exercises 5 sets a day with 10 repeats (fast and sustained
contractions), increasing number of sets 5 each week. Bladder training: avoid bladder-
irritating and diuretic beverages, return to normal fluid intake (1500 to 2100 mL),
encouraged to gradually lengthen the period between micturitions, techniques such as
selective contraction of pelvic floor muscles during urgency, deep and slow breathing to
combat urge feeling, trying to keep mind busy rather than concentrating on bladder
C (n = 16) Pharmacotherapy plus physiotherapy: as per A + B.
Outcomes Number of daytime voids (mean, SD, N):
A 8.9 (2.8), 14. B 6.7 (3.8), 15. C 6.9 (2.4), 16
Number of night-time voids (mean, SD, N):
A 2.1 (1.8), 14. B 0.4 (0.9), 15. C 1.1 (0.9), 16.
Number of incontinence episodes per 24 hours (mean, SD, N):
A 1.5 (2.0), 14. B 0.1 (0.2), 15. C 0.5 (0.8), 16
Urine leakage (units?) (mean, SD, N):
A 1.1 (1.15), 14. B 1.2 (1.22), 15. C 1.0 (0.92), 16.
*QoL score (mean, SD, N):
A 26.3 (19.5), 14. B 12.6 (15.1), 15. C 10.1 (12.2), 16.
Adverse effects:
Dry mouth: A + C 7/31. B 0/15
Visual impairment: A 1/15. B 0. C 0
Notes *QoL tool: not named in paper but reference 20 (Wagner 1996) indicates I-QOL was
used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated.
Allocation concealment (selection bias) Unclear risk Randomisation list created by a statistician.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Physiotherapy applications were per-
formed by the first author, and assessments
were performed by the first author
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physiotherapy applications were per-
formed by the first author, and assessments
were performed by the first author
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one patient in the pharmacotherapy
group did not complete the study because
of blurred vision
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Methods Study design: RCT.
Multicentre or single-centre: multicentre.
Setting: USA.
Period: June 2011 - December 2013
Sample size: The sample size calculationwas determinedusing the 2-sidedChi-square test
with a significance level of 5% and 80% power based upon the following assumptions:
(1) proportion of responders at end of 12 weeks of treatment would be 50% in the active
(test) group and 25% in the inactive (control) group; (2) a responder was defined as
a subject who experienced decrease of ≥ 50% in mean UUI episodes (leaks) between
baseline and week 12 of the study; (3) 20 % dropout rate
Follow-up: 12 weeks
Participants N: 163 randomised
Mean age (SD):
A 60.8 (14.3)
B 62.4 (13.8)
Sex: 138 female, 25 male
Inclusion criteria: males and females, at least 18 years of age. Failure on primary OAB
treatment, such as behaviour modification or fluid/diet management, AND at least one
(1) anti-cholinergic drug (unless patient was contra-indicated for anti-cholinergic use).
Symptoms of OAB for at least 6 months
Exclusion criteria: Dysfunctional voiding symptoms unrelated to OAB, such as clinically
significant bladder outlet obstruction, and urinary retention (pvr > 100 cc). Morbidly
obese, defined as having BMI > 40 kg/m2. Stress predominant MUI. Neurological dis-
ease affecting urinary bladder function, including but not limited to Parkinson’s disease,
multiple sclerosis, stroke, spinal cord injury and uncontrolled epilepsy. Pelvic surgery
(such as sub-urethral sling, pelvic floor repair) within the past 6 months. Intravesical
or urethral sphincter Botulinum Toxin Type A injections within the past 12 months.
Any neuromodulation therapy for overactive bladder within the past 3 months. Fail-
ure to respond to previous neuromodulation therapy for OAB. Leading edge of any
vaginal prolapse is beyond hymenel ring. Prior peri-urethral or transurethral bulking
agent injections for bladder problems within the past 12 months. Any skin conditions
affecting treatment or assessment of the treatment sites. History of lower back surgery
or injury that could impact placement of the patch, or where underlying scar tissue or
nerve damage may impact treatment. Presence of an implanted electro-medical device (e.
g. pacemaker, defibrillator, InterStim®, etc.), or any metallic implant in the lower back.
Pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to
become pregnant during the course of the study. Known latex allergies, or allergies or
hypersensitivity to patch materials that will be in contact with the body (e.g., hydro-
gel, acrylic-based adhesive, polyurethane). Uncontrolled diabetes and/or diabetes with
peripheral neuropathy. Current UTI or history of recurrent UTIs (>3 UTIs in the past
year). History of lower tract genitourinary malignancies within the last 6 months or any
previous pelvic radiation. Any clinically significant systemic disease or condition that in
the opinion of the Investigator would make the patient unsuitable for the study
Interventions A (n = 80) 1 VERV electrode patch worn per week for 12 weeks
B (n = 83) 1 sham electrode patch worn per week for 12 weeks
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Outcomes Change in Urgency (Urinary) Incontinence Episodes per day (median (IQR), N):
A -3.7 (-4.7 to -1.0), 68. B -1.7 (-3.3 to -1.0), 75. P = 0.2191)
Change in Urinary Frequency per day (median (IQR), N):
A -1.0 (-2.7 to 0.3), 80. B -1.3 (-3.0 to -0.3), 83. P = 0.2893
Change in Volume Per Void (mL) (median (IQR), N):
A 1.0 (-26.6 to 23.5), 80. B 8.8 (-24.3 to 33.3), 83. P = 0.3387
Change in urgency episodes (median (IQR), N):
A -1.7 (-3.3 to 0.3), 80. B -1.7 (-3.3 to 0.3). P = 0.6557
Change in OAB-Symptom Composite Score (median (IQR), N):
A -5.8 (-14.7 to 1.3), 80. B -8.0 (-15.3 to 0.3), 83. P = 0.4354
Change in OAB-q score (median (IQR), N):
A 8.8 (1.6 to 20.0), 56. B 9.2 (-0.8 to 27.2), 66. P = 0.9918
Percentage of participants with improvement in severity according to Patient Perception
of Bladder Condition scale:
A 53.7% of 80 (43/80). B 44.2% of 83 (37/83)
Percentage of participants with overall improvement according to Treatment Benefit
Scale:
A 55.4% of 56 (31/56). B 42.4% of 66 (28/66)
Percentage of participants with Improvement as measured by Overactive Bladder Satis-
faction With Treatment Questionnaire:
A 65.3% of 32 (21/32). B 57.6% of 34 (20/34)
Percentage of participants improved as measured by clinicians using Clinical Global
Impressions:
A 23.2% of 80 (19/80). B 24.2% of 83 (20/83)
Participants with adverse effects:
A 30/80. B 29/82
Notes Emailed author asking for means (SDs) 6 January 2015
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Allocation: randomized”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Masking: Double Blind (Subject, Investi-
gator)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Masking: Double Blind (Subject, Investi-
gator)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. Adequate expla-
nation for withdrawals
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Methods Study design: RCT
Multicentre or single-centre: NR
Setting: Russia
Period: 2008-2010
Details of sample size calculation: NR
Follow-up: 1-month treatment, 12 months’ follow-up
Participants N: 229 randomised, 208 analysed at 12 months
Mean (SD) age: 66.3 (range 65-77)
Sex: women
Inclusion criteria: elderly womenwith urodynamic impairments and clinically confirmed
OAB
Exclusion criteria: not reported
Interventions All groups: trospium 60 mg + solifenacin 40 mg for 6 weeks then one of the following,
beginning 2.5 months after end of drug treatment:
A (n = 59) drugs: trospium 60 mg + solifenacin 40 mg for a month
B (n = 51) detrusor electrical stimulation: an active electrode (50 to 70 cm2) above
the pubis, and a passive electrode (150 cm2) in lumbosacral area, diadynamic current,
frequency 20 Hz, modulation depth 50% to 75%, intensity 20-40 mA, exposure 15
minutes, a course consisting of 15 procedures every other day
C (n = 63) conservative treatment: laseropuncture by helium-neon laser (632.8 nm) at
acupuncture points RP 6, RP 9, VC 2 within 1 to 1.5 minutes for each point every day,
light guide output power - 2 mW,
25 procedures.
D (n = 56) placebo
Outcomes Daily urinary incontinence episodes (mean, SD, N)
6 months: A 1.1 (0.7), 59. B 2.2 (0.9), 51. C 3.8 (0.8), 63. D 2.7 (1.1), 56
12 months: A 1.5 (0.9), 59. B 3.7 (1.3), 51. C 5.5 (1.4), 63. D 4.8 (2.4), 56
Volume at FDV, mL (mean, SD, N):
6 months: A 289.3 (37.6), 59. B 297.0 (45.3), 51. C 254.5 (49.1), 63. D 279.7 (54.8),
56
12 months: A 257.5 (28.9), 59. B 210.9 (28.7), 51. C 199.3 (49.4), 63. D 192.9 (28.
9), 56
Volume at maximal desire to urinate, mL (mean, SD, N):
6 months: A 313.7 (47.1), 59. B 334.8 (38.3), 51. C 286.0 (36.6), 63. D 311.5 (51.7),
56
12 months: A 279.9 (33.8), 59. B 251.9 (42.9), 51. C 178.9 (29.0), 63. D 206.3 (SD
missing), 56
Maximum bladder pressure, cmH2O (mean, SD, N):
6 months: A 32.8 (6.0), 59. B 35.4 (9.3), 51. C 38.9 (7.8), 63. D 31.0 (7.9), 56
12 months: A 28.8 (4.7), 59. B 30.9 (4.9), 51. C 29.8 (6.3), 63. D 23.9 (5.4), 56
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk “we randomized 229 women”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14 participants withdrew due to side ef-
fects, 2 discontinued due to the lack of
an immediate positive effect; and 2 with-
drew for reasons unrelated to the treatment
course
Numbers of withdrawals not reported per
treatment group.
Lima 2011
Methods Study design: RCT.
Multicentre or single centre: not reported.
Setting: not reported.
Period: not reported.
Sample size: not reported.
Follow-up: not reported.
Participants N: 45.
Sex: women.
Mean age: not reported.
Inclusion criteria: patients with overactive bladder symptoms
Exclusion criteria: not reported.
Interventions A (n = 16) PFMT
B (n = 14) Intravaginal electrostimulation. Twelve 30-minute sessions
C (n = 15) Transcutaneous posterior tibial nerve stimulation. Twelve 30-minute sessions
Outcomes Symptoms of urgency incontinence, defined as ‘absence, a little, more or less and much’
Notes No useable data
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported.
Lo 2003
Methods Study design: RCT.
Single centre.
Setting: Department of a Regional Hospital in Perth, Western, Australia
Period: not reported.
Sample size: 50 participants in each group would be sufficient to give 0.8 power at the
0.05 alpha level for for two - sided alternative. Calculation of sample size was performed
using the PASS statistical software (NCSS, Kaysville, Utah, USA). Parameters used in
the calculations were derived from Jundt et al and Lamhut
Follow-up: four weeks
Participants N: 24 randomised and analysed
Sex: women.
Mean age (SD):
A (n =12) 52.1 (17.5)
B (n = 12) 55.1 (15.1)
Inclusion criteria: female, aged 20 years or older, with stress or UUI
Exclusion criteria: altered mental state, urinary incontinence caused by problems other
than stress or urge, transient incontinence, or severe disability requiring full assistance
with all acts of daily living
Interventions A (n = 12) PFMT. 12 sessions (3 per week for 4 weeks): 10 sets of 5 contractions with
30-second rest between each set. Then repeated after an hour
B (n = 12) Interferential therapy (ITT) plus PFMT. 12 sessions (3 per week for 4 weeks)
of 50 pelvic floor contractions followed by ITT with Nemectrodyne 5 stimulator then
another 50 contractions. Two anterior flat electrodes placed over obturator foramen
1.5cm to 2cm lateral to symphasis, two posterior electrodes placed medial to ischial
tuberosities either side of anus. ITT was at highest tolerable frequency between 0-100Hz
for 15 minutes (session 1), then 30 minutes for sessions 2-12
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Outcomes Pelvic floor muscle strength measured with perineometer (mean, SD, N):
A 9.55 (3.50), 12. B 8.08 (4.83), 12
Pad test (g) (mean, SD, N):
A 1.25 (1.76), 12. B 9.00 (29.3), 12.
Frequency (number of micturitions per day) (mean, SD, N):
A 6.29 (2.2), 12. B 7.24 (2.62), 12.
Nocturia (number of nocturia episodes per night) (mean, SD, N):
A 0.45 (0.86), 12. B 0.99 (1.04), 12.
Change in pelvic floor muscle strength (mean, SD, N):
A 2.03 (2.10), 12. B 2.04 (2.47), 12. (P = 0.253)
Change in pad test (g) (mean, SD, N):
A -4.33 (8.37), 12. B -85.1 (150), 12. (P = 0.101)
Change in frequency (mean, SD, N):
A -0.07 (1.76), 12. B -1.81 (1.62), 12. (P = 0.006)
Change in nocturia (mean, SD, N):
A -0.49 (0.89), 12. B 0.86 (1.14), 12. (P = 0.199)
No improvement in stop/start test, defined as change from unable to stop to being able
to slow, or change from able to slow to able to stop:
A 9/12. B 6/12 (P = 0.2)
No improvement in urgency (not defined):
A 8/12. B 4/12
Notes We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
No useable data. Not stratified by stress/urgency incontinence
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were randomly allocated as
soon as they gave written consent, using the
sealed envelope method”
Allocation concealment (selection bias) Unclear risk Sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were not blinded due to the
nature of the interventions but unclear if
this would have effect on outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Only the assessor but not the patients
could be blinded.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported.
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Lobel 1998
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: USA
Period: NR
Details of sample size calculation: NR
Follow-up: 5 weeks’ treatment then another 5 weeks’ treatment if improvement observed
after first 5 weeks, then follow-up six months after end of 10 weeks’ treatment
Participants N: 42 recruited, 37 randomised and analysed.
Mean (SD) age: 61 (17)
Sex: women
Inclusion criteria: DO
Exclusion criteria: NR
Interventions A (n = 18) ES once a week for 5 weeks
B (n = 19) ES twice a week for 5 weeks
Medicon MS-210 with vaginal and anal probes
Outcomes Incontinence episodes after 5 weeks (mean, N): 12 (37)
Participants not improved after 5 weeks (N): 0
Participants satisfied enough to request no further treatment:
25% (9)
Adverse effects:
Discomfort: 16% (6/37)
Leg tremor: 8% (3/37)
UTI: 8% (3/37)
Notes Data not presented by treatment - not useable.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized into two treatment groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not possible.
Other blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/42 participants withdrew before treat-
ment; no explanation reported. All partici-
pants treated included in analysis. Nowith-
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drawals due to adverse effects
Marques 2008
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: Brazil
Period: NR
Details of sample size calculation: NR
Follow-up: 4 weeks
Participants N: 43 randomised
Mean (SD) age: NR
Sex: women
Inclusion criteria: OAB
Exclusion criteria: NR
Interventions A (n = ?) ES 30 minutes, twice per week for 4 weeks transcutaneous electrical nerve
stimulation, biphasic with 200ms pulse duration, 10Hz frequency, variation of intensity
and frequency through one channel and two electrodes
B (n = ?) unclear if sham or no active treatment: ‘same protocol but without electrical
stimulation.’
Outcomes Daytime frequency: difference between groups P = 0.0001 (in favour of intervention)
Nocturia: difference between groups P = 0.0186 (in favour of intervention)
Improvement in SUI: difference between groups P = 0.0273 (in favour of intervention)
Urgency symptoms: difference between groups P = NS
Participants with no involuntary detrusor contraction: A 4/?. B 5/?
Notes No useable data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized’ ‘divided into two different
groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
83Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Marques 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear howmany participants included in
analysis
Monga 2011
Methods Study design: RCT
Multicentre or single-centre: multi-centre
Setting: NR
Period: NR
Details of sample size calculation: NR
Follow-up: 4 weeks
Participants N: 74 randomised, 64 analysed.
Mean (SD) age: NR
Sex: men and women
Inclusion criteria: ≥ 18 years, OAB symptoms ≥ 6 months, failure of OAB therapies
such as behaviour modification and failure of ≥ anti-cholinergic drug for OAB
Exclusion criteria: NR
Interventions Patient managed neuromodulation system (PMNS): transdermal amplitude-modulated
signal through a patch applied to the skin, controlled by wireless handheld remote
control. Patch worn for 4 weeks, placed by investigator initially
A (n = 30) Investigator Placement Group. Participants returned every 7 days for patch
removal and placement of a new patch on contra-lateral side
B (n = 34) Subject Placement Group. Participants returned on day 7 for investigator
observation of patch self-placement and replaced patch at home for the remaining 2
weeks
Outcomes Urgency urinary incontinence episodes (mean, SD, N):
2.2 (2.5), 64.
% change from baseline in urgency urinary incontinence episodes (mean, SD, N):
-2.7% (3.1), 64.
Change from baseline in urgency urinary incontinence episodes (mean, SD, N):
-47.8 (60.6), 64.
Voiding frequency (mean, SD, N):
9.4 (2.7), 64.
% change from baseline in voiding frequency (mean, SD, N):
-1.9% (2.5), 64.
Change from baseline in voiding frequency (mean, SD, N):
-15.0 (19.1)
Volume per void (mean, SD, N):
187.6 (75.0), 64.
% change from baseline in volume per void (mean, SD, N):
8.2% (46.7), 64.
Change from baseline in volume per void (mean, SD, N):
7.5 (26.4), 64.
Urgency episodes (mean, SD, N):
7.8 (3.3), 64.
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% change from baseline in urgency episodes (mean, SD, N):
-2.2 (2.8), 64.
Change from baseline in urgency episodes (mean, SD, N):
-21.2 (28.6), 64.
Notes Not useable - results not presented per treatment group.
Contacted author requesting data per group 17 February 2015. Author responded “The
device has been withdrawn. Probably doesn’t need to be in the review.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “subjects were randomized”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No explanation reported for withdrawals.
Data not presented per treatment group
Monteiro 2014
Methods Study design: RCT
Multicentre or single-centre: single
Setting: Brazil
Period: February - June 2008
Details of sample size calculation: ‘Pocock formula, with 47% of neurogenic overactive
bladder prevalence and decrease of 30% after treatment’
Follow-up: 45 days’ treatment, 12 months’ follow-up.
Participants N: 24 randomised and analysed.
Mean (SD) age: A 65.1 (3.6). B 56.1 (10.9)
Sex: men
Inclusion criteria: ≥ 18 years with neurogenic OAB, with stroke occurring between 6
months and 3 years before recruitment
Exclusion criteria: implanted cardiac pacemaker, UTI, bladder cancer, pre-existing uri-
nary incontinence before stroke, or surgery in the urogenital region
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Interventions A (n = 12) ES of posterior tibialis nerve. Negative electrode was placed on the medial
malleolus, and the positive electrode was placed 10 cm above the negative electrode,
also on the medial side. The rhythmic flexion of the second toe during the stimulation
determined the correct position of the negative electrode. The intensity level was set below
the threshold that causes motor contraction because the patient should be comfortable
and no pain should occur during the procedure. ES of the posterior tibialis nerve was
performed for 30 minutes twice weekly over 12 sessions (45 days), with a frequency of
10 Hz and a pulse width of 200 µs in continuous mode
B (n = 12) no active treatment for overactive bladder. 12 stretching sessions of the lower
limbs
Outcomes Participants with no improvement in OAB symptoms:
12 months: A 0/12. B 9/12.
Participants with urinary urgency:
45 days: A 7/12. B 10/12.
12 months: A 6/12. B 9/12.
Participants with urgency urinary incontinence:
45 days: A 8/12. B 9/12.
12 months: A 7/12. B 8/12.
Participants with nocturnal enuresis:
45 days: A 0/12. B 2/12.
12 months: A 0/12. B 2/12.
Participants with nocturia:
45 days: A 5/12. B 9/12.
12 months: A 1/12 B 6/12.
Participants with increased daytime frequency:
45 days: A 3/12. B 11/12.
12 months: A 0/12. B 9/12
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk All participants were numbered sequen-
tially from 1 to 24 and divided into 2
groups of 12 patients assigned to the treat-
ment group
Allocation concealment (selection bias) Unclear risk All participants were numbered sequen-
tially from 1 to 24 and divided into 2
groups of 12 patients assigned to the treat-
ment group
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported. Impossible to blind partici-
pants.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in
analysis. One dropout. “One patient in the
placebo group died after treatment, but was
analyzed as if improved.”
Oldham 2013
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: UK
Period: NR
Details of sample size calculation: the study was powered to detect a 3 point (common
standard deviation of 6) between group difference on the ICIQ-UI (scale of 0-21) with
80% power at a 5% level of significance
Follow-up: 12 weeks
Participants N: 124 randomised, 97 analysed.
Mean (SD) age: A 47.9 (8.9). B 48.2 (8.6)
Sex: women
Inclusion criteria: women, 18-65 years with self-reported SUI, UUI, or MUI
Exclusion criteria: Pregnancy or a baby in the last 3 months. Recent abdominal surgery
and previous or current active therapy for pelvic malignancy. Implanted pacemaker.
Manual dexterity insufficient to place the device. Previous treatment for incontinence
(including supervised pelvic floor muscle exercises (PFME). Presence of a neurological
condition such as multiple sclerosis or Parkinson’s disease
Interventions A (n = 64) electrical stimulation. Pelviva device inserted like a tampon into the vagina.
The stimulation programme is delivered using a duty cycle of 10 sec stimulation fol-
lowed by 10-second rest that runs for a period of 30 minutes, pre-programmed to au-
tomatically gradually ramp-up the intensity of stimulation over a 24-second period to
reach a therapeutic level and switch off automatically after 30 minutes. During the 10
seconds “on time” the device delivers 10 repeats of a short high intensity burst of 50 Hz
stimulation immediately preceded by a doublet (125 Hz), superimposed on continuous
low frequency 2 Hz stimulation
Plus standardised advice about how and when to undertake PFME. These included 10
slow and controlled squeezing and lifting contractions and 10 quick contractions each
repeated 3 to 4 times a day
B (n = 60) unsupervised conservative treatment (no active treatment). Standardised
advice about how and when to undertake PFME. These included 10 slow and controlled
squeezing and lifting contractions and 10 quick contractions each repeated 3-4 times a
day
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Outcomes Participants with no improvement in symptoms (i.e. same or worse ICIQ score):
A 9/49. B 14/46
*A UUI 5/50. B 6/47.
*A MUI 8/50. B 19/47.
*A UUI+MUI 13/50. B 25/47
Participants with urinary incontinence (SUI, UUI or MUI)
A 94% (i.e. 46/49) B 100% (i.e. 46/46)
International Consultation on Incontinence Questionnaire - Urinary Incontinence
(ICIQ-UI) score (higher score is increased severity) (median, range, N):
A 6 (0-17), 49. B 9 (3-18), 46.
Leak frequency (0-5 scale, higher score is more leaks) (median, range, N):
A 1 (0-4), 49. B 2 (1-4), 46.
Leak interference (0-10 scale, higher score is more interference) (median, range, N):
A 3 (0-10), 49. B 4 (0-10), 46.
Leak amount (0-6 scale, higher score is greater amount) (median, range, N):
A 2 (0-6), 49. B 2 (2-4), 46.
Adverse effects: A 0/49. B 0/46.
Notes *Outcome data not separated by SUI/UUI/MUI - contacted author3 February 2015,
replied with supplementary data
Femeda, the company responsible for developing and producing the Pelviva device was
the trial sponsor. The sponsor was responsible for developing the Pelviva device, was the
funder of the study, and was engaged in the development of the trial design. The sponsor
has provided full access to the data and is fully informed of this publication process. The
primary author (J.O.) takes full responsibility for the integrity of the data and accuracy
of the data analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “subjects were assigned by a simple com-
puter generated AB randomization list to
either the exercise or Pelviva group.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Participants could not be blinded to the
treatment group and were aware of the
study hypothesis. Every care was taken to
ensure the assessor remained blind to treat-
ment allocation and participants were ad-
vised not to discuss their treatment with
them.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “the assessor remained blind to treatment
allocation”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No differential dropout. No explanations
for withdrawals.
Ozdedeli 2010
Methods Study design: RCT.
Single-cetre.
Setting: Department of Physical Medicine and Rehabilitation, University Hospital
Bornova, Turkey
Period: May 2004 and January 2005.
Sample size: not reported.
Follow-up: 6 weeks’ treatment, 18 weeks’ follow-up
Participants N: 35 randomised, 31 analysed.
Age (median, range)
A 60.0 (37 to 78)
B 57.5 (36 to 78)
Sex: women.
Inclusion criteria: women with urgency incontinence and OAB or MUI with predomi-
nantly OAB symptoms
Exclusion criteria: history of pelvic surgery, a neurological deficit or peripheral neuropa-
thy that may cause neurogenic bladder, presence of a medical condition that may pre-
clude anticholinergic drug use, pregnancy or suspicion of pregnancy, cardiac pacemaker,
genitourinary infection or haemorrhage, deterioration in cognitive or intellectual func-
tions, anatomical abnormality that hinders the use of vaginal probe, and post-voiding
residual volume > 100 mL
Interventions A (n = 17) trospium hydrochloride (Spasmex): 30 mg in the mornings and 15 mg in the
evenings for 6 weeks
B (n=18) intravaginal ES: three 20-minute sessions perweek for six weeks usingMyomed
134 dual-channel combined biofeedback and electrical stimulator. Treatment paused for
menstruation. Biphasic symmetrical rectangular pulse with 5 Hz frequency, 0 to 80 mA
(the maximal current the patient could tolerate) for a total duration of 100 µs
Both groups: educated in bladder drills and Kegel exercises by a physician. Instructed
to examine frequency-volume chart to determine the longest interval to initially hold
urination and sustain urge symptoms, then taught to increase this interval by 15-minute
increments, with the aim of achieving a 3- to 4-hour interval and voided volume of
300 to 400 mL. Received instructional leaflet showing behavioural modifications to get
incontinence and urgency attacks under control
Outcomes **UNCLEAR FROM TABLE 2 IF MEAN OR MEDIAN, RANGE OR 95%CI -
HAVE ASSUMED MEDIAN & RANGE**
Maximal detrusor pressure at 6 weeks (median, range, N):
A 22 (4-49), 15. B 12 (2-56), 16.
Maximal detrusor pressure at 10 weeks (median, range, N):
A 29 (2-55), 15. B 30.5 (2-46), 16.
Maximal detrusor pressure at 18 weeks (median, range, N):
A 28 (3-48), 15. B 19 (3-48), 16.
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Maximal cystometric capacity at 6 weeks (median, range, N):
A 405.0 (195-550), 15. 442.0 (62-550), 16.
Maximal cystometric capacity at 10 weeks (median, range, N):
A 389 (94-500), 15. B 493.5 (58-550), 16.
Maximal cystometric capacity at 18 weeks (median, range, N):
A 378.0 (94-450), 15. B 500.0 (125-540), 16.
Volume at FDV at 6 weeks (median, range, N):
A 209 (116-295), 15. B 204.0 (60-410), 16.
Volume at FDV at 10 weeks (median, range, N):
A 156.0 (50-349), 15. B 205.0 (58-320), 16.
Volume at FDV at 18 weeks (median, range, N):
A 149.5 (65-250), 15. B 150.0 (72-234), 16.
Frequency of urgency per 24 hours at 6 weeks (median, range, N):
A 2.7 (0-8.0), 15. B 1.7 (0-13.0), 16.
Frequency of urgency per 24 hours at 10 weeks (mean, range, N):
A 3.5 (0.3-7.0), 15. B 1.3 (0-12.4), 16.
Frequency of urgency per 24 hours at 18 weeks (median, range, N):
A 4.4 (0-6.0), 15. B 3.0 (0-7.0), 16.
Number of incontinence episodes per 24 hours at 6 weeks (median, range, N):
A 1 (0-5), 15. B 0.3 (0-9), 16.
Number of incontinence episodes per 24 hours at 10 weeks (median, range, N):
A 1.2 (0-4), 15. B 0 (0-9), 16.
Number of incontinence episodes per 24 hours at 18 weeks (median, range, N):
A 2.4 (0-5), 15. B 0 (0-2), 16.
Voiding frequency (number of micturitions per 24 hours) at 6 weeks (median, range,
N):
A 6.0 (3.3-14.7), 15. B 7.0 (0.6-15.4), 16.
Voiding frequency (number of micturitions per 24 hours) at 10 weeks (median, range,
N):
A 8.0 (5.7-14.0), 15. B 6.1 (1.2-13.2), 16.
Voiding frequency (number of micturitions per 24 hours) at 18 weeks (median, range,
N):
A 8.2 (5.7-14.1), 15. B 6.5 (5.3-11.3), 16.
Severity of urgency (measured on visual analogue scale, higher score indicates greater
severity) at 6 weeks (median, range, N):
A 23.0 (1-84), 15. B 31.5 (0-73), 16.
Severity of urgency (measured on visual analogue scale, higher score indicates greater
severity) at 10 weeks (median, range, N):
A 31 (11-84), 15. B 26.0 (0-79), 16.
Severity of urgency (measured on visual analogue scale, higher score indicates greater
severity) at 18 weeks (median, range, N):
A 35.5 (11-86), 15. B 15.0 (1-58), 16.
IIQ-7 score (lower score indicates higher satisfaction) at 6 weeks (median, range, N):
A 23.8 (0-100), 15. B 28.5 (0-76.1), 16.
IIQ-7 score (lower score indicates higher satisfaction) at 10 weeks (median, range, N):
A 52.3 (0-85.6), 15. B 16.7 (0.52.3), 16.
IIQ-7 score (lower score indicates higher satisfaction) at 18 weeks (median, range, N):
A 51.2 (4.8-68.1), 15. B 4.8 (0-57.8), 16.
90Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ozdedeli 2010 (Continued)
Beck Depression Inventory (lower score indicates lower depression) at 6 weeks (median,
range, N):
A 12.0 (4-34), 15. B 16.0 (1-23), 16.
BeckDepression Inventory (lower score indicates lower depression) at 10 weeks (median,
range, N):
A 14.0 (5-40), 15. B 13.0 (3-23), 16.
BeckDepression Inventory (lower score indicates lower depression) at 18 weeks (median,
range, N):
A 10.0 (5-40), 15. B 9.0 (6-18), 16.
Number of participants satisfied or very satisfied at 6 weeks:
A 93.3% (14/15). B 87.6% (14/16).
Adverse effects:
A 8/17. B 5/18
[Xerostomia (dry mouth): A 5/17. B 0/18. Constipation: A 1/17. B 0/18. Haematuria
secondary to nephrolithiasis: A 1/17. B 0/18. UTI: A 1/17. B 2/18. Vaginal discomfort:
A 0/17. B 1/18. Vaginal haemorrhage: A 0/17. B 1/18.]
Notes Table 2 unclear if mean or median, range etc. No P values
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization list was generated by a
blinded researcher (the third author) using
a table of random numbers.”
Allocation concealment (selection bias) Low risk “The randomization results were kept in
sealed envelopes, one for each patient”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “There was no complete blindness in the
study, since stimulation was applied by a
separate researcher.” Impossible to blind
participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The examination and data collection were
carried out by a different researcher.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A: two withdrawals, one because all
complaints were resolved, one developed
haematuria
B two withdrawals, one menorrhagia and
one vaginal pain.
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Peters 2009
Methods Study design: RCT.
Multicentre: 11 centres in the United States
Setting: not reported.
Period: June 2006 to September 2008.
Sample size: The sample size used to support this analysis was based on the assumptions of
significance level of five%, power of 80%, and expectedmean reduction in voids of 1.8 for
tollerodine and 3.6 for PTNS based on previously published efficacy data. Secondary end
points were analysed using 2 sided t tests with 95% confidence intervals. An independent
biostatistician performed all analyses using SAS® Version 9.2. All voiding diary data
were sent to the biostatistician for compilation and analysis
Follow-up: 12 weeks.
Participants N: 100 randomised, 85 analysed
Mean (SD) age:
A 57.5 (15.2).
B 58.2 (11.3)
Sex: 94 women, 6 men
Inclusion criteria: adults with overactive bladder symptoms, with or without a history
of previous anticholinergic drug use, with at least eight voids per 24 hours documented
by history and physical and voiding diary
Exclusion criteria: OAB pharmacotherapy within the previous month, primary com-
plaint of SUI, demonstrated sensitivity to tolterodine or its ingredients, pacemakers or
implantable defibrillators, excessive bleeding, urinary or gastric retention, nerve damage
or neuropathy, uncontrolled narrow angle glaucoma, positive urinalysis for infection or
pregnancy, or current pregnancy or planning to become pregnant during the trial
Interventions A (n = 50) percutaneous tibial nerve stimulation. One session per week for 12 weeks (no
details reported on frequency, make/model of stimulator etc)
B (n = 50) tolterodine. extended release 4 mg daily for 90 days (decreased to 2 mg if
intolerability was experienced - two participants reduced to 2 mg)
Outcomes Number of participants not cured or improved (subject assessment):
A 9/44. B 19/42.
Number of participants not cured or improved (investigator assessment):
A 9/44. B 17/42.
Number of voids per 24 hours (mean, SD, N):
A 9.8 (3.0), 41. B 9.9 (3.8), 43.
Number of nocturia episodes (mean, SD, N):
A 1.7 (1.1), 41. B 1.9 (1.6), 43.
Number of urgency incontinence episodes per 24 hours (mean, SD, N):
A 1.2 (1.6), 41. B 1.8 (2.5), 43.
Number of moderate to severe urgency episodes per 24 hours (mean, SD, N):
A 3.9 (2.8), 41. B 4.5 (3.6), 43.
Volume voided per 24 hours (cc) (mean, SD, N):
A 185.5 (81.1), 41. B 158.7 (99.8), 43.
Change in number voids per 24 hours (mean, SD, N):
A -2.4 (4.0), 41. B -2.5 (3.9), 43.
Change in number of nocturia episodes per 24 hours (mean, SD, N):
A -0.7 (1.0), 41. B -0.6 (1.7), 43.
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Change in number of urgency incontinence episodes per 24 hours (mean, SD, N):
A -1.0 (2.2), 41. B -1.7 (3.8), 43.
Change in number of moderate to severe urgency episodes per 24 hours (mean, SD, N):
A -2.2 (4.3), 41. B -2.9 (4.8), 43.
Change in volume voided per 24 hours (cc) (mean, SD, N):
A 32.8 (61.3), 41. B 17.6 (58.4), 43.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random blocks design stratified by inves-
tigational site.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawn prior to 12 week follow-up:
withdrew consent n = 5; lost to follow-up
n = 1; withdrew consent n = 3; treatment
unsuccessful n = 3; others n = 1
Peters 2010
Methods Study design: RCT
Multicentre or single-centre: multicentre
Setting: USA
Period: September 2008 to January 2009
Sample size: 214 participants, 107 per study arm, calculated using a 2-sided Fisher’s exact
binomial test based on an estimated 60% responder rate in the PTNS group and a 40%
responder rate in the sham group with a 5% significance level and 80% power
Follow-up: 13 weeks
Participants N: 220 randomised (174 women, 46 men), 208 analysed.
Mean age (no SD):
A 62.5.
B 60.2
Inclusion criteria: > 18 years of age, score of > 4 on the OAB-q short form for urgency,
average urinary frequency of > 10 voids per day, self-reported bladder symptoms > 3
months, self-reported failed conservative care, discontinued all antimuscarinics for > 2
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weeks, capable of giving informed consent, ambulatory and able to use toilet indepen-
dently without difficulty, capable and willing to follow all study-related procedures
Exclusion criteria: pregnant or planning to become pregnant during study duration,
neurogenic bladder,
Botox® use in bladder or pelvic floor muscles within past one year, pacemakers or
implantable defibrillators, current UTI, current vaginal infection, Use of Interstim®,
use of Bion®, Current use of TENS in pelvic region, back or legs, previous PTNS
treatment, use of investigational drug/device therapy within past 4 weeks, participation
in any clinical investigation involving or impacting gynecologic, urinary or renal function
within past 4 weeks
Interventions A (n = 110) electrical stimulation. Percutaneous tibial nerve stimulation. One 30-minute
session per week for 12 weeks. 34-gauge needle electrode inserted at a 60 degree angle
approximately 5 cm cephalad to the medial malleolus, slightly posterior to the tibia.
PTNS surface electrode placed on the ipsilateral calcaneus and 2 inactive sham surface
electrodes, 1 under the little toe and 1 on the top of the foot. Current level of 0.5 to 9
mA at 20 Hz was selected based on each participant’s foot and plantar motor and sensory
responses
B (n = 110) sham ES. One 30-minute session per week for 12 weeks. Streitberger
placebo needle was used to simulate the location and sensation of PTNS needle electrode
insertion. An inactive PTNS surface electrode was placed on the ipsilateral calcaneus.
Two active TENS surface electrodes were placed, 1 under the little toe and 1 on the top
of the foot
Outcomes ‘responder was defined as reporting bladder symptoms as moderately or markedly im-
proved on a 7-level GRA at week 13’
Moderate or marked improvement on global response assessment:
A 60/110. B 23/110
[i.e. no improvement in OAB symptoms:
A 50/110. B 87/110]
No improvement in urinary urgency:
A 59/103. B 81/105.
No improvement in urinary frequency:
A 54/103. B 82/105.
No improvement in urgency incontinence:
A 64/103. B 81/104
Frequency of voiding per 24 hours (mean, SD, N):
A 9.8 (2.8), 103. B 11.0 (3.1), 105.
Frequency of nocturia (mean, SD, N):
A 2.1 (1.4), 103. B 2.6 (1.6), 105.
Mean voided vol (cc) (mean, SD, N):
A 183.0 (75.6), 103. B 172.6 (90.6), 102.
Adverse effects:
A 6/110. B 0/110.
Change in OAB-Q symptom score (mean, SD, N) (lower score is better):
A -36.7 (21.5), 101. B -29.2 (20.0), 102.
Change in SF-36 score (mean, SD, N) (higher score is better):
A 34.2 (21.3), 103. B 20.6 (20.6), 105.
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All subjects were randomized 1:1 at the
first intervention visit to PTNS or sham
using a random block design stratified by
investigational site.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects and study coordinators were
blinded to the intervention”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. ITT analysis car-
ried out for primary outcome
Preyer 2007
Methods Study design: RCT.
Multicentre or single-centre: not reported.
Setting: not reported.
Period: June 2004 and July 2006.
Sample size: not reported.
Follow-up: 12 weeks
Participants N: 31 randomised (n analysed unclear).
Sex: women.
Mean (SD) age: 59.4 (10.9)
Inclusion criteria: adults with urgency incontinence and urge symptoms
Exclusion criteria: contraindications against anticholinergics, pregnancy, tolterodine be-
fore
Interventions A (n = 16) peripheral tibial neurostimulation, one 30-minute session per week for 12
weeks
B (n =15) tolterodine 2 mg daily for 12 weeks.
Outcomes Change in number of micturitions per 24 hours (mean, 95%CI [SD]*, N):
A -0.1 (-3.3 to 3.6 [7.04]), 16. B -0.7 (-2.3 to 3.7 [5.93]), 15. (P = 0.77)
Change in number of incontinence episodes per 24 hours (mean, 95%CI [SD]*, N):
A -1.3 (0.6 to 3.2 [2.65]), 16. B -2.6 (0.1 to 5.3 [5.14]), 15
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Change in number of urgency episodes per 24 hours (mean, 95%CI [SD]*, N):
A -9.3 (7.0 to 11.7 [4.80]), 16. B -9.5 (6.3 to 12.7 [6.32]), 15
Side effects: A 1/16. B 6/15.
Change in QoL (instrument used not reported) (mean, 95%CI [SD]*, N):
A 4.4 (1.7 to 7.1 [5.51]), 16. 4.6 (2.1 to 7.0 [4.84]), 15.
.
Notes *SD calculated by FS
Dropouts: A 3. B 2. Unclear if these participants included in analysis
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three patients (10.3%) in the peripheral
tibial neurostimulation group and; two pa-
tients (6.9%) in the drug group (toltero-
dine)
Sancaktar 2010
Methods Study design: RCT.
Multicentre or single - centre: not reported.
Setting: Turkey
Period: Not reported.
Sample size: Not reported.
Follow-up: 12 weeks.
Participants N: 40 randomised.
Sex: women.
Mean age (range):
Overall 46.4 (33 to 61)
Mean (SD): A 45.4 (8.7). B 47.4 (10.1)
Inclusion criteria: severe OAB symptoms defined as median 6 urgency incontinence
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episodes per 48 hours
Exclusion criteria: stress incontinence, genital prolapse higher than Stage II on POP-Q
system, ocular, cardiological, neurological or metabolic disease, history of pelvic surgery
ultrasonographic evidence of postvoidal retention more than 100 mL and bladder ca-
pacity less than 200 mL, menopausal symptoms indicating significant decrease in QoL,
presence of UTI, prior treatment for OAB
Interventions A (n = 20) tolterodine 4 mg daily for 12 weeks.
B (n = 20) Stoller Afferent Neuro-stimulation (SANS) plus tolterodine 4 mg daily for 12
weeks. One 30-minute session per week for 12 weeks. 34-G acupuncture needle inserted
at 30º angle into 2cm to 3 cm superior-medial aspect of tibial medial malleolus along
posterior tibial nerve trace. 20 Hz frequency, 0.2 ms duration, amplitude of stimulus
adjusted according to participant toleration
Outcomes Frequency per 24 hours (mean, SD, N):
A 6.4 (0.6), 18. B 4.5 (0[sic]), 20. (P < 0.05)
Urgency episodes per 24 hours (mean, SD, N):
A 7.6 (0.9), 18. B 5.7 (0.6), 20. (P < 0.05)
Incontinence episodes per week (mean, SD, N):
A 12.3 (0.8), 18. B 6.4 (0.5), 20. (P < 0.001)
IIQ-7 score (mean, SD, N) (higher score is worse incontinence):
A 11.2 (2.7), 18. B 9.0 (0.8), 20.
Adverse events:
Severe dry mouth: A 3/18. B 2/20
Severe constipation: A 2/18. B 2/20
Headache: A 1/18. B. 0/20
Local irritation on puncture site: A N/A. B 1
> 1 adverse event: A 2/18. B 1/20
Notes We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was obtained using a list
of random numbers.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 withdrawals from tolterodine alone
group; no reason reported
Schmidt 2009
Methods Study design: RCT.
Multicentre or single-centre: single-centre.
Setting: Hosptial das Clínicas de Porto Alegre (HCPA), Brazil
Period: January 2006 at May 2007.
Sample size: To detect a difference of one standard deviation in the study variables after
12 weeks of treatment, the sample size was established as 11 patients per group. This
sample size assumes a significance level of 5% power of 90% and a correlation between
measurements at the two different points of 0.5
Follow-up: 12 weeks’ treatment, 6 months’ follow-up
Participants N: 32 patients randomised.
Sex: Women.
Age mean (SD):
A 54.7 (6.94)
B 49.18 (6.06)
C 52.09 (13.78)
Inclusion criteria: women were older than 30 years of age; SUI or MUI; had not received
any clinical or surgical treatment during the previous 6 months; were free of significant
genial prolapse (below stage 2 on the pelvic organ prolapse quantification system; and had
no urethral sphincter involvement (leak point pressure less than 60 cmH 0).The criteria
for prolapse classification were defined in accordance with International Continence
Society (ICS) guidelines
Exclusion criteria: Not reported.
Interventions All participants received identical specially designed equipment, providing real-time in-
formation on the contraction waveform and information or guidance. Vaginal probe
transducer for monitoring pelvic muscle contraction pressure during exercises. Pro-
grammable for either PFMT plus biofeedback, PFMT plus ES or PFMT without feed-
back
All participants same exercise programme: supine position with rapid contractions (2
seconds contraction, 4 seconds rest) then slow contractions (4 seconds contraction, 4
seconds of rest), repeated 3 times with rest interval
A (n = 10) PFMT plus biofeedback for 12 weeks. Device displays information on con-
traction intensity
B (n = 11) PFMT plus electrical stimulation for 12 weeks. Frequency 50 Hz and pulse
duration of 300 µs
C (n = 11) PFMT alone for 12 weeks. Participants received no information from device
on contraction intensity
Outcomes Subjective self-evaluation at 12 weeks:
Cure or significant improvement: 71.9% (23/32)
Partial improvement: 18.8% (6/32)
Poor response: 9.4% (3/32)
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Perineometric intensity (pelvic floor muscle strength) (IC cm H2O) (mean, SD, N):
12 weeks: A 57.93 (26.15), 10. B 49.7 (25.87), 11. C 47.67 (25.26), 11
6 months: A 51.12 (28.69), 10. B 41.85 (26.1), 11. C 48.88 (19.25), 11
Number of daytime micturitions (median, IQR, N):
12 weeks: A 7 (4-8.25), 10. B 5 (5-6), 11. C 7 (5-10), 11.
6 months: A 7.5 (6-9.25), 10. B 4.5 (4-6), 11. C 1.5 (0-3), 11
Number of nocturia episodes (median, IQR, N):
12 weeks: A 1 (1-2), 10. B 0 (0-1), 11. C 2 (1-2), 11.
6 months: A 1.5 (0-3), 10. B 1 (0.75-2.25), 11. C, 1 (0.75-2.25), 11
Number of SUI episodes (median, IQR, N):
12 weeks: A 1 (0-2), 10. B 0 (0-1), 11. C 2 (0-3), 11.
6 months: A 1 (0.75-2.25), 10. B 0.5 (0-1.25), 11. C 0 (0-5.25), 11
Number of UUI episodes (median, IQR, N):
12 weeks: A 0 (0-1.25), 10. B 0 (0-0), 11. C 1 (0-2), 11.
6 months: A 0.5 (0-1), 10. B 0 (0-0), 11. C 2 (1-3), 11.
King’s Health Questionnaire scores (mean, SD, N):
12 weeks: A 44.25 (9.11), 10. B 33.12 (19.54), 11. C 48.7 (22.21), 11
6 months: A 41.12 (15.44), 10. B 28.25 (11), 11. C 49.3 (24.96), 11
Notes No useable data because SUI and MUI participants not separated. Cure/significant
improvement not stratified by treatment group
Emailed author 19/12/2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly allocated”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported. Blinding of participants not
possible.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The examiner who performed perineom-
etry was blinded to the patients [sic] group.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in the
analysis. No dropouts reported
99Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schreiner 2010
Methods Study design: RCT.
Multicentre or single-centre: single-centre.
Setting: Urogynecology Section of the Gynecology Department in São Lucas Hospital
of Pontificia Universidade Católica do Rio Grande do Sul, Brazil
Period: February 2008 to October 2008
Sample size: not reported.
Follow-up: 12 weeks’ treatment, 2 years’ follow-up
Participants N: 52 randomised, 51 analysed.
Mean (SD) age:
Overall: 68.3 (5.3)
A 67.6 (5.2)
B 68.9 (5.4)
Sex: women
Inclusion criteria: UUI and age of 60 years of more.
Exclusion criteria: the presence of urinary infection during the recruitment process, prior
surgery for urinary incontinence, history of genito-urinary cancer, pior pelvic irradiation,
pure SUI, genital prolapse above the second degree of Baden Walker, and inability to
perform the Kegel exercises
Interventions All participants: PFMT (Kegel exercises); 15 contractions three times per day for 12
weeks
A (n = 25) transcutaneous tibial nerve stimulation. One 30-minute session per week for
12 weeks. Pulse duration 200 ms, frequency 10 Hz
B (n = 26) PFMT only.
Outcomes Daytime frequency (mean, SD, N):
A 5.9 (1.4), 25. B 6.8 (1.9), 26.
Change in daytime frequency (mean, SD, N):
A -1.4 (2), 25. B -0.2 (0.9), 26.
Number of nocturia episodes (mean, SD, N):
A 1.3 (1.5), 25. B 2.4 (1.3), 26.
Change in nocturia (mean, SD, N):
A -1.6 (1.1), 25. B -0.4 (1.1), 26
Number of SUI episodes (mean, SD, N):
A 2.4 (3.4), 25. B 4.0 (6.0), 26.
Change in SUI episodes (mean, SD, N):
A -1.1 (4.9), 25. B -1.9 (3.1), 26.
Number of UUI episodes (mean, SD, N):
A 1.8 (2.7), 25. B 4.6 (3.7), 26.
Change in UUI episodes (mean, SD, N):
A -6.3 (5.3), 25. B -1.3 (1.6), 26.
Number of participants with > 50% reduction in UUI episodes:
A 76.0% (19/25). B 26.9% (7/26) (P = 0.001)
Subjective global satisfaction:
12 weeks: A 68.0% (17/25). B 34.6% (9/26) (P = 0.017)
2 years: A 64.7%. B NR
Number of participants with UUI:
A 44.0% (11/25). B 80.8% (20/26)
100Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schreiner 2010 (Continued)
ICIQ-SF score (mean, SD, N):
A 7.9 (4.5), 25. B 10.6 (4.4), 26.
Adverse effects:
A 0. B 0.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients were randomly divided
(through simple random number genera-
tor) into two groups.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient of group EE left the study due
to health problems unrelated to the therapy
Seth 2014
Methods Study design: RCT
Multicentre or single-centre: single
Setting: UK
Period: NR
Details of sample size calculation: NR
Follow-up: 12 weeks
Participants N: 48 randomised and 35 analysed.
Mean (SD) age: NR
Sex: NR
Inclusion criteria: either multiple sclerosis or idiopathic OAB
Exclusion criteria: NR
Interventions A (n = 24*) 30 minutes stimulation once per day for 12 weeks with geko device
B (n = 24*) 30 minutes stimulation once per week for 12 weeks with geko device
Outcomes Improvement in ICIQOAB score: -10.2 (-13.5 to -6.9, P = 0.001)
Improvement in ICIQLUTS-QOL score: -40.8 (-57.4 to -24.3, P = 0.000)
*Responders: 18/34
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Notes N randomised per group not reported. Outcome data not presented per group
Contacted author for more information 5 February 2014 - replied with data marked*
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 48 randomised, 35 completed study (dif-
ferential attrition: 20 with MS, 15 with id-
iopathic OAB). Unclear how many with-
drew from each group. Unclear if all
randomised participants were included in
analysis
Shepherd 1984
Methods Study design: RCT
Multicentre or single-centre: single
Setting: UK
Period: NR
Details of sample size calculation: NR
Follow-up: 12 weeks.
Participants N: 107 randomised, 94 analysed.
SUI 42
UUI 26
MUI 39
Mean (SD) age: NR
Sex: women
Inclusion criteria: SUI, UUI or MUI
Exclusion criteria: NR
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Interventions A (n = 53) ES under general anaesthesia. Single session. Scott electrode in vagina, large
indifferent electrode under buttocks. Current up to 40 v, 10-50 Hz for 20 minutes
B (n = 54) sham treatment. Single session. Vaginal electrode but no current
Outcomes Participants with no improvement in frequency of incontinence:
A 16/45. B 18/49
Participants not dry:
A 37/45. B 43/49
Participants with no improvement in pad changes:
A 27/45. B 31/49
Participants with no improvement in objectively measured pelvic floor control:
A 23/45. B 23/49
Participants with no improvement in incontinence:
A 18/45. B 16/49.
Notes Not useable because data not presented by SUI/UUI/MUI groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Allocated at random into trial and control
groups.”
Allocation concealment (selection bias) Low risk “a sealed envelope was opened stating
which group the patient was in”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants blinded. Other blinding not
reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients’ subjective statements
were recorded by a single observer who was
unaware of the treatment allocation”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nodifferential dropout.No explanation re-
ported for withdrawals
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Shepherd 1985
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: UK
Period: NR
Details of sample size calculation: NR
Follow-up: 6 months
Participants N: 40 randomised, 15 analysed.
Mean (SD) age: NR
Sex: women
Inclusion criteria: genuine stress incontinence or DO
Exclusion criteria: NR
Interventions A (n = 6 SUI, 4 DO) ES. Intra-vaginal cushion attached to stimulator worn around the
waist. Cushion worn for 8 hours per 24, night or day according to participant preference.
Stimulation: 50 Hz (SUI participants), 10 Hz (DO participants)
B (n = 3 SUI, 2 DO) sham ES. Identical device to Group A but not activated
Outcomes Subjective and objective improvement in symptoms
Notes No useable data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants given identical devices but
unaware which were activated. “The code
was held by themanufacturer and only bro-
ken when the trial was completed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal per group not reported. Sub-
stantial withdrawal overall: 15/40 com-
pleted trial
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Methods Study design: RCT.
Multicentre or single-centre: single-centre.
Setting: Department of Urology, Lahey Clinic, Burlington, Massachusetts
Period: October 1992 to January 1994.
Sample size: not reported.
Follow-up: 16 weeks.
Participants N: 57 randomised in total. 38 with DI randomised and analysed
Mean age (range):
A 65 (45-82)
B 60 (44-73)
Sex: Women.
Inclusion criteria: genuine SUI or DI.
Exclusion criteria: type 3 SUI, pregnancy, history of prolonged urinary retention, vaginal
vault prolapse, diminished sensory perception or cardiac pacemaker
Interventions A (n = 20) propantheline bromide 7.5 mg to 45 mg 2 to 3 times daily (‘or until side
effects prevented its continuance’) for at least 4 months
B (n = 18) ES. 5-second impulse time, duty cycle 1-2, increasing monthly treatment
time from 15, 30, 45 and 60 minutes. Amplitude started at 5 mA and did not exceed
25 mA. Twice daily for 4 months
Outcomes Number of participants cured (defined as cessation of incontinence and no longer re-
quiring pads):
A 3/20. B 4/18
Number of participants with objective improvement (defined as reduction of ≥ 50% in
episodes and pads, and ≤ 10 voiding episodes per 24 hours):
A 7/20. B 9/18
Number of participants with no improvement:
A 10/20. B 5/18.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “patients were randomized to 1 of 2 treat-
ment arms”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blindparticipants. Blinding
of others not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported.
Soomro 2001
Methods Study design: cross-over RCT.
Multicentre or single-centre: single-centre.
Setting: University of New South Wales, New South wales, Australia
Period: not reported.
Sample size: the study was designed to obtain a type 1 error of 5% and a power of 85%
which gave a sample size of 35
Follow-up: 6 weeks.
Participants N: 43 randomised and analysed.
Mean (SD) age: 50 (15)
Sex: 13 males, 30 females.
Inclusion criteria: history of frequency, urgency and urge incontinence with no previous
treatment for at least 6 months
Exclusion criteria: not reported.
Interventions A (n = 43) oxybutynin 2.5 mg twice daily, titrated to 5 mg 3 times daily by day 7
B (n = 43) transcutaneous electrical nerve stimulation 20 Hz, pulse width 0.2 ms on a
continuous mode up to 6 hours daily for 6 weeks
All participants had washout period of 2 weeks then 6 weeks of the other treatment
Outcomes Number of daily voids (mean, SD, N):
A 9 (5), 43. B 9 (4), 43.
Number of participants with no subjective improvement:
A 30/40. B 29/38
Total bladder capacity (mL) (mean, SD, N):
A 303.3 (142.5), 43. B 222.1 (99.2), 43
Volume at first desire to void (mL) (mean, SD, N):
A 191.8 (130.1), 43. B 117.4 (84.7), 43.
Residual volume (mL) (mean, SD, N):
A 81.3 (81.3), 43. B 38.9 (55.03), 43.
Volume at instability (mL) (mean, SD, N):
A 180.9 (92.8), 43. B 96.3 (55.9), 43.
Number of participants with > 25% improvement in bladder capacity:
A 6/43. B 2/43.
Number of participants with > 25% improvement in daily voids:
A 21/43. B 24/43.
Number of participants with side effects (N unclear):
Dry mouth: A 87.2% (37/43). B 6.2% (3/43)
Blurred vision: A 52.6% (23/43). B 6.2% (3/43)
Dry skin: A 29.7% (13/43). B 6.2% (3/43)
Skin irritation: A 25.6% (11/43). B 28.1% (12/43)
Cost per participant:
A oxybutynin £15.00 for 6 weeks
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B ES, including consumables, £60 for 6 weeks
Notes N assumed to be 43 unless otherwise stated.
Data not useable. Cross-over design requires paired difference and SD for each outcome
but paper reports insufficient data for analysis
Contacted author asking for further data 26 January 2015.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized to initial treat-
ment with either transcutaneous electrical
nerve stimulation or oxybutynin. After a
washout period of 2 weeks, patients were
started on the second arm of treatment”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blindparticipants. Blinding
of others not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if data available for all participants.
Also risk of carry-over effect is unclear
Sotelo 2011
Methods Study design: RCT
Multicentre or single-centre: single
Setting: USA
Period: NR
Details of sample size calculation: NR
Follow-up: 8 days
Participants N: 50 randomised and analysed.
Mean (SD) age: 57
Sex: NR
Inclusion criteria: OAB
Exclusion criteria: NR
Interventions A (n = 15) ES, no tub bathing or exercise. Horizontal placement of electrode patch near
sacral nerve
B (n = 15) ES, no tub bathing or exercise. 30-degree angle placement of electrode patch
near sacral nerve
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C (n = 5) ES, with daily tub bathing or swimming. Horizontal placement of electrode
patch near sacral nerve
D (n=5)ES,with daily tubbathing or swimming. 30-degree angle placement of electrode
patch near sacral nerve
E (n = 5) ES, with daily 30-minute exercise regimen. Horizontal placement of electrode
patch near sacral nerve
F (n = 5) ES, with daily 30-minute exercise regimen. 30-degree angle placement of
electrode patch near sacral nerve
Outcomes Adverse effects: 1 participant (not reported by group)
Patch awareness, discomfort, bother, 1-10 VAS (mean, SD), N):
A+B: 1.4 (1.1), 30. C+D: 1.2 (0.9), 10. E+F: 1.3 (1.0), 10.
Notes No useable data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized to one of two sacral placement
angles”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data not reported per group
Souto 2014
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: Brazil
Period: August 2008 - May 2010
Details of sample size calculation: ‘a prior power calculation…even after dropout, 80%
sample power was kept (post hoc analysis)
Follow-up: 12 weeks’ treatment, 6 months’ follow-up.
Participants N: 75 randomised, 58 analysed.
Mean (range) age: A 56.9 (33-77. B 57.7 (34-79). C 60.1 (33-77)
Sex: women
Inclusion criteria: clinical complaints of OAB: urinary frequency, nocturia, and/or ur-
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gency incontinence with negative urinalysis and urine culture
Exclusion criteria: previous treatment, residual urine, cognitive and psychiatric deficits,
pregnancy, glaucoma, stress urinary incontinence, any pelvic organ prolapse quantifica-
tion system (POPQ) C grade II, neurogenic OAB, those using anticholinergic drugs,
calcium antagonists, b-antagonists, and dopamine antagonists
Interventions A (n = 25) ES of posterior tibial nerve using Neurodyn Portable. 10 Hz frequency, pulse
width of 250 µs. Two 30-minute sessions per week for 12 weeks
B (n = 25) slow release oxybutynin 10 mg, once daily for 12 weeks
C (n = 25) multimodal treatment, A + B
Outcomes Frequency (mean*, N):
12 weeks: A 8, 18. B 7.9, 19. C 7.6, 21. (P = 0.75)
24 weeks: A 7.9, 18. B 9.2, 19. C 7.8, 21 (P = 0.51).
Participants with urinary incontinence:
12 weeks: A 11% (2/18). B 31% (6/19). C 19% (4/21).
24 weeks: A 14% (3/18). B 34% (6/19). C 18% (4/21).
Participants with nocturia:
12 weeks: A 11% (2/18). B 5% (1/19). C 14% (3/21). (P = 0.24)
24 weeks: A 13% (2/18). B 15% (3/19). C 14% (3/21). (P = 0.51)
International Consultation on Incontinence Questionnaire (ICIQ-SF) score (mean*,
range, N):
12 weeks: A 7.2 (0-18), 18. B 9.8 (0-18), 19. C 7.9 (0-14), 21
24 weeks: A 8.3 (0-20), 18. B 13.3 (8-20), 19. C 7.4 (0-14), 21
ICIQ-OAB (mean*, range, N):
12 weeks: A 5.9 (1-11), 18. B 4.6 (0-10), 19. C 2.9 (0-5), 21
24 weeks: A 6.1 (1.-12), 18. B 9.2 (4-13), 19. C 3.0 (0-5), 21
Bother: 0-10 analogue scale (mean, range, N):
12 weeks: A 3.9 (0-8), 18. B 3.4 (0-9), 19. C 1.7 (0-4), 21.
24 weeks: A 4.2 (0-8), 18. B 7.0 (2-10), 19. C 1.6 (0-4), 21
Notes *SD not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ‘patients were divided randomly
into three groups using online randomiza-
tion’
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants. Person-
nel not reported.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ‘Patients who failed to comply with the 12
weeks of treatment (Week 12) and/or did
not attend the reassessment after treatment
(Week 24) at 6 months follow-up were ex-
cluded from analysis.’
No differential withdrawal. No reasons
given for withdrawals
Spruijt 2003
Methods Study design: RCT.
Single centre.
Setting: Vrije University Medical Center Amsterdam.
Period: January 1996 and May 1998
Sample size: 75 patients for this study (alpha=5%, beta 10%, estimated difference=10%)
Follow-up: eight weeks.
Participants N: 72 enrolled, 37 randomised, 35 analysed
Sex: women.
Median age (range):
A 72 (65 to 92)
B 74 (66 to 86)
Inclusion criteria: women ≥ 65 with symptoms of stress, urgency or mixed urinary
incontinence for ≥ three months, urinary leakage of 10 cc or more per 24 hours
Exclusion criteria: persistent urinary tract infection (positive urine culture after antibiotic
treatment), recurrent UTI (within four weeks after treatment), bladder pathology or
dysfunction because of fistula, tumour, pelvic irradiation, neurological or other chronic
conditions (diabetes mellitus, Parkinson´ s disease), any incontinence treatment during
the past 6 months, genital prolapse to, or beyond, the introitus having a pacemaker, and
insufficient mental condition/cognition
Interventions A (n = 25) ES. Three 30-minute sessions, with 5 minutes rest between each 15 minutes
of treatment, per week for 8 weeks. Frequency 50 Hz for predominant SUI and 20 Hz
for predominant UUI. 2-s contraction time and duty cycle of 1-2 s, stimulation intensity
gradually increasing up to the level of tolerable discomfort (0-100 mA)
B (n = 12) PFMT. Verbal instructions on performing Kegel exercises at home for 8 weeks
Outcomes Urinary leakage per day (mg) (mean, range, N):
A 65 (0-489), 24. B 26 (4-157), 11.
Number of participants with no objective improvement:
A 17/24. B 7/11.
Pelvic muscle strength (mean, range, N):
A 15.375 (1.75-40.00), 24. B 10.00 (3.25-23.00).
Number of participants with DI defined as spontaneous detrusor contraction(s) of 15
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cm H2O or more on (ambulant) urodynamic registration (ICS standard).:
A 14/24. B 5/11.
Number of participants with no subjective improvement (measured with PRAFAB score)
:
A 13/24. B 6/11.
Notes No useable data - not presented by SUI/UUI/MUI participants.
Authors contacted for data 09-02-2015
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked randomisation according to
Pocock’s method
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was one patient in each group lost to
follow-up.
Svihra 2002
Methods Study design: quasi-RCT
Multicentre or single-centre: not reported.
Setting: Slovakia.
Period: 2001.
Sample size: not reported.
Follow-up: 5 weeks
Participants N: 28.
Sex: women.
Mean age (range): 54 (45-63)
Inclusion criteria: OAB without bladder outlet obstruction confirmed by urodynamic
examination
Exclusion criteria: not reported.
Interventions A (n = 9) SANS electrical stimulation (Stoller Afferent Neuro Stimulation). One 30-
minute session per week for five weeks. Frequency 1 Hz, square impulse duration 0.1ms,
intensity 25 mA
B (n = 10) oxybutynin 3 mg three times per day
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C (n = 9) no active treatment
Outcomes IPSS (mean, SD, N)
A 6 (4), 9. B not reported. C not reported.
Incontinence Quality of Life Questionnaire (I-QoL) score (mean, SD, N):
A 68 (20), 9. B not reported. C not reported.
Behavioural Urge Score (BUS) (mean, SD, N):
A 0.43 (0.16), 9. B not reported. C not reported.
Change in IPSS (mean, N):
A 60%, 9. B 80%, 10. C 20%, 9.
Change in I-QoL (mean, N):
A 100%, 9. B 90%, 10. C 25%, 9.
Change in BUS (mean, N):
A 30%, 9. B 30%, 10. C 5%, 9.
Number of participants with no significant improvement in IPSS, IQoL, BUS:
A 4/9. B not reported. C 9/9
Number of participants with adverse effects:
A 0/9. B 2/10 (dry mouth). C not reported.
Notes Only adverse events data are useable.
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Nine randomly chosen females formed the
group with SANS stimulation, ten females
formed the oxybutynin group and nine fe-
males the group without treatment.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported.
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Methods Study design: RCT
Multicentre or single-centre: single
Setting: Finland
Period: NR
Details of sample size calculation: NR
Follow-up: 2 weeks’ treatment then 6 months’ follow-up
Participants N: 80 randomised, unclear how many analysed.
Mean (SD) age: A women 42.2 (8.9). A men 45.3 (6.3). B women 45.7 (10.7). B men
41.8 (11.8)
Sex: 50 women, 30 men
Inclusion criteria: stable phase of MS, baseline Expanded Disability Score≤ 6.5, LUTS,
postvoid residual volume < 100 mL
Exclusion criteria: pregnancy, cardiac pacemaker or any metallic implant near the treated
area, history of pelvic malignancy, dementia or any nervous system disorder other than
MS
Interventions A (n = 40) ES. 6 sessions over two weeks. Intravaginal electrodes for women, intra-anal
for men. 10 minutes of each frequency: 5 to 10 Hz, 10 to 50 Hz, 50 Hz (7s pulse, 25 s
pause), with 3 minutes rest in between. Currents at maximal tolerated intensity. After 6
ES sessions biofeedback used to teach PFME, participants advised to continue PFME 3
to 5 times per week for ≤ 6 months
B (n = 40 no active treatment.
Outcomes Urgency, urine leakage, volume of urine loss, voiding need during daytime, slow urine
flow, sensation of incomplete bladder emptying, need of assistance in emptying bladder
Notes No useable data: no outcomes reported by treatment group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Men and women were separately random-
ized into a treatment group”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No outcomes reported for control group
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Methods Study design: cross-over RCT.
Multicentre or single-centre: not reported.
Setting: Italy.
Period: June 2010 to October 2011
Sample size: not reported.
Follow-up: approximately 6months (40 days’ drug treatment, 6 weeks ES, with 3-month
washout period in between)
Participants N: 40 randomised, 30 analysed.
Sex: women.
Mean age (range): 62 (35-81).
Inclusion criteria: women with OAB syndrome.
Exclusion criteria: stress incontinence,UTI, neurological disease, bladder lithiasis, genital
prolapse higher than stage II on POP-Q system, uncontrolled narrow angle glaucoma,
pelvic tumors, postvoid residual urine ≥ 100 mL, or previously treated with pelvic
surgery, radiation therapy or antimuscarinic agents
Interventions A (n = 20) solifenacin succinate, 5 mg daily for 40 days. 3-month washout period then
percutaneous tibial nerve stimulation, 30-minute session twice a week for 6 weeks
B (n = 20) reverse of group A.
Outcomes Number of voids per 24 hours (mean, SD, N):
Post-SS: A 10 (2.1), 14. B 10.4 (1.8), 16.
Post-ES: A 8.5 (2.3), 14. B 9.4 (1.9), 16.
Number of nocturia episodes:
Post-SS: A 1.9 (1.4), 14. B 2.1 (1.4), 16.
Post-ES: A 1.6 (1.3), 14. B 1.7 (0.9), 16.
Number of urgency incontinence episodes:
Post-SS: A 2.6 (1.6), 14. B 2.7 (1.6), 16.
Post-ES: A 1.7 (1.3), 14. B 1.7 (1.5), 16.
Voided volume (cc?) (mean, SD, N):
Post-SS: A 147.4 (27.5), 14. B 145.5 (29.6), 16.
Post-ES: A 157.5 (25.5), 14. B 156.1 (18.4), 16.
QoL measured with Overactive Bladder Questionnaire Short Form (6 item OAB-qSF
score [mean, SD, N]) (lower score is better):
Post-SS: A 3.2 (1.1), 14. B 3.5 (1.2), 16.
Post-ES: A 2.7 (1.0), 14. B 3.0 (1.0), 16.
QoL measured with Overactive Bladder Questionnaire Short Form (13 item OAB-qSF
score [mean, SD, N]) (lower score is better):
Post-SS: A 3.1 (1.1), 14. B 3.4 (1.2), 16.
Post-ES: A 2.9 (0.9), 14. B 2.9 (1.1), 16.
Urgency measured with Patient Perception of Intensity of Urgency Scale (PPIUS score
[mean, SD, N]) (lower score is better):
Post-SS: A 2.7 (1.2), 14. B 2.7 (1.3), 16.
Post-ES: A 2.1 (0.9), 14. B 2.2 (1.1), 16.
Improvement measured with Patient Global Impression of Improvement questionnaire
(PGI-I score [mean, SD, N]) (lower score is more improvement)
Post-SS: A 2.9 (1.1), 14. B 3.1 (1), 16.
Post-ES: A 2.1 (0.7), 14. B 2.3 (0.7), 16.
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Notes Include data from first period of randomisation only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Follow-up was performed by a physician
who was not involved in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk A: 2 participants withdrew due to side ef-
fects, 2 withdrew after SS due to improved
symptoms, 2 refused to undergo further
therapy
B: 3 withdrew due to improved symptoms,
1 refused to undergo further therapy
Vohra 2002
Methods Study design: RCT.
Single-centre.
Setting: Bedford, UK
Period: not reported.
Sample size: not reported.
Follow-up: 12 weeks
Participants N: 22 randomised, 21 analysed
Sex: not reported.
Mean age (range): 52.6 (28-78)
Inclusion criteria: symptoms of at least six months duration, clinical diagnosis of urgency,
frequency syndrome and urodynamic findings of DO
Exclusion criteria: not reported.
Interventions A (n = 11) Stoller Afferent Nerve Stimulation (SANS) one 30-minute session per week
for 12 weeks. Stimulation of posterior tibial nerve with percutaneous needle, current up
to 10 mA
B (n = 10) sham treatment without nerve stimulation.
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Outcomes Number of participants with no improvement:
A 2/11. B 10/10.
Notes ---
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were computer randomised to ei-
ther the treatment arm or as controls”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one patient discontinued the treat-
ment.
Walsh 2001
Methods Study design: RCT.
Multicentre or single-centre: not reported.
Setting: not reported.
Period: not reported.
Sample size: not reported.
Follow-up: not reported.
Participants N: 146 randomised and analysed.
Mean age (range): 47 (17-79)
Sex: 35 men /111 women.
Inclusion criteria: urgency incontinence; idiopathic detrusor instability (DI), sen-
sory urge (SU), or detrusor hyperreflexia (DH) secondary to either spinal injury,
myelomeningocele, or multiple sclerosis
Exclusion criteria: not reported.
Interventions A (n = 74) transcutaneous neurostimulation. One session: electrode pads of a transcu-
taneous neurostimulator (Coba 208 neurostimulator unit, Tenscare Ltd., Surrey, U.K.)
were affixed bilaterally to the skin overlying the S3 dermatomes (situated at the junction
of buttock and upper thigh) in all patients. Standard urodynamic filling cystometry was
performed via a dual-lumen 7-Ch fluid filled catheter system at a 50 mL/minute fill rate
B (n = 72) sham treatment. Standard urodynamic filling cystometry was performed via a
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dual-lumen 7-Ch fluid filled catheter system at a 50 mL/minute fill rate. Electrode pads
on place but without applying current
Outcomes Infused bladder volume (mL) at FDV (mean, SD, N):
A 167.2 (11.3), 74. B 114.2 (10.7), 72.
Detrusor pressure at FDV (mean, SD, N):
A 8.4 (1.3), 74. B 9.4 (1.5), 72.
Infused bladder volume (mL) at strong desire to void (SDV) (mean, SD, N):
A 247.4 (12.8), 74. B 193.7 (18.4), 72.
Detrusor pressure at SDV (mean, SD, N):
A 10.9 (3.1), 74. B 10.6 (1.8), 72.
Infused bladder volume (mL) at sensation of urgency (Urge) (mean, SD, N):
A 331.5 (15.9), 74. B 255.4 (11.4), 72.
Detrusor pressure at Urge (mean, SD, N):
A 18.6 (3.2), 74. B 22.6 (5.3), 72.
Maximum infused cystometric capacity (mL) (CMax) (mean, SD, N):
A 404.2 (26.7), 74. B 315.9 (22.9), 72.
Detrusor pressure at CMax (mean, SD, N):
A 20.5 (3.2), 74. B 25.9 (3.5), 72.
Notes We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized into age- and
gender-matched control and study groups.
”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study and
were included in the analysis
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Methods Study design: RCT.
Multicentre or single-centre: not reported.
Setting: Taiwan.
Period: July 2001 to December 2002.
Sample size: on the basis of the outcome measures (including QOL assessment, blad-
der diary, patient perception of improvement and satisfaction with treatment, and the
improvement rate of ES, PFMT, and BAPFMT, which was 49%, 82,39%, and 80.7%,
respectively), the authors conducted a test with a significance level of 0.05 and power
of 0.9 and anticipated that groups of equal size were required. The total sample size
required was at least 109.5
Follow-up: 12 weeks.
Participants N: 120 randomised, 103 analysed
Mean age:
A 50.09
B 52.32
C 55.74
Sex: women.
Inclusion criteria: OAB symptoms for≥ 6months, 16-75 years old, frequency of voiding
≥ 8 times per day, ≥ 1 urgency incontinence episode per day
Exclusion criteria: pregnancy, deafness, neurologic disorders, diabetes mellitus, pace-
maker or intrauterine device use, genital prolapse greater than Stage II of the Interna-
tional Continence Society grading system, residual urine greater than 100 mL, and uri-
nary tract infection
Interventions A (n = 40) PFMT. At least 3 times daily, performed according to PERFECT scheme
(power/endurance/repetition//fast contraction),
B (n = 38) biofeedback-assisted PFMT. Intravaginal electromyogram probe (Periform,
NeenHealth-Care) twice per week, participants contracted or relaxed pelvic floormuscles
according to visual EMG signals. Also encouraged to perform PFMT at home according
to PERFECT scheme
C (n = 42) ES. Two 20-minute sessions per week with intravaginal electrode (Periform,
Neen HealthCare); biphasic, symmetric, pulsed current with frequency of 10 Hz, pulse
width 400µs, duty cycle of 10 seconds on, 5 seconds off, and intensity varying with
patient tolerance (minimum 20 to 63 mA, maximum 40 to 72 mA)
Outcomes Number of participants with urgency incontinence (no improvement):
A 21/34. B 17/34. C 17/35
Number of participants with no improvement in OAB:
A 21/34. B 17/34. C 17/35
King’s Health Questionnaire total score (mean, SD, N) (lower score is better):
A 50.27 (171.42), 34. B 185.86 (176.57), 34. C 180.08 (176.03), 35
Data for all 9 KHQ domains available: see Table II
Notes Gives data for incontinence episodes per day but then states “We decided not to use this
parameter as an outcome measure because of the large number of incomplete records,
which could have resulted in a statistical bias.”
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “The allocation of the three study groups
was undertaken by sequentially opening a
sealed envelope, prepared by the Biostatis-
tics Center for Chang Gung Medical Col-
lege in blocks of 6”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants could not be blinded.
“The physiotherapist conducted the regi-
mens while unaware of the progress and
outcomes of the interventions.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The principal investigator was not in-
volved in any of the interventions and was
unaware of the group allocation.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. Adequate expla-
nation for dropouts.
Wang 2006
Methods Study design: RCT.
Multicentre or single-centre: single-centre
Setting: Taiwan
Period: July 2004 - November 2005
Sample size: On the basis of the reduction rate of urge incontinence after ES, oxybutynin,
and placebo (51%,7; 76%,5; and 19%, 8 respectively), we conducted a test with a
significance level of 0.05 and power of 0.95 and anticipated that groups of equal size
were required. We concluded that at least 72 women were required
Follow-up: 12 weeks
Participants N: 74 randomised, 68 analysed
Sex: women
Mean age (SD): not reported
Inclusion criteria: OAB≥ 6 months, age 16-80, in particular urinary urgency four times
or more per day
Exclusion criteria: pregnancy, neurologic disorders, diabetes mellitus, demand cardiac
pacemaker or intrauterine device use, genital prolapse greater than Stage II of the Inter-
national Continence Society grading system, a postvoid residual urine volume greater
than 100 mL, overt SUI, a history of anti-incontinence surgery, and UTI
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Interventions A (n =25) ES. Two 20-minute sessions per week. biphasic, symmetric, pulsed current
with a frequency of 10 Hz, pulse width of 400 s, duty cycle of 10 seconds on and 5
seconds off, and intensity varying with patient tolerance (minimum 20 to 63 mA and
maximum 40 to 72 mA)
B (n =26) oxybutynin 2.5 mg, three times per day for 12 weeks
C (n = 23) placebo tablets identical to oxybutynin, 3 times per day for 12 weeks
Outcomes No improvement in urgency:
A 10/24. B 14/23. C 19/21.
Daily voided volume (mL) (median, range, N):
A 2270 (1210-3106), 24. B 2100 (1619-3200), 23. C 2305 (1351-3221) 21
Pad count (median, range, N):
A 0 (0-2), 24. B 0 (0-2.5), 23. C 1 (0-3), 21.
Urgency episodes per 24 hours (median, range, N):
A 1.0 (0.0-12.3), 24. B 6 (0.5-13), 23. C 7.4 (3.9-13.4), 21
Frequency per 24 hours (median, range, N):
7.8 (1.8-13.0), 24. B 7.4 (2-14), 23. C 10 (6.6-16.3), 21.
Nocturia episodes per night (median, range, N):
A 0 (0-3.0), 24. B 0 (0-2.0), 23. C 1 (0-3.6), 21.
Urgency incontinence episodes per 24 hours (median, range, N):
A 0.5 (0-2), 24. B 0 (0-2), 23. C 1 (0-2), 21.
Change in daily voided volume (mL) (median, range, N):
A 70 (-216 to 1190), 24. B 10.5 (-1031 to 962), 23. C -14.5 (-590 to 413), 21
Change in pad count (median, range, N):
A -0.9 (-2.1 to 2), 24. B 0 (-1 to 2), 23. C 0 (-4 to 3), 21
Change in urgency episodes per 24 hours (median, range, N):
A -3 (-14 to 0.5), 24. B -3 (-12 to -0.1), 23. C -1.3 (-10.5 to 2)
Change in frequency per 24 hours (median, range, N):
A -3.0 (-14 to 0.5), 24. B -2.15 (-12.8 to 2.3), 23. C -0.75 (-6.5 to 2.3)
Change in nocturia episodes per night (median, range, N):
A -0.8 (-6.5 to 0.4), 24. B 0 (-2 to 1), 23. C 0 (-1.5 to 2)
Change in urgency incontinence episodes per 24 hours (median, range, N):
A 0 (-2 to 2), 24 B 0 (-1 to 1), 23. C 0 (-2 to 1), 21.
Notes Contacted author December 2014 to clarify if this is different study from Wang 2009.
Awaiting reply.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “The allocation of the three study groups
was undertaken by sequentially opening a
sealed envelope, prepared by the Biostatis-
tics Center for Chang Gung Medical Col-
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lege in blocks of six for each patient”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “For the pharmacotherapy groups, the pa-
tients and all investigators were unaware of
the regimen they received from the central
pharmacy of our hospital.”
Not possible to blind ES group.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The principal investigator was not in-
volved in any of the interventions and was
unaware of the group allocation.’
‘For the pharmacotherapy groups, the pa-
tients and all investigators were unaware of
the regimen they received from the central
pharmacy of our hospital.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One woman in the ES group withdrew
because of fear of the electricity. Three
women in the oxybutynin group withdrew,
all because of intolerable dry mouth. Two
women in the placebo group withdrew be-
cause they felt no response.”
Wang 2009
Methods Study design: RCT.
Multicentre or single-centre: single-centre
Setting: Taiwan
Period: July 2006 to November 2007.
Sample size: calculations for the treatment and placebo groups were based on the as-
sumption that participants in the treatment groups had a 0.76 probability and others in
the placebo group had a 0.36 probability of achieving a better outcome (increased UFI)
.To achieve 0.80 power with 0.05 significance level, it required at least 24 participants
in each group
Follow-up: 12 weeks.
Participants N: 73 randomised, 73 analysed
Sex: women.
Mean age (SD): overall 53.14 (9.98)
A 51.46 (9.92)
B 54.92 (9.83)
C 53.17 (10.30)
Inclusion criteria: OAB for ≥ six months (symptom of urgency ≥ 3 times daily)
Exclusion criteria: pregnancy, neurologic disorders, diabetes mellitus, demand cardiac
pacemaker or intrauterine device use, genital prolapse greater than the International
Continence Society (ICS) grading system stage II, overt SUI, a history of anti-icontinence
surgery, UTI and patients receiving any OAB treatment during the 14-day whashout/
run-in period preceding randomisation
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Interventions A (n = 26) ES. Two 20-minute sessions per week for 12 weeks with intravaginal electrode
(Periform,NeenHealthCare). Biphasic, symmetric, pulsed current with varying intensity
B (n = 24) Oxybutynin. Three 2.5 mg per day for 12 weeks.
C (n = 23) placebo. One tablet identical to oxybutynin, three times per day for 12 weeks
Outcomes No improvement in urgency:
A 9/26. B 12/24. C 20/23.
Number of micturitions per 24 hours (median, range, N):
A 7.05 (2.7, 12), 26. B 5.35 (1, 13.1), 24. C 8.8 (4.1, 13), 23
Number of incontinence episodes (median, range, N):
A 0.85 (0, 2.8), 26. B 0.3 (0, 2.1), 24. C 0.8 (0, 4.3), 23.
Number of urgency episodes (median, range, N):
A 2.4 (0, 6.9), 26. B 3.05 (1, 8.1), 24. C 7.2 (3.5, 10.2), 23
Number of nocturia episodes per night (median, range, N):
A 1.65 (0, 4.3), 26. 1.45 (0, 5.4), 24. C 3 (0.1, 4.1), 23.
Change in number of micturitions per 24 hours (median, range, N):
A 3.6 (−2.1, 7.2), 26. B 5.3 (−3.5, 10.9), 24. C 1.6 (−5.2, 7.7), 23
Change in number of incontinence episodes (median, range, N):
A 0 (−2.8, 3.3), 26. B 0.4 (−0.3, 3.2), 24. C 0.2 (−2.5, 2.2), 23
Change in number of nocturia episodes per night (median, range, N):
A 2.8 (−2.7, 7.8), 26. B. 2.35 (−3.1, 6.2), 24. C −0.3 (−6.2, 4.7), 23
Change in number of nocturia episodes per night (median, range, N):
A 0 (−3.2, 3.5), 26. B 0.45 (−5.4, 3), 24. C 0 (−4.1, 2.7), 23
King’s Health Questionnaire total score (median, range, N):
A 142.25 (-11.5, 432.4), 26. B 104.75 (-49.9, 383.8), 24. C 36.7 (-137.2, 525), 23
All nine KHQ domains available: see Table 5
Notes Contacted author to clarify if this study is study is separate from Wang 2006. Awaiting
reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Predetermined computer-generated ran-
domization code’ was used. Participants
were ‘assigned randomly in sequential or-
der.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The principal investigator was not in-
volved in any of the interventions and was
unaware of the group allocation.”
“For the pharmacotherapy groups, [groups
B and C] the subjects and all investigators
were unaware of the regimen they received
from the central pharmacy of our hospital.
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”
Group C received “a placebo looking ex-
actly the same as Oxybutynin.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three patients in the ES and four each in
the oxybutynin and placebo groups with-
drew after randomisation, leaving 23 in the
ES, 20 in the oxybutynin, and 19 in the
placebo group who completed the study
Reasons for withdrawal not reported.
ITT analysis carried out “based on the data
obtained from initially randomized 73 sub-
jects.”
Wise 1992
Methods Study design: comparative (unclear if randomised)
Multicentre or single-centre: single
Setting: UK
Period: NR
Details of sample size calculation: NR
Follow-up. NR
Participants N: 40 recruited.
Mean (SD) age: NR
Sex: women
Inclusion criteria: urodynamically proven idiopathic DO
Exclusion criteria: NR
Interventions A (n = ?)ES. Daily session at home for 6 weeks with intravaginal maximal electrical
stimulator
B (n = ?) terodiline 25 mg daily for 6 weeks
Outcomes Reduction in symptoms: urgency, frequency, urgency incontinence, stress incontinence
Notes No data reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Wise 1993
Methods Study design: RCT.
Multicentre or single-centre: not reported.
Setting: UK
Period: not reported.
Sample size: not reported.
Follow-up: 6 weeks.
Participants N: 60 randomised
Sex: women.
Mean age: not reported.
Inclusion criteria: urodynamically proved DI
Exclusion criteria: not reported.
Interventions A (n = 32) oxybutynin hydrochloride 5 mg
B (n = 28) electrical stimulation. 20-minute sessions. Participants taught to insert vaginal
electrodes and gradually increase stimulus to just below level of discomfort. Frequency
20 hz, current 0-90 mA
Outcomes Adverse effects:
A 7/32. B 0/28.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Sixty women were recruited and ran-
domised”
Allocation concealment (selection bias) Unclear risk Not reported.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Differential dropout: “Nine patients in the
oxybutynin group failed to complete the
full treatment period. In seven cases this
was due to unacceptable drug side effects.
All patients in the MES group completed
six weeks therapy and all found themethod
of treatment acceptable.”
Yamanishi 2000a
Methods Study design: RCT.
Multicentre or single-centre:
Setting: Japan.
Period: not reported.
Sample size: not reported
Follow-up: After 4-week treatment, patients who were cured or improved were followed
up monthly on the basis of the records in the frequency/volume chart to evaluate post-
stimulation effects. If the patient relapsed, the stimulation was repeated periodically in
the same way using the same device until continence was regained
Participants N: 68 randomised, 58 analysed.
Sex: 29 men and 39 women.
Mean age (range): 70 (35-87)
Inclusion criteria: urinary incontinence due to DO.
Exclusion criteria: not reported.
Interventions A (n = 37) electrical stimulation. Two 15-minute sessions per day for 4 weeks. Alternating
pulses of 10-Hz square waves of 1-ms pulse duration and a maximum output current of
60 mA, stimulation up to maximum tolerable level
B (n = 31) sham device identical to active device but with no stimulus output
Outcomes Number of daytime voids (mean, N [SD not reported]:
A 8, 32. B 7.5, 26.
Number of nighttime voids (mean, N [SD not reported]:
A 2, 32. B 2.3, 26.
Number of leaks (mean, N [SD not reported]:
A 1.2, 32. B 2.4, 26.
Bladder capacity at first desire to void (mL) (mean, SD, N):
A 174.2 (83.1), 32. B 130.0 (69.9), 26.
Maximum cystometric capacity (mL) (mean, SD, N):
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A 285.0 (143.4), 32. B 182.9 (99.0), 26.
Detrusor pressure at maximum sensation (cm H2O) (mean, SD, N):
A 34.6 (12.5), 32. B 50.9 (29.8). 26.
Number of pad changes per 24 hours (mean, SD, N):
A 0.8 (1.2), 37. B 1.1 (2.0), 31.
Urgency score (0-3 scale: from 0 = none to 3 = very much) (mean, SD, N):
A 1.7 (0.7), 37. B 2.0 (0.8), 31.
Quality of life score (0-3 scale: from 0 = delighted to 3 = mostly dissatisfied) (mean, SD,
N):
A 1.6 (0.7), 37. B 2.2 (0.9), 31.
Number with detrusor overactivity: A 24/32, B 24/26
Number of participants with no improvement in detrusor overactivity:
A 4/32[FS1] . B 17/26[FS2]
Subjective impressions (very good or good, fair or not good): number of participants
with fair or not good (i.e. not satisfied):
A 13/32. B 17/26.
Not cured (cure defined as ‘no incontinence on the frequency/volume chart and no
detrusor overactivity according to cystometry’) i.e. number of participants with urgency
urinary incontinence:
A 25/32. B 25/26.
Not improved (improvement defined as ‘if the frequency of the incontinence decreased
bymore than 50% compared with the baseline level or the cystometric capacity increased
by more than 50 mL) i.e. number of participants with no improvement in urgency
urinary incontinence:
A 6/26. B 19/28.[FS3]
Adverse effects:
A 2/37. B 2/31
Notes No SDs.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to either
the active or the sham device.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The sham device was identical to the ac-
tive device in appearance but with no stim-
ulus output.’ ‘Neither doctors, nurses, nor
patients knew which device was active or
sham.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential attrition. “Four patients
(three in the active group and one in the
sham group) did not return after the first
visit, and four patients (two at both groups)
discontinued because of disagreeable feel-
ings or vaginal pain”
Yamanishi 2000b
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: Japan
Period: NR
Details of sample size calculation: NR
Follow-up: single session
Participants N: 32 randomised and analysed.
Mean (SD) age: A 66.8 (11.4). B 57.1 (20.1). Overall 62.3 (16.6)
Sex: 15 men, 17 women
Inclusion criteria: detrusor overactivity
Exclusion criteria: NR
Interventions A (n = 17) functional ES. Alternating pulses of 10-Hz square waves 1 ms duration,
maximum output current 60 mA. Stimulation up to maximum tolerable level. Device
designed for home use. Surface electrodes for men (dorsal part of penis), vaginal plug
for women
B (n = 15) functional magnetic stimulation. Magnetic coil on armchair seat; perineum
positioned to feel highest contraction of vaginal/anal sphincter. Intensity gradually in-
creased up to tolerable limit, continuous eddy current 10Hz, maximum output at the
100% setting of at least 270J
Outcomes Participants with detrusor overactivity DO):
A 17/17. B 12/15
Bladder capacity at first desire to void, mL (mean, SD, N):
A 220.4 (110.9), 17. B 225.1 (123.7), 15.
Maximum cystometric capacity, mL (mean, SD, N):
A 266.9 (151.0), 17. B 290.5 (146.3), 15.
Detrusor pressure at maximum capacity, cmH20 (mean, SD, N):
A 15.4 (10.5), 17. B 13.9 (15.4), 15.
Amplitude of detrusor overactive contraction, cmH20 (mean, SD, N):
A 51.3 (36.9), 17. B 51.5 (48.2), 15.
Bladder compliance at maximum sensation, mL/ cmH20 (mean, SD, N):
A 24.3 (18.3), 17. B 32.7 (25.6), 15.
Adverse effects: A 0/17. B 0/15.
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”
Allocation concealment (selection bias) Unclear risk “using envelopes containing a card indicat-
ing FES or FMS”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in
analysis. No withdrawals reported
BMI: body mass index
DI: detrusor instability
DO: detrusor overactivity
ES: electrical stimulation
FES: functional electrical stimulation
GSUI: stress urinary incontinence
HRT: hormone replacement therapy
ITT analysis: intention-to-treat analysis
IQR: interquartile range
LUTS: lower urinary tract symptoms
MS: multiple sclerosis
MUI: mixed urinary incontinence
OAB: overactive bladder
PFME: pelvic floor muscle exercises
PFMT: Pelvic floor muscle training
QoL: quality of life
RCT: randomised controlled trial
SANS: Stoller Afferent Neuro-stimulation
SD: standard deviation
SUI: stress urinary incontinence
UI: urinary incontinence
UTI: urinary tract infection
UUI: urgency urinary incontinence
VAS: visual analogue score
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelghany 2001 Non-randomised controlled trial.
Abel 1996 Non-randomised controlled trial.
Al-Mulhim 2002 Non-randomised controlled trial.
Almeida 2004 Non-randomised controlled trial.
Angioli 2013 Non-randomised controlled trial.
Baynham 2003 Not non-implanted device.
Bazarim 2011 Not OAB.
Bidmead 2002 Not OAB.
Blok 2003 Not non-implanted device.
Bocker 2002 Not OAB.
Bolukbas 2005 Non-randomised controlled trial.
Borawski 2007 Not non-implanted device.
Bourcier 1994 Not OAB.
Boy 2007 Non-randomised controlled trial.
But 2003 Not electrical stimulation.
Caputo 1993 Non-randomised controlled trial.
Caraballo 2001 Non-randomised controlled trial.
Casolati 2011 Non-randomised controlled trial.
Chandi 2002 Non-randomised controlled trial.
Congregado 2004 Non-randomised controlled trial.
Das 2002 Not non-implanted device.
De Laet 2005 Non-randomised controlled trial.
Delneri 2000 Not OAB.
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Doganay 2010 Non-randomised controlled trial.
Dunkley 2002 Not electrical stimulation.
Edwards 1973 Not electrical stimulation.
Edwards 2000 Not OAB.
Elgamasy 1996 Non-randomised controlled trial.
Esa 1991 Non-randomised controlled trial.
Everaert 1999 Not OAB.
Fall 1977 Non-randomised controlled trial.
Fehrling 2007 Non-randomised controlled trial.
Finazzi-Agró 2011 Non-randomised controlled trial.
Franco 2011 Non-randomised controlled trial.
Fujishiro 2002 Not electrical stimulation.
Geirsson 1997 Non-randomised controlled trial.
Glybochko 2010 Ineligible intervention.
Govier 2001 Non-randomised controlled trial.
Gungor 2011 Non-randomised controlled trial.
Hasan 1994 Not non-implanted device.
Hoffmann 2005 Not OAB.
Holtedahl 1998 RCT of PFMT + ES + oestrogen versus ‘wait’ group.Women have SUI or undefined UI, but no definite
diagnosis of OAB
Indrekvam 2001 Non-randomised controlled trial.
Jacomo 2013 Non-randomised controlled trial.
Jahr 2005 Non-randomised controlled trial.
Karademir 2005 Ineligible comparison.
Kirschner-Hermanns 2003 Non-randomised controlled trial.
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Kralj 2001 Non-randomised controlled trial.
Kölle 1995 Non-randomised controlled trial.
Latini 2006 Non-randomised controlled trial.
Lu 2012 Non-randomised controlled trial.
Lucio 2013 Not OAB.
MacDiarmid 2010 Non-randomised controlled trial.
Macdiarmid 2010 Non-randomised controlled trial.
Madersbacher 2004 Non-randomised controlled trial.
Marcelissen 2011 Non-randomised controlled trial.
Marchal 2011 Non-randomised controlled trial.
Mauroy 2001 Non-randomised controlled trial.
McClurg 2004 Not OAB.
McClurg 2006 Not OAB.
McClurg 2008 Not OAB.
Mcguire 2009 Not non-implanted device.
McIntoshi 1993 Non-randomised controlled trial.
Memtsa 2009 Non-randomised controlled trial.
Mok 2007 Not electrical stimulation.
Moore 2003 Not electrical stimulation.
NCT00534521 2007 Not OAB.
NCT00547378 2007 Not non-implanted device.
NCT00695058 2008 Withdrawn prior to enrolment.
NCT00928499 2009 Not non-implantable device.
NCT01023269 2009 Not non-implanted device.
NCT01043848 2009 Not OAB.
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NCT01972061 2013 Not RCT.
NCT02029027 2012 Not OAB.
NCT02107820 2014 Ineligible comparator.
NCT02176642 2014 Ineligible comparator.
NCT02185235 2014 Not OAB.
NCT02190851 2014 Not OAB.
NCT02239796 2014 Not OAB.
Neimark 2010 Non-randomised controlled trial.
Nuhoglu 2006 Non-randomised controlled trial.
Oh-Oka 2007 Non-randomised controlled trial.
Okada 1998 Non-randomised controlled trial.
Onal 2012 Non-randomised controlled trial.
Parsons 2004 Not OAB.
Pennisi 1994 Non-randomised controlled trial.
Perissinotto 2013 Not OAB.
Peters 2012 Non-randomised controlled trial.
Petersen 1994 Non-randomised controlled trial.
Polo 2012 Non-randomised controlled trial.
Portigliotti 1996 Non-randomised controlled trial.
Preisinger 1990 Not OAB.
Rasero 2005 Non-randomised controlled trial.
Reilly 2008 Not non-implanted device.
Ricci 2004 Not non-implanted device.
Sale 1994 Not electrical stimulation.
Seif 2003 Non-randomised controlled trial.
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Seo 2004 Not OAB.
Shafik 2004 Unclear if RCT/OAB.
Shah 2012 Non-randomised controlled trial.
Siegel 1997 Non-randomised controlled trial.
Stein 1995 Non-randomised controlled trial.
Surwit 2010 Non-randomised controlled trial.
Suzuki 2007 Not electrical stimulation.
Van Del Pal 2006 Non-randomised controlled trial.
Van Meel 2012 Non-randomised controlled trial.
Van-Balken 2001 Non-randomised controlled trial.
Van-Balken 2006 Non-randomised controlled trial.
Vandoninck 2004 Non-randomised controlled trial.
Vecchioli-Scaldazza 1997 Non-randomised controlled trial.
Veloso 2011 Non-randomised controlled trial.
Voorham 2006 Non-randomised controlled trial.
Voorham-Van Der Zalm Ineligible intervention and comparator is urodynamic evaluation only
Wallis 2006 Not electrical stimulation.
Walsh 2000 Ineligible intervention.
Webb 1992 Not non-implanted device.
Wooldridge 2009 Non-randomised controlled trial.
Yamanishi 2006 Not electrical stimulation.
Yamanishi 2012 Not electrical stimulation.
Yamanishi 2013 Not electrical stimulation.
Yasar 2009 Non-randomised controlled trial.
Yaski 2013 Non-randomised controlled trial.
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Yasuda 1994 Not OAB.
Yokoyama 2004 Non-randomised controlled trial.
Yoong 2010 Non-randomised controlled trial.
Yoong 2013 Non-randomised controlled trial.
ES: electrical stimulation
OAB: overactive bladder
PPMT:
RCT: randomised controlled trial
SUI: stress urinary incontinence
Characteristics of studies awaiting assessment [ordered by study ID]
Abdelbary 2015
Methods Study design: RCT
Multicentre or single-centre:
Setting: Egypt
Follow-up: 6 weeks’ treatment, 6 months’ follow-up
Participants N: 315 randomised, 300 analysed
Mean (SD) age: A 49.7 (6.0) B 47.7 (6.0). C 48.0 (6.0)
Sex: women
Inclusion criteria:≥ 40 years, no evidence of urinary tract infection, no SUI, no previous history of anti-incontinence
or pelvic surgery or anti-incontinence drugs (within 3 months), and no history of bladder malignancy
Exclusion criteria: NR
Interventions A (n = 105) vaginal ES twice weekly for 12 sessions
B (n = 105) local vaginal oestrogen 0.625 mg/g (Premarin), 2 g daily for 6 weeks
C (n = ) ES plus local vaginal oestrogen
Outcomes Voids per day
Voids per night
Incontinence episodes
Urgency episodes
QoL score
Functional bladder capacity
Detrusor overactivity
Notes
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Methods RCT
4 weeks’ treatment
Participants N: 28 randomised
Sex: women
Inclusion criteria: female, ≥ 60 years with likely urinary dysfunction, was identified by a score ≥ 8 points on OAB-
V8 questionnaire
Exclusion criteria: urinary infection, identified by urine test, history of treatment for OAB and hormone replacement
therapy in the last six months, prior surgery to treat UI, neurological diseases base, genital-urinary cancer history,
complaints of pain in the lower abdomen for more than six months, prior pelvic irradiation, genital prolapse above
third degree of Baden and Walker scale, use of cardiac pacemakers, metal implants in foot and right ankle region,
inability to respond to questionnaires properly and abstentions to treatment
Interventions A (n = 15) tibial nerve stimulation (TNS).8 sessions (2 x 30-minute sessions per week). F = 10 Hz, T = 200 µs.
Sensory threshold, activating
superficial cutaneous nerve fibres with larger diameter
B (n =13) TNS 8 sessions (2 x 30-minute sessions per week). F = 10 Hz, T = 200 µs. Motor threshold, non-painful
contraction is induced and ‘the stimulation can simply make pain relief in the same way that sensory stimulation
level (blocking activation of the peripheral or central inhibition.’
Outcomes ICIQ-OAB score
Bother of daytime frequency, nocturia, urgency, urgency incontinence
Micturitions per 24 hours
Nocturia episodes
Urgency episodes
Urgency incontinence episodes
Notes
Chen 2015
Methods Study design: RCT
Follow-up: 4 weeks’ treatment
Participants N: 100 randomised
Inclusion criteria: neurogenic detrusor overactivity (DO) secondary to spinal cord injury
Exclusion criteria: urinary tract infection, tumour of the urinary system, urinary calculus, vesicoureteral reflux con-
firmed by video urodynamics, bladder compliance > 10 mL/cmH2O.
Interventions A (n = 50) percutaneous tibial nerve stimulation using adhesive skin surface electrodes. Continuous, bi-polar square
wave form with pulse duration of 200 µs and stimulation frequency of 20 Hz. The stimulator was controlled to
determine the minimal current needed to induce a toe twitch. The intensity was then increased to the highest level
tolerated by the patient who cannot induce lower limb muscle spasm in complete SCI patients and uncomfortable
feeling on stimulating sites in incomplete SCI patients
B (n = 50) solifenacin succinate 5 mg per day
Outcomes Volume per catheterisation
Leakage volume per day
I-QoL
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Notes
Eftekhar 2014
Methods Study design: RCT
Multicentre or single-centre: single
Setting: Iran
Follow-up: 12 weeks’ treatment
Participants N: randomised and analysed.
Sex: women
Inclusion criteria: women with neurologic bladder confirmed by urodynamic diagnosis
Exclusion criteria: NR
Interventions A: posterior tibial nerve stimulation. 34-gauge needle placed 5 cm near internal malleolus. Sessions lasted 30 minutes
B: 4 mg tolterodine daily for 3 months
Outcomes Sexual function
Subjective assessment of pelvic disorders
Notes
Franco 2011a
Methods Study design: prospective comparative clinical study (unclear if randomised)
Follow-up: 12 weeks’ treatment
Participants N: 42 randomised
Inclusion criteria: OAB or MUI
Interventions A (n = 20) intravaginal ES therapy. Once a week for 12 weeks
B (n = 22) tibial nerve stimulation. Once a week for 12 weeks
Outcomes Generic QoL
I-QoL
Number of micturitions
Eisodes of nocturia
Episodes of urinary leakage
Number of pads
Discomfort measured by VAS
Notes
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Gonzalez 2015
Methods Study design: randomised cross-over trial
Follow-up: switch modalities at three months, follow-up at 6 months
Participants N: 82 randomised
Inclusion criteria: OAB symptoms
Exclusion criteria: unable to comply with follow-up or had a history of neurological disease
Interventions A: behavioural therapy. One-to-one interview and assessment with a continence physiotherapist and written infor-
mation
B: transcutaneous posterior tibial nerve stimulation and behavioural therapy. Twice a week for 6 weeks
Outcomes visual analogue scale (VAS)
incontinence severity index (ISI)
Patient’s Global improvement (PGI-I)
OAB-q
Notes
Lin 2004
Methods Study design: RCT
Follow-up: 4 weeks’ maximum treatment
Participants N: 60 randomised
Interventions A (n = 35) vaginal/anorectal ES, 8-70 mA, 20 minutes, 20-30 sessions
B (n = 25) 2 mg tolterodine daily, 2-4 weeks
Outcomes Cure rate
Satisfaction
Side effects
Notes Awaiting translation.
Manriquez 2013
Methods Study design: RCT
Follow-up: 12 weeks’ treatment
Participants N: 56 randomised
Sex: women
Inclusion criteria: OAB according to ICI 2002 definition
Exclusion criteria:
Interventions A transcutaneal tibial nerve stimulation, twice a week with at least 48-hour intervals for 12 weeks
B oxibutinin 10 mg
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Manriquez 2013 (Continued)
Outcomes Frequency
Urgency
Urgency incontinence
Daily pads
Notes
Orhan 2015
Methods Study design: RCT
Period: January 2010 and April 2011
Details of sample size calculation:
Follow-up: 12 weeks’ treatment
Participants N: 30 randomised
Inclusion criteria: people OAB in whom all conventional therapies had failed
Exclusion criteria: NR
Interventions A: percutaneous posterior tibial nerve stimulation
B: anticholinergic agent
C:percutaneous tibial nerve stimulation plus anticholinergic agent
Outcomes Urinary Distress Inventory (UDI-6)
Incontinence Impact Questionnaire (IIQ-7)
Overactive Bladder symptom scores (OABSS)
Notes
Phillips 2012
Methods Study design: RCT
Follow-up: 4 weeks
Participants N: 74 randomised
Sex: male and female
Inclusion criteria: symptoms OAB with UUI for at least 6 months, previously failed other therapies, including ≥
anti-cholinergic drug
Exclusion criteria: NR
Interventions A (n = not reported) patient-managed neuromodulation system (PMNS) patch - subject placement
B (n = not reported) patient-managed neuromodulation system (PMNS) patch - investigator placement
Outcomes % reduction in UUI episodes
OAB-q score
Notes No useable data. Numbers per group not reported
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Preyer 2015
Methods Study design: RCT
Follow-up: 3 months’ treatment
Participants N: 36 randomised
Mean (SD) age:
Sex: women
Inclusion criteria: female; minimum age of 18 years; complaints of OAB dry or wet consistent with the IUGA/ICS
criteria; no prior treatment with
percutaneous tibial nerve stimulation or anticholinergics
Exclusion criteria:
pregnancy or intention to become pregnant during the study period; active or recurrent urinary tract infections (more
than 4 per year); residual urine of more than 100 mL; history of urinary fistula, bladder or kidney stones, interstitial
cystitis; history of cystoscopic abnormalities or possiblemalignancy, diabetesmellitus, cardiac pacemaker or implanted
defibrillator; history of anatomic or posttraumatic malformations of the lower limbs; immobility; contraindications
for anticholinergics or percutaneous tibial nerve stimulation; disability to understand the study requirements and
procedures, advantages and possible side effects
Interventions A (n = ) percutaneous tibial nerve stimulation. One 30-minute session per week for 3 months
B (n = ) tolterodine 2 mg twice daily
Outcomes
Notes
Schreiner 2014
Methods Study design: RCT
Follow-up: 3 months’ treatment, 12 months’ follow-up
Participants N: 106 randomised.
Sex: women
Inclusion criteria: elderly women (> 60 years) with UUI
Exclusion criteria:
Interventions A (n = 50) conservative treatment. 12 weeks of bladder retraining and pelvic floor muscle exercises
B (n = 51) transcutaneous tibial nerve ES
Outcomes ICIQ-SF
Recurrence of incontinence
Satisfaction
Notes
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Slovak 2015
Methods Study design: RCT
Period: June 2013 and December 2014
Details of sample size calculation:
Follow-up: 4 weeks’ treatment
Participants N: 22 randomised
Inclusion criteria: people with idiopathic OAB symptoms who had not responded or could not tolerate (due to side
effects) conventional drug therapy,
Exclusion criteria:
Interventions A (n = ) ES with unilateral posterior tibial nerve stimulation with conventional TENS* machine using a pair of
adhesive surface electrodes and a stimulus intensity just below that which would cause a motor contraction of toes/
shoulder muscles. Electrodes placed above and below the medial malleolus on the right ankle
B (n = ) ESwith bilateral posterior tibial nerve stimulation. Electrodes placed in same position as unilateral stimulation
group but on the both ankles
C (n = ) sham stimulation, electrodes placed on the anterior aspect of the left shoulder
Outcomes Micturitions per 24 hours
Urgency episodes
Number of responders
Notes *no explanation given for TENS abbreviation
Zhao 2000
Methods
Participants
Interventions
Outcomes
Notes Awaiting translation.
DO: detrusor overactivity
ICIQ: International Consultation on Incontinence Questionnaire
IUGA: International Urogynecological Association
MUI: mixed urinary incontinence
OAB: overactive bladder
QoL: quality of life
RCT: randomised controlled trial
SCI: spinal cord injury
SD: standard deviation
SUI: stress urinary incontinence
TNS: tibial nerve stimulation
UI: urinary incontinence
UUI: urgency urinary incontinence
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Characteristics of ongoing studies [ordered by study ID]
Biemans 2010
Trial name or title
Methods Study design: RCT
Multicentre or single-centre: NR
Setting: The Netherlands
Period: planned to be April 2009 - October 2010
Details of sample size calculation: NR
Follow-up: 12 weeks
Participants Inclusion criteria: OAB, defined as urgency and frequency (more than 8 voids per 24 hours and the sudden
urge to void can hardly be suppressed); urgency incontinence (urgency leading to urinary leakage occurring
at least three times weekly); age > 18 years
Exclusion criteria: symptoms existing for less than 6 months; pregnancy; active urinary tract or recurrent
urinary tract infection; severe cardiopulmonary disease; diabetes with peripheral nerve involvement; neuro-
logical disorders; flowmetrie < 15 mm/sec; previous treatment for OAB
Interventions 1. Posterior tibial nerve stimulation
2. Bladder training
Outcomes Primary outcomes: ICIQ-ui-sf scores; percentage of 70% improvement on the ICIQ-ui-sf scores
Secondary outcomes: incontinence episodes per week; frequency of micturition per 24 hours
Starting date
Contact information
Notes Contacted author asking for data 06-01-2015
NCT01464372 2011
Trial name or title Electromagnetic Stimulation for the treatment of urge urinary incontinence and overactive bladder (ELEC
STIM)
Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: USA
Follow-up: unclear
Participants N: 130
Sex: women
Inclusion Criteria: age 18+, UUI, urinary frequency
Exclusion Criteria: primary complaint of stress incontinence, neurogenic bladder, overflow Incontinence,
functional incontinence
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NCT01464372 2011 (Continued)
Interventions A: Electrical Field Stimulation Device
B: Sham Nerve Stimulation Device
Outcomes Reduction of incontinence episodes
Serious Adverse Events or Unanticipated Adverse Device Effects
Starting date October 2011
Contact information info@emkinetics.com
Notes Study terminated. Contacted manufacturer 20-02-2015.
NCT01783392 2013
Trial name or title Peripheral Electrical Stimulation for the Treatment of Overactive Bladder (PESTOB)
Methods Study design: RCT
Multicentre or single-centre:
Setting:
Follow-up: 4 weeks
Participants N: 36
Sex: men and women
Inclusion criteria: at least 18 years, documented symptoms of idiopathic overactive bladder for at least 3
months, failure onprimaryOAB treatment, such as behaviourmodificationor fluid/dietmanagement, patients
can remain on stable medication, willing and capable of understanding and complying with all requirements
of the protocol
Exclusion criteria: urinary retention or post voiding residual greater than 100 mL, clinically significant
bladder outlet obstruction, stress predominant MUI, neurological disease affecting urinary bladder function,
including but not limited to Parkinson’s disease, multiple sclerosis, stroke, spinal cord injury, pelvic surgery
(such as sub-urethral sling, pelvic floor repair) within the past 6months, denovoOAB following pelvic surgery
sub-urethral sling Intravesical or urethral sphincter Botulinum Toxin Type A injections within the past 6
months, Percutaneous Tibial Nerve Stimulation therapy for overactive bladder within the past 6 months,
any form of electric stimulation to the pelvis or lower limbs within 4 weeks, vaginal prolapse greater than
Stage II in the anterior compartment of the vagina using International Continence Society (ICS) Pelvic
Organ ProlapseQuantification (POPQ) criteria, prior periurethral or transurethral bulking agent injections
for bladder problems within the past 12 months, history of pelvic radiation therapy, any skin conditions
affecting treatment sites, lackingdexterity to properly utilise the components of the stimulator system, presence
of an implanted electro-medical device (e.g. pacemaker, defibrillator, InterStim®, etc), pregnant, nursing,
suspected to be pregnant (by urine pregnancy method), or plans to become pregnant during the course of the
study, recurrent urinary tract infections (UTI) (> 3 UTI’s in the past year), history of, or current, lower tract
genitourinary malignancies, any clinically significant systemic disease or condition that in the opinion of the
Investigator would make the patient unsuitable for the study, any other clinical trial within 6 months
Interventions A: Unilateral Posterior Tibial Nerve Stimulation. 40 minutes every day for a duration of 4 weeks. The patient
places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior
tibial nerve and sets the stimulation intensity to a comfortable level
B: Bilateral Posterior Tibial Nerve Stimulation. 40 minutes every day for a duration of 4 weeks. The patient
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NCT01783392 2013 (Continued)
places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior
tibial nerve on both legs and sets the stimulation intensity to a comfortable level
C: Shoulder stimulation. 40 minutes every day for a duration of 4 weeks. The patient places the cathode and
the anode electrodes on the lateral side of the left shoulder
Outcomes Change in frequency of voiding
Change in Patient Perception of Bladder Condition (PPBC)
Changes in symptom severity score and health-related quality of life score (HRQL) based on OAB-question-
naire
Changes in the mental/physical scores of RAND36
Change in urinary symptoms score and bother symptom score based on the ICIQ-OAB questionnaire
Starting date March 2013
Contact information Martin Slovak m.slovak@sheffield.ac.uk
Notes Contacted February 2015. Manuscript due for submission shortly
NCT01912885 2012
Trial name or title Comparison of posterior tibial nerve electrical stimulation protocols for overactive bladder syndrome
Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: Brazil
Participants N: 145
Sex: women
Inclusion Criteria: age 18 +, cognitive level adequate for understanding orientations during treatment; clinical
diagnosis of OAB syndrome for at least six months prior to the study
Exclusion Criteria: pregnant women or women who wish to get pregnant; neurological disease; urinary
infection; nephrolithiasis; SUI; MUI; women in pharmacological treatment for OAB; women undergoing
hormone replacement therapy in the last six months; peripheral neuropathy; cystocele stage two or higher
Interventions A: Placebo: Electrodes will be fixated to one leg and sessions will be held once a week
B: ES on one leg once a week
C: ES on one leg twice a week
D: ES on two legs once a week
E: ES on two legs once a week
F: ES on two legs twice a week
Outcomes Change in urinary frequency in 12 sessions
Number of micturitions per day
Change in Nocturia in 12 sessions.
Number of micturitions per night, interrupting sleep
Change in urinary urgency in 12 sessions
Number of urgent micturitions per day
Change in urinary urge-incontinence in 12 sessions
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NCT01912885 2012 (Continued)
Number of leaks per day
Starting date March 2012
Contact information Nanci Valeis nanci.valeis@hc.fm.usp.br
PI Munick L Pierre
Notes Currently recruiting participants
NCT01940367 2013
Trial name or title Electrical nerve stimulation for overactive bladder a comparison of treatments
Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: USA
Participants N: 114
Sex: women
Inclusion criteria: Female age >18 years, predominant complaint urge urinary incontinence (3 ormore episodes
per week) OR overactive bladder (8 or more voids per day, and/or 2 or more voids per night), failed trial
of conservative therapy (bladder training, fluid modification, diet modification, caffeine restriction, pelvic
floor training), failed trial of anticholinergic either due to inability to take the medication, adverse reaction to
medication, or no improvement onmedication, willing andmentally competent to participate in study, willing
to complete study questionnaires, no contraindications to undergoing percutaneous tibial nerve stimulation
or TENS therapy
Exclusion criteria: Age < 18 years, presence of urinary fistula, recurrent or current urinary tract infection (5 or
more infections in the last 12months), bladder stones, bladder cancer or suspected bladder cancer, haematuria,
pregnancy or planning to become pregnant during the study (urine pregnancy test will be administered
to those who are premenopausal and who have not had a hysterectomy), central or peripheral neurologic
disorders such asmultiple sclerosis, Parkinson’s disease, spina bifida, or other spinal cord lesion, metal implants
such as pacemaker, implantable defibrillator, or metal implants where percutaneous tibial nerve stimulation
or TENS device needs to be placed (sacrum or ankle/leg), uncontrolled diabetes, diabetes with peripheral
nerve involvement, anticoagulants, current use of anticholinergics or use within the last 4 weeks, current use
of botulinum toxin bladder injections or bladder botulinum toxin injection within the last year, current use
of InterStim® therapy or currently implanted InterStim® device or leads, bladder outlet obstruction, urinary
retention or gastric retention, painful bladder syndrome/interstitial cystitis
Interventions A: Percutaneous tibial nerve stimulation once weekly for 30 minutes for 12 weeks. If at 12 weeks they are
considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion:
participants will come in every 2 weeks for the next 8 weeks for 30-minute treatments (4 visits total), then
every 3-4 weeks for 30-minute treatments for the remaining 32 weeks of the year (8-10 visits)
B: TENS. Home TENS device (EMPI TENS Select) and for self-treatment daily for 2 hours per day (1 hour
in the morning and 1 hour in the evening) for 12 weeks. If considered to have a positive response with TENS
treatment at 12 weeks, participants will continue by weaning use over a three-month time period, beginning
with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours
per day
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NCT01940367 2013 (Continued)
Outcomes Success at 1 year, defined as a 50% or more reduction in the total number of incontinence episodes, or a 25%
or more reduction in number of daily or nightly voids AND that the patient continues to use the therapy at
one year. Therefore primary response is: 50% reduction in incontinence, OR 25% reduction in nightly voids
AND continued use of therapy at one year
Participant compliance defined as 75% adherence to the recommended use for each device
Changes in the OAB-q
Changes in urodynamic studies
Starting date October 2013
Contact information PI Mary E McVearry
Shannon Lamb, Physician, Walter Reed National Military Medical Cente
Notes Due to complete December 2016
NCT02110680 2014
Trial name or title
Methods RCT
Setting: Israel
Follow-up: 12 weeks
Participants Estimated enrolment: 40
Inclusion Criteria:
• male and female patients
• age above 18
• OAB symptoms more than 6 months before run into the study
• OAB symptoms refractory to medical oral and cognitive treatments
• Adverse events or unwillingness to continue with above mentioned treatments
• patients with OAB symptoms with no evidence of neuropathic nature
• patients who signed informed consent fully understanding the treatment and study design
Exclusion Criteria:children, patients who unable or did not sign an informed consent or do not understand
the study design and the treatment, implanted electric devices (e.g. cardiac stimulators etc.), post voiding
residual more than 100 mL, neuropathic OAB or pelvic ongoing malignancy or prior pelvic radiation,treated
in the last 6 months with SNM, posterior tibial nerve stimulation or intravesical Botox injections, denovo
OAB after recent implantation of tension-free vaginal tape (TVT) procedure, SUI predominant complaints
in patients with MUI, significant pelvic organ prolapse in women or an evidence of significant bladder outlet
obstruction in male patients, history of recurrent urinary tract infections (UTIs) during the last 2 years, any
medical condition that involves skin on the lower extremity, bilateral leg amputation, any medical condition
that in the investigator’s opinion could have an adverse impact on the patient during the study, participation
in a clinical study at the last 6 months
Interventions TENS at posterior tibial nerve area
Sham comparator: TENS at shoulder area
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Outcomes Day and night-time frequency of micturitions
OAB-q
Patient perception of bladder condition (PPBC)
Patient perception of global improvement (PPGI)
Quality of life 5 dimensions (EQ5D)
Starting date April 2014
Contact information Michael Vainrib, M.D. mvainrib@gmail.com
Notes Estimated Study Completion Date:
NCT02311634 2014
Trial name or title
Methods RCT
Setting: China
Follow-up: 4 weeks’ treatment, 1 year follow-up
Participants N = 80
Inclusion Criteria:
• Female, 25-85 years
• UUI history
• Positive pad test result
• Urodynamic study: A decrease in bladder capacity at the first desire for urination; a decrease in
maximum bladder capacity; low compliance bladder
Exclusion Criteria:
• UUI that can be relieved by drugs
• Neurogenic or non-neurogenic UUI
• Other types of incontinence such as SUI and overflow incontinence
Interventions Electrical pudendal nerve stimulation at a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60
minutes three times a week for a total of four weeks
Transvaginal ES at a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies
of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation); 20 minutes three times a week for a total of
four weeks
Outcomes Severity of UUI symptoms
24-hour urine leakage amount
Starting date December 2014
Contact information Xiaoming Feng, Ph.D fengtcm@126.com
Notes Estimated Study Completion Date: Jan 2016
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NCT02377765 2014
Trial name or title
Methods RCT
Setting: UK
Follow-up: 6 months
Participants N = 24
Inclusion Criteria:
• Female.
• Over 18 years of age.
• Clinically diagnosed of idiopathic OAB according to the definition by the International Continence
Society (Haylen et al, 2012) given above.
• Good response to PTNS. For the purpose of this study, responders will be considered those
participants who have achieved a reduction in the number of micturitions per 24 hours by > 30%.
• Able and willing to give informed consent.
Exclusion Criteria:
• Patients who do not comprehend the physiotherapist’s instructions or who are unable to co-operate.
• Pregnancy, or plans of becoming pregnant during the course of the study. The main acupuncture point
that will be used (SP6) has been reported to induce uterine activity (Hecker et al, 2001).
• Presence of a relevant neurological condition (causing neurogenic DO or peripheral neuropathy).
• Previous history of continence surgery.
• Women with a pace-maker fitted.
• Women with uncorrectable coagulopathies or on anticoagulant medication.
• Presence of dermatological lesions (e.g. dermatitis, eczema...) in the medial aspect of lower leg and/or
feet.
• No anticholinergic medication will be allowed during the study period with minimum wash-out
period of 15 days before randomisation.
Interventions Percutaneus Stimulation
PTNS performed bilaterally every 4 weeks within the Physiotherapy Department
Transcutaneous Stimulation
TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg
at least 3 times per week
Outcomes Symptom severity measured by OAB-q
Changes in 24-hour micturition frequency
Mean number of micturition episodes recorded in 3-day bladder chart
Starting date February 2014
Contact information Louise Hardman l.hardman@lwh.nhs.uk
Notes Due to complete: Feb 2016
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Trial name or title
Methods RCT
Setting: Brazil
Follow-up: 8 weeks’ treatment, 3 months’ follow-up
Participants N = 30
Inclusion Criteria:
- Women with UUI or MUI older than 18 years
Exclusion Criteria:
• Presence of vaginal or urinary infection
• Not able to understand or sign the informed consent
• Not able to understand or are unable to perform the proposed treatment
• Pregnancy or the postpartum period covering the period up to 6 months after delivery
• Women in previous use of chronically used drugs (antidepressants, diuretics, and others) that can
evidently alter the urinary function.
• SUI of pure or mixed incontinence with a predominance of stress component neurogenic bladder
• Use of Botox® in the bladder or pelvic muscles in the last year
• Use Interstim® or Bion®
• Use pacemaker or implantable defibrillator
• Current use of TENS in the pelvic region, lower back or legs
• Previous use of percutaneous tibial stimulation
• Drug/experimental devices in the past 4 weeks
• Participation in any clinical research involving or affecting the urinary or renal function in the last 4
weeks
• Pelvic radiotherapy;
• Changes in sensibility lower limb
Interventions Transcutaneous electrical stimulation of the tibial nerve at home:
Development of an innovative portable equipment, with domestic technology for home application of the
posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Fre-
quency: 20 Hz, Pulse width: 200 us; duration: 15 minutes daily
Active Comparator: “Pelvic Floor Exercises”:
This group will make pelvic muscle training 3 times a day . In dorsal decubitus posture, legs flexed and
abductee. Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and
contractions keeping 4 seconds and relaxing 8 seconds for 10 times
Outcomes Number of participants with UUI
Starting date January 2014
Contact information Magda Ms Aranchip mchipe@hotmail.com
Luciana Dr Paiva luciana.paiva@ufrgs.br
Notes Due to complete August 2015
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Trial name or title
Methods RCT
Setting: Brazil
Follow-up: unclear
Participants N = 12
Inclusion Criteria:
• Female
• Age between 40 and 60 years
• Clinical Diagnosis of OAB syndrome non neurogenic type
• Score Questionnaire OAB-V8, sum equal to or greater than eight (8)
• Calendar indicating voiding more than 8 micturitions in 24 hours
• Complaints of urinary urgency
Exclusion Criteria:
• With a diagnosis of lower urinary tract
• Signs of leukorrhoea/diagnosis of vaginitis
• Pregnant women
• Diagnosed with bladder cancer and other pelvic organs
• With a history of pelvic radiotherapy
• With change in the sensitivity of the pelvis and lower limbs region
• With diabetes mellitus
• With known neurologic diseases
• Patients on medications that may affect the autonomic nervous system, including anticholinergics,
alpha-adrenergic antagonists, tricyclic antidepressants, serotonin, antimuscarinic, beta-receptor agonists or
antagonists and antihypertensive agents
• Use of cardiac pacemakers
Interventions Transcutaneous electric stimulation: Two self-adhesive electrodes, one immediately behind the medial malle-
olus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the
tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is
then changed to 10Hz, the pulse width set at 200 “microseconds” and adjusted according to the intensity
threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation
in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects.
The application time is 30 minutes
Placebo: active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to
that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10
cm above will be used.The application time 30 minutes
Outcomes Parasympathetic and sympathetic system values obtained from heart rate variability (HRV) after TENS
application
Starting date March 2014
Contact information None given
Notes Due to complete August 2014
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Trial name or title
Methods RCT
Setting: Canada
Follow-up: 12 weeks
Participants N = 60
Inclusion Criteria:
1. Female, >18 years of age, with the clinical diagnosis of OAB
2. Failure of behavioural measures and pharmacologic therapy to adequately control OAB symptoms
3. Baseline patient perception of bladder condition score of 2 or higher
Exclusion Criteria:
1. Current or previous percutaneous or sacral neuromodulation therapy
2. Stress predominant urinary incontinence
3. Newly added bladder medication or dose change with the last 2 months (tamsulosin, silodosin,
alfuzosin, terazosin, baclofen, diazepam, amitriptyline, imipramine, DDAVP, tolterodine, oxybutynin,
fesoterodine, darifenacin, solifenacin, trospium, mirabegron)
4. Intravesical botulinum toxin use within the last 1 year
5. Implanted pacemaker or defibrillator
6. History of epilepsy
7. Unable or unwilling to commit to study treatment schedule
8. Pregnant, or possible pregnancy planned for the duration of the study period
9. Active skin disease of the lower legs (dermatitis, cellulitis, eczema, trauma)
10. Documented allergy to patch electrodes or their adhesive
11. Abnormal sensory function of the lower limb
12. Metallic implant within the lower limb
Interventions Sham transcutaneous tibial nerve stimulation: Transcutaneous stimulation in a location and with settings not
related to the bladder nerves, 3x/week for 30 minutes for 12 weeks. patch electrodes applied posterior to the
lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be
used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the
patients at home 3x/week for 30 minutes, over 12 weeks
Transcutaneous tibial nerve stimulation Patch electrodes applied posterior to the medial malleolus, and 5-
10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation
setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient’s
maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for
30 minutes, over 12 weeks
Outcomes OAB-q SF
Voiding diary
24-hour pad weights
Physician assessment of treatment benefit
Starting date November 2015
Contact information None given
Notes Due to complete Nov 2017
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Trial name or title
Methods RCT
Setting: Canada
Follow-up: 3 months
Participants N = 60
Inclusion Criteria:
1. >18 years of age, with a clinical condition associated with neurogenic bladder dysfunction (multiple
sclerosis, Parkinson’s disease, stroke, dementia, cerebral palsy, spinal cord injury)(27)
2. Failure of behavioural measures and/or pharmacologic therapy to adequately control neurogenic
bladder symptoms
Exclusion Criteria:
1. Current or previous percutaneous/transcutaneous tibial nerve stimulation or sacral neuromodulation
therapy
2. Stress predominant urinary incontinence
3. Newly added bladder medication or dose change with the last 2 months (tamsulosin, silodosin,
alfuzosin, terazosin, baclofen, diazepam, amitriptyline, imipramine, DDAVP, tolterodine, oxybutynin,
fesoterodine, darifenacin, solifenacin, trospium, mirabegron)
4. Intravesical botulinum toxin use within the last 1 year
5. Implanted pacemaker or defibrillator
6. History of epilepsy
7. Unable or unwilling to commit to study treatment schedule
8. Pregnant, or possible pregnancy planned for the duration of the study period
9. Active skin disease of the lower legs (dermatitis, cellulitis, eczema, trauma)
10. Documented allergy to patch electrodes or their adhesive
11. Metallic implant within the lower limb
Interventions Sham tibial nerve stimulation
Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve
Tibial nerve stimulation
Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve
Device: EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine
Percutaneous patch electrodes are used to deliver low level electrical currents
Outcomes Neurogenic bladder symptom score questionnaire
Qualiveen-Short Form Questionnaire
Patient-reported urinary frequency, urgency, incontinence episodes
24-hour incontinence pad weights
Physician assessment of patient benefit
Starting date December 2015
Contact information Mary McKibbon mary.mckibbon@sjhc.london.on.ca
Notes Due to complete Dec 2016
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Trial name or title
Methods RCT
Setting: Brazil
Follow-up: 12 weeks
Participants N = 30
Inclusion Criteria:
• Female, age 40-90
• Clinical diagnosis of PD according to the criteria of the London Brain Bank
• Complaint urinary storage symptoms such as urinary urgency (sudden urge, abrupt and imperious to
urinate, which is difficult to be inhibited), with or without urge incontinence (urine leakage after
emergency), frequency (number of urination> 7/day) and nocturia (the number of micturitions > 1/night).
Exclusion Criteria:
• Damage to the peripheral sacral nerves
• Infection of the lower urinary tract untreated
• Diabetes mellitus
• Chronic pulmonary disease worsened
• Pregnancy and postpartum
• Urinary Incontinence of pure SUI or MUI with predominance of the stress component
• Pacemaker or defibrillator
• Metal prostheses
• Application of botulinum toxin into the bladder and/or pelvic muscles last year
• Current TENS treatment in the pelvic region, lower back and/or legs
• Prior urinary incontinence surgery
• Current bladder carcinoma
• Cognitive impairment likely to prevent implementation of the proposed treatment
• Not able to understand/sign informed consent
Interventions Back Tibial Nerve Electrostimulation
The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole
positioned on the inner malleolus and the positive approximately 0.5 cm below the previous, and connected to
a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department
of the HCPA
Placebo Electrostimulation
Outcomes Hoehn and Yahr Disability Stage of scale
Starting date July 2014
Contact information Tatiane Gomes de Araujo tatinhaga@yahoo.com.br
Notes Due to complete December 2017
DO: detrusor overactivity
ES: electrical stimulation
ICIQ: International Consultation on Incontinence Questionnaire
MUI: mixed urinary incontinence
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OAB: overactive bladder
RCT: randomised controlled trial
SUI: stress urinary incontinence
PTNS: posterior tibial nerve stimulation
TPTNS: transcutaneous posterior tibial nerve stimulation
TEVS: transcutaneous electrical nerve stimulation
UUI: urgency urinary incontinence
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D A T A A N D A N A L Y S E S
Comparison 1. Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants with
OAB symptoms
2 61 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.43, 1.06]
1.1 ES versus no active
treatment
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.35, 1.28]
1.2 ES versus sham treatment 1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.37, 1.28]
2 Number of participants with
no improvement in OAB
symptoms
8 647 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.47, 0.63]
2.1 ES versus no active
treatment
2 121 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.22, 0.63]
2.2 ES versus placebo 2 94 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.30, 0.62]
2.3 ES versus sham treatment 4 432 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.51, 0.73]
3 Number of participants with
no improvement in OAB
symptoms: neurogenic v
idiopathic
8 647 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.47, 0.63]
3.1 Idiopathic OAB 7 623 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.48, 0.66]
3.2 Neurogenic OAB 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.81]
4 Number of participants with
no improvement in OAB
symptoms: different ES routes
8 647 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.47, 0.63]
4.1 Percutaneous tibial nerve
stimulation
3 269 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.42, 0.65]
4.2 VERV electrode patches 1 163 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.13]
4.3 Posterior tibial nerve
stimulation with surface
electrodes
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.00, 0.81]
4.4 Intravaginal 3 191 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.33, 0.62]
5 Number of participants with
no improvement in urgency
symptoms
4 330 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.52, 0.73]
5.1 ES versus placebo 2 94 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.30, 0.62]
5.2 ES versus sham treatment 2 236 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.58, 0.86]
6 Number of participants with
no improvement in urinary
frequency
2 236 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.53, 0.81]
6.1 ES versus sham treatment 2 236 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.53, 0.81]
7 Number of participants not
satisfied
2 98 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.38, 0.97]
7.1 ES versus sham treatment 2 98 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.38, 0.97]
8 Number of participants with
urgency urinary incontinence
3 122 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.62, 0.99]
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8.1 ES versus no active
treatment
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.47, 1.63]
8.2 ES versus sham treatment 2 98 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.59, 0.97]
9 Number of participants with
no improvement in urgency
urinary incontinence
4 324 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.32, 0.86]
9.1 ES versus sham treatment 4 324 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.32, 0.86]
10 Number of participants with
no improvement in urgency
urinary incontinence
4 324 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.32, 0.86]
10.1 Percutaneous tibial nerve
stimulation
3 270 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.36, 0.97]
10.2 Intravaginal 1 54 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.16, 0.72]
11 Number of participants with
no improvement in ICIQ-SF
score
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
11.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 OAB-Q total score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Change in OAB-Q total score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 OAB-Q severity score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Change in OAB-Q severity
score
2 240 Mean Difference (IV, Fixed, 95% CI) -8.77 [-14.18, -3.36]
15.1 ES versus sham treatment 2 240 Mean Difference (IV, Fixed, 95% CI) -8.77 [-14.18, -3.36]
16 Urgency score (non validated
instrument)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Quality of life score (non
validated instrument)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Change in SF-36 score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Number of incontinence
episodes per 24 hours
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 ES versus placebo 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Number of micturitions per 24
hours
3 285 Mean Difference (IV, Fixed, 95% CI) -1.09 [-1.70, -0.47]
20.1 ES versus sham treatment 3 285 Mean Difference (IV, Fixed, 95% CI) -1.09 [-1.70, -0.47]
21 Number of nocturia episodes 2 245 Mean Difference (IV, Fixed, 95% CI) -0.37 [-0.73, -0.02]
21.1 ES versus sham treatment 2 245 Mean Difference (IV, Fixed, 95% CI) -0.37 [-0.73, -0.02]
22 Number of pads per day 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Number of participants with
no improvement in nocturia
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
23.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 Number of participants with
no improvement in incomplete
bladder emptying
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
24.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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25 Number of participants with no
improvement in weak urinary
stream
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
25.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
26 Number of participants with no
improvement in intermittency
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
26.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Number of participants with
no improvement in urinary
straining
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
27.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
28 Number of participants with no
improvement in urine leakage
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
28.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
29 Number of participants with no
improvement in interference in
everyday life
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
29.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
30 Number of participants with
detrusor overactivity (objective
evaluation)
2 118 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.54, 0.85]
30.1 ES versus sham treatment 2 118 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.54, 0.85]
31 Number of participants
with no improvement in
detrusor overactivity (objective
evaluation)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
31.1 ES versus sham treatment 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
32 Number of participants with
nocturnal enuresis
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
32.1 ES versus no active
treatment
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
33 Detrusor Activity Index Score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
33.1 ES versus no treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
34 Maximum cystometric capacity
(mL)
3 251 Mean Difference (IV, Fixed, 95% CI) 87.44 [79.50, 95.37]
34.1 ES versus sham treatment 3 251 Mean Difference (IV, Fixed, 95% CI) 87.44 [79.50, 95.37]
35 Maximum bladder pressure
(cmH20)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
35.1 ES versus placebo: end of
treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
35.2 ES versus placebo: 12
months after baseline
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
36 Volume voided per 24h (mL) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
36.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
37 Volume at first desire to void
(mL)
2 154 Mean Difference (IV, Fixed, 95% CI) 16.55 [5.88, 27.22]
37.1 ES versus sham treatment 1 47 Mean Difference (IV, Fixed, 95% CI) -13.76 [-63.65, 36.
12]
37.2 ES versus placebo 1 107 Mean Difference (IV, Fixed, 95% CI) 18.0 [7.08, 28.92]
38 Pelvic floor muscle strength
(cmH2O)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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38.1 ES versus sham treatment 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
39 Number of participants with
adverse effects
3 450 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.90, 1.03]
39.1 ES versus sham treatment 3 450 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.90, 1.03]
40 Other data Other data No numeric data
Comparison 2. Electrical stimulation versus conservative treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants with
OAB symptoms
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 ES versus PFMT 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Number of participants with
no improvement in OAB
symptoms
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 ES versus PFMT 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 ES versus PFMT +
biofeedback
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Number of participants with
urgency urinary incontinence
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 ES versus PFMT 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 ES versus PFMT +
biofeedback
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Number of participants not
satisfied
2 124 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [1.21, 4.75]
4.1 ES versus PFMT 2 124 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [1.21, 4.75]
5 King’s Health Questionnaire
score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 ES versus PFMT +
biofeedback
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Number of micturitions per 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Number of nocturia episodes 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Number of incontinence
episodes per 24 hours
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 ES versus laseropuncture 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Number of pads per day 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Number of participants with
OAB (objective evaluation)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 ES versus PFMT 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Number of participants with
detrusor overactivity
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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11.1 ES versus magnetic
stimulation
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Detrusor Activity Index Score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 ES versus PFMT+BT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Maximum cystometric capacity
(mL)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 ES versus magnetic
stimulation
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Post micturition residual
volume
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Bladder capacity at first desire
to void
3 188 Mean Difference (IV, Fixed, 95% CI) 8.45 [-5.07, 21.96]
15.1 ES versus magnetic
stimulation
1 32 Mean Difference (IV, Fixed, 95% CI) -4.70 [-86.54, 77.
14]
15.2 ES versus PFMT 1 42 Mean Difference (IV, Fixed, 95% CI) -13.80 [-55.19, 27.
59]
15.3 ES versus laseropuncture 1 114 Mean Difference (IV, Fixed, 95% CI) 11.60 [-2.92, 26.12]
16 Volume at maximum desire to
void
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 ES versus laseropuncture:
end of treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 ES versus laseropuncture:
12 months after baseline
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Maximum bladder pressure
(cmH20)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 ES versus laseropuncture:
end of treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 ES versus laseropuncture:
12 months after baseline
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Involuntary detrusor
contraction volume
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Involuntary detrusor
contraction maximal pressure
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 ES versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Number of participants with
adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
20.1 ES versus magnetic
stimulation
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. Electrical stimulation versus drugs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants with
OAB symptoms
3 193 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.07]
1.1 ES versus tolterodine 2 150 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.36, 0.93]
1.2 ES versus oxybutynin 1 43 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.64, 2.67]
2 Number of participants with
no improvement in OAB
symptoms
5 265 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.48, 0.90]
2.1 ES versus propantheline
bromide
1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.23, 1.32]
2.2 ES versus tolterodine 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.43, 2.06]
2.3 ES versus oxybutynin 3 163 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.42, 0.90]
3 Number of participants with
no improvement in OAB
symptoms: routes of ES
5 265 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.48, 0.90]
3.1 Transcutaneous posterior
tibial nerve stimulation
1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.23, 1.13]
3.2 Intravaginal/transanal 4 201 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.49, 0.99]
4 Number of participants not
satisfied
3 138 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.62, 1.77]
4.1 ES versus trospium
hydrochloride
1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.05, 5.29]
4.2 ES versus oxybutynin 2 107 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.64, 1.89]
5 Number of participants with
urinary incontinence
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 ES versus oxybutynin after
12 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 ES versus oxybutynin after
24 weeks
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Number of participants with
no improvement in urgency
urinary incontinence
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 ES versus tolterodine 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 OABq-SF score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 ES versus solifenacin
succinate
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Patient Global Impression of
Improvement questionnaire
(PGI-I) score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 ES versus solifenacin
succinate
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Urgency score (Patient
Perception of Intensity of
Urgency (PPIUS))
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 ES versus solifenacin
succinate
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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10 Number of incontinence
episodes per 24 hours
3 237 Mean Difference (IV, Random, 95% CI) 0.84 [-1.71, 3.39]
10.1 ES versus tolterodine 1 84 Mean Difference (IV, Random, 95% CI) -0.60 [-1.49, 0.29]
10.2 ES versus oxybutynin 1 43 Mean Difference (IV, Random, 95% CI) 0.90 [-6.45, 8.25]
10.3 ES versus trospium +
solifenacin
1 110 Mean Difference (IV, Random, 95% CI) 2.2 [1.78, 2.62]
11 Change in number of
incontinence episodes per 24
hours
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 ES versus tolterodine 2 115 Mean Difference (IV, Fixed, 95% CI) 0.80 [-0.40, 2.00]
12 Number of urgency episodes
per 24h
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 ES versus tolterodine 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Change in number of urgency
episodes per 24 hours
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 ES versus tolterodine 2 115 Mean Difference (IV, Fixed, 95% CI) 0.60 [-1.14, 2.35]
14 Number of urgency
incontinence episodes per 24
hours
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 ES versus solifenacin
succinate
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Number of micturitions per 24
hours
4 194 Mean Difference (IV, Fixed, 95% CI) 0.24 [-0.49, 0.98]
15.1 ES versus tolterodine 1 84 Mean Difference (IV, Fixed, 95% CI) -0.10 [-1.56, 1.36]
15.2 ES versus oxybutynin 2 80 Mean Difference (IV, Fixed, 95% CI) 0.87 [-0.18, 1.91]
15.3 ES versus solifenacin
succinate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.60 [-2.04, 0.84]
16 Change in number of
micturitions per 24 hours
3 176 Mean Difference (IV, Fixed, 95% CI) 0.34 [-0.49, 1.16]
16.1 ES versus tolterodine 3 176 Mean Difference (IV, Fixed, 95% CI) 0.34 [-0.49, 1.16]
17 Number of nocturia episodes
per night
3 157 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.41, 0.37]
17.1 ES versus tolterodine 1 84 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.78, 0.38]
17.2 ES versus oxybutynin 1 43 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.35, 0.95]
17.3 ES versus solifenacin
succinate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.06, 0.66]
18 Change in number of nocturia
episodes per night
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 ES versus tolterodine 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Number of participants with
nocturia
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
19.1 ES versus oxybutynin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Number of pads per day 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 ES versus oxybutynin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Number of participants with
OAB (objective evaluation)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
21.1 ES versus oxybutynin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Maximum cystometric capacity
(mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 ES versus oxybutynin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Volume voided per 24h (mL) 2 114 Mean Difference (IV, Fixed, 95% CI) 11.61 [-3.95, 27.18]
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23.1 ES versus tolterodine 1 84 Mean Difference (IV, Fixed, 95% CI) 26.80 [-12.01, 65.
61]
23.2 ES versus solifenacin
succinate
1 30 Mean Difference (IV, Fixed, 95% CI) 8.70 [-8.29, 25.69]
24 Change in voided volume per
24h (mL)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
24.1 ES versus tolterodine 2 145 Mean Difference (IV, Fixed, 95% CI) -8.92 [-28.97, 11.
13]
25 Volume at first desire to void
(mL)
2 153 Mean Difference (IV, Fixed, 95% CI) -44.33 [-57.33, -31.
34]
25.1 ES versus oxybutynin 1 43 Mean Difference (IV, Fixed, 95% CI) -28.5 [-65.21, 8.21]
25.2 ES versus trospium +
solifenacin
1 110 Mean Difference (IV, Fixed, 95% CI) -46.60 [-60.49, -32.
71]
26 Volume at maximum desire to
void (mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26.1 ES versus trospium +
solifenacin: end of treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.2 ES versus trospium +
solifenacin: 12 months after
baseline
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Maximum bladder pressure
(cmH2O)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
27.1 ES versus trospium +
solifenacin: end of treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27.2 ES versus trospium +
solifenacin: 12 months after
baseline
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
28 Post micturition residual
volume (mL)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
28.1 ES versus oxybutynin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
29 Involuntary detrusor
contraction volume
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
29.1 ES versus oxybutynin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30 Involuntary detrusor
contraction maximal pressure
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
30.1 ES versus oxybutynin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
31 Number of participants with
adverse effects
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
31.1 ES versus oxybutynin 2 79 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.07, 1.49]
31.2 ES versus tolterodine 2 94 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.21, 1.89]
31.3 ES versus trospium
hydrochloride
1 35 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.43, 1.25]
32 Other data Other data No numeric data
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Comparison 4. Electrical stimulation plus another treatment versus other treatment alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants not
satisfied
2 82 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.24]
1.1 ES + PFMT versus PFMT 2 82 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.24]
2 Number of participants with
urgency urinary incontinence
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 ES + PFMT versus PFMT
alone
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Number of participants with
no improvement in urgency
urinary incontinence
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 ES + PFMT versus PFMT
alone
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Incontinence Impact
Questionnaire score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 ES + drugs versus drugs
alone
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 International Consultation on
Incontinence Questionnaire
(short form) score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 ES + PFMT versus PFMT
alone
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 I-QOL score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 ES + PFMT + drugs versus
drugs
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 SF-Qualiveen score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 ES + PFMT + biofeedback
versus PFMT + biofeedback
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 York Incontinence Perception
Scale score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 ES + PFMT versus PFMT 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Number of incontinence
episodes per 24h
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 ES + drugs versus drugs 1 38 Mean Difference (IV, Fixed, 95% CI) -0.9 [-1.06, -0.74]
9.2 ES + PFMT versus PFMT 2 119 Mean Difference (IV, Fixed, 95% CI) -0.83 [-1.47, -0.19]
9.3 ES + PFMT + drugs versus
drugs
1 30 Mean Difference (IV, Fixed, 95% CI) -1.0 [-2.12, 0.12]
10 Number of urgency episodes
per 24 hours
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 ES + drugs versus drugs
alone
1 38 Mean Difference (IV, Fixed, 95% CI) -1.90 [-2.39, -1.41]
10.2 ES + PFMT versus
PFMT alone
1 51 Mean Difference (IV, Fixed, 95% CI) -2.8 [-4.57, -1.03]
10.3 ES + PFMT +
biofeedback versus PFMT +
biofeedback
1 31 Mean Difference (IV, Fixed, 95% CI) 0.58 [-0.91, 2.07]
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11 Change in number of nocturia
episodes
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 ES + PFMT versus
PFMT alone
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Number of micturitions per 24
hours
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 ES + PFMT versus
PFMT
2 63 Mean Difference (IV, Fixed, 95% CI) -0.75 [-1.62, 0.12]
12.2 ES + drugs versus drugs 1 40 Mean Difference (IV, Fixed, 95% CI) -1.40 [-4.18, 1.38]
12.3 ES + PFMT + drugs
versus drugs
1 31 Mean Difference (IV, Fixed, 95% CI) -2.0 [-3.84, -0.16]
13 Change in number of
micturitions per 24 hours
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 ES + PFMT versus
PFMT alone
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Number of nocturia episodes 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 ES + PFMT versus
PFMT alone
1 51 Mean Difference (IV, Fixed, 95% CI) -1.10 [-1.87, -0.33]
14.2 ES + PFMT + drugs
versus drugs
1 30 Mean Difference (IV, Fixed, 95% CI) -1.0 [-2.04, 0.04]
15 Detrusor Activity Index Score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 ES+PFMT+BT versus
PFMT+BT alone
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Bladder hyperactivity score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 ES + PFMT +
biofeedback versus PFMT +
biofeedback
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Pelvic floor muscle strength
(cmH2O)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 ES + PFMT versus
PFMT
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Number of participants with
adverse effects
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 ES + drugs versus drugs 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.04, 4.55]
18.2 ES + PFMT versus
PFMT
1 51 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.3 ES + PFMT + drugs
versus drugs
1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.15]
19 Other data Other data No numeric data
Comparison 5. Electrical stimulation plus another treatment versus no active treatment, placebo or sham treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 York Incontinence Perception
Scale score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 ES + PFMT versus no
active treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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2 Number of incontinence
episodes per 24h
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 ES + PFMT versus no
active treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Number of micturitions per 24h 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 ES + PFMT versus no
active treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Detrusor Activity Index score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 ES + PFMT versus no
active treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Pelvic floor muscle strength
(cmH2O)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 ES + PFMT versus no
active treatment
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. One type of electrical stimulation versus another
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants not
satisfied
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 200µs pulse width versus
500µs pulse width
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Maximum cystometric capacity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 150Hz versus 10Hz 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Volume at first desire to void 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 150Hz versus 10Hz 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 1 Number of participants with OAB symptoms.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 1 Number of participants with OAB symptoms
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus no active treatment
Monteiro 2014 6/12 9/12 44.2 % 0.67 [ 0.35, 1.28 ]
Subtotal (95% CI) 12 12 44.2 % 0.67 [ 0.35, 1.28 ]
Total events: 6 (Electrical stimulation), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
2 ES versus sham treatment
Bellette 2009 9/21 10/16 55.8 % 0.69 [ 0.37, 1.28 ]
Subtotal (95% CI) 21 16 55.8 % 0.69 [ 0.37, 1.28 ]
Total events: 9 (Electrical stimulation), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
Total (95% CI) 33 28 100.0 % 0.68 [ 0.43, 1.06 ]
Total events: 15 (Electrical stimulation), 19 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.5 0.7 1 1.5 2
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Analysis 1.2. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 2 Number of participants with no improvement in OAB symptoms.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 2 Number of participants with no improvement in OAB symptoms
Study or subgroup favours ES Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus no active treatment
Monteiro 2014 0/12 9/12 4.1 % 0.05 [ 0.00, 0.81 ]
Oldham 2013 13/50 25/47 11.2 % 0.49 [ 0.29, 0.84 ]
Subtotal (95% CI) 62 59 15.4 % 0.37 [ 0.22, 0.63 ]
Total events: 13 (favours ES), 34 (Control)
Heterogeneity: Chi2 = 2.95, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 3.66 (P = 0.00025)
2 ES versus placebo
Wang 2006 10/24 19/21 8.8 % 0.46 [ 0.28, 0.75 ]
Wang 2009 9/26 20/23 9.2 % 0.40 [ 0.23, 0.69 ]
Subtotal (95% CI) 50 44 18.1 % 0.43 [ 0.30, 0.62 ]
Total events: 19 (favours ES), 39 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.50 (P < 0.00001)
3 ES versus sham treatment
Booth 2013 4/15 9/13 4.2 % 0.39 [ 0.15, 0.96 ]
Kennelly 2011 37/80 46/83 19.7 % 0.83 [ 0.62, 1.13 ]
Peters 2010 50/110 87/110 37.9 % 0.57 [ 0.46, 0.72 ]
Vohra 2002 2/11 10/10 4.8 % 0.22 [ 0.07, 0.66 ]
Subtotal (95% CI) 216 216 66.6 % 0.61 [ 0.51, 0.73 ]
Total events: 93 (favours ES), 152 (Control)
Heterogeneity: Chi2 = 8.55, df = 3 (P = 0.04); I2 =65%
Test for overall effect: Z = 5.44 (P < 0.00001)
Total (95% CI) 328 319 100.0 % 0.54 [ 0.47, 0.63 ]
Total events: 125 (favours ES), 225 (Control)
Heterogeneity: Chi2 = 15.58, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 7.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.36, df = 2 (P = 0.07), I2 =63%
0.1 0.2 0.5 1 2 5 10
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Analysis 1.3. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 3 Number of participants with no improvement in OAB symptoms: neurogenic v idiopathic.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 3 Number of participants with no improvement in OAB symptoms: neurogenic v idiopathic
Study or subgroup favours ES Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Idiopathic OAB
Booth 2013 4/15 9/13 4.2 % 0.39 [ 0.15, 0.96 ]
Kennelly 2011 37/80 46/83 19.7 % 0.83 [ 0.62, 1.13 ]
Oldham 2013 13/50 25/47 11.2 % 0.49 [ 0.29, 0.84 ]
Peters 2010 50/110 87/110 37.9 % 0.57 [ 0.46, 0.72 ]
Vohra 2002 2/11 10/10 4.8 % 0.22 [ 0.07, 0.66 ]
Wang 2006 10/24 19/21 8.8 % 0.46 [ 0.28, 0.75 ]
Wang 2009 9/26 20/23 9.2 % 0.40 [ 0.23, 0.69 ]
Subtotal (95% CI) 316 307 95.9 % 0.56 [ 0.48, 0.66 ]
Total events: 125 (favours ES), 216 (Control)
Heterogeneity: Chi2 = 12.29, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 7.34 (P < 0.00001)
2 Neurogenic OAB
Monteiro 2014 0/12 9/12 4.1 % 0.05 [ 0.00, 0.81 ]
Subtotal (95% CI) 12 12 4.1 % 0.05 [ 0.00, 0.81 ]
Total events: 0 (favours ES), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 328 319 100.0 % 0.54 [ 0.47, 0.63 ]
Total events: 125 (favours ES), 225 (Control)
Heterogeneity: Chi2 = 15.58, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 7.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.88, df = 1 (P = 0.09), I2 =65%
0.002 0.1 1 10 500
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Analysis 1.4. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 4 Number of participants with no improvement in OAB symptoms: different ES routes.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 4 Number of participants with no improvement in OAB symptoms: different ES routes
Study or subgroup favours ES Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Percutaneous tibial nerve stimulation
Booth 2013 4/15 9/13 4.2 % 0.39 [ 0.15, 0.96 ]
Peters 2010 50/110 87/110 37.9 % 0.57 [ 0.46, 0.72 ]
Vohra 2002 2/11 10/10 4.8 % 0.22 [ 0.07, 0.66 ]
Subtotal (95% CI) 136 133 46.9 % 0.52 [ 0.42, 0.65 ]
Total events: 56 (favours ES), 106 (Control)
Heterogeneity: Chi2 = 3.50, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 5.88 (P < 0.00001)
2 VERV electrode patches
Kennelly 2011 37/80 46/83 19.7 % 0.83 [ 0.62, 1.13 ]
Subtotal (95% CI) 80 83 19.7 % 0.83 [ 0.62, 1.13 ]
Total events: 37 (favours ES), 46 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
3 Posterior tibial nerve stimulation with surface electrodes
Monteiro 2014 0/12 9/12 4.1 % 0.05 [ 0.00, 0.81 ]
Subtotal (95% CI) 12 12 4.1 % 0.05 [ 0.00, 0.81 ]
Total events: 0 (favours ES), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
4 Intravaginal
Oldham 2013 13/50 25/47 11.2 % 0.49 [ 0.29, 0.84 ]
Wang 2006 10/24 19/21 8.8 % 0.46 [ 0.28, 0.75 ]
Wang 2009 9/26 20/23 9.2 % 0.40 [ 0.23, 0.69 ]
Subtotal (95% CI) 100 91 29.3 % 0.45 [ 0.33, 0.62 ]
Total events: 32 (favours ES), 64 (Control)
Heterogeneity: Chi2 = 0.29, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 5.04 (P < 0.00001)
Total (95% CI) 328 319 100.0 % 0.54 [ 0.47, 0.63 ]
Total events: 125 (favours ES), 225 (Control)
Heterogeneity: Chi2 = 15.58, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 7.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 11.71, df = 3 (P = 0.01), I2 =74%
0.002 0.1 1 10 500
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Analysis 1.5. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 5 Number of participants with no improvement in urgency symptoms.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 5 Number of participants with no improvement in urgency symptoms
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus placebo
Wang 2006 10/24 19/21 15.4 % 0.46 [ 0.28, 0.75 ]
Wang 2009 9/26 20/23 16.2 % 0.40 [ 0.23, 0.69 ]
Subtotal (95% CI) 50 44 31.6 % 0.43 [ 0.30, 0.62 ]
Total events: 19 (Electrical stimulation), 39 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.50 (P < 0.00001)
2 ES versus sham treatment
Booth 2013 4/15 9/13 7.3 % 0.39 [ 0.15, 0.96 ]
Peters 2010 59/103 81/105 61.1 % 0.74 [ 0.61, 0.90 ]
Subtotal (95% CI) 118 118 68.4 % 0.70 [ 0.58, 0.86 ]
Total events: 63 (Electrical stimulation), 90 (Control)
Heterogeneity: Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 3.54 (P = 0.00040)
Total (95% CI) 168 162 100.0 % 0.62 [ 0.52, 0.73 ]
Total events: 82 (Electrical stimulation), 129 (Control)
Heterogeneity: Chi2 = 8.20, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 5.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.44, df = 1 (P = 0.02), I2 =82%
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Analysis 1.6. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 6 Number of participants with no improvement in urinary frequency.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 6 Number of participants with no improvement in urinary frequency
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 4/15 7/13 8.5 % 0.50 [ 0.19, 1.32 ]
Peters 2010 54/103 82/105 91.5 % 0.67 [ 0.54, 0.83 ]
Total (95% CI) 118 118 100.0 % 0.66 [ 0.53, 0.81 ]
Total events: 58 (Electrical stimulation), 89 (Control)
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.98 (P = 0.000069)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 7 Number of participants not satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 7 Number of participants not satisfied
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Amaro 2006 4/20 7/20 27.2 % 0.57 [ 0.20, 1.65 ]
Yamanishi 2000a 13/32 17/26 72.8 % 0.62 [ 0.38, 1.03 ]
Total (95% CI) 52 46 100.0 % 0.61 [ 0.38, 0.97 ]
Total events: 17 (Electrical stimulation), 24 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.8. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 8 Number of participants with urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 8 Number of participants with urgency urinary incontinence
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus no active treatment
Monteiro 2014 7/12 8/12 19.2 % 0.88 [ 0.47, 1.63 ]
Subtotal (95% CI) 12 12 19.2 % 0.88 [ 0.47, 1.63 ]
Total events: 7 (Electrical stimulation), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
2 ES versus sham treatment
Amaro 2006 3/20 6/20 14.4 % 0.50 [ 0.14, 1.73 ]
Yamanishi 2000a 25/32 25/26 66.3 % 0.81 [ 0.67, 0.99 ]
Subtotal (95% CI) 52 46 80.8 % 0.76 [ 0.59, 0.97 ]
Total events: 28 (Electrical stimulation), 31 (Control)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Total (95% CI) 64 58 100.0 % 0.78 [ 0.62, 0.99 ]
Total events: 35 (Electrical stimulation), 39 (Control)
Heterogeneity: Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
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Analysis 1.9. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 9 Number of participants with no improvement in urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 9 Number of participants with no improvement in urgency urinary incontinence
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ES versus sham treatment
Booth 2013 8/15 11/13 25.4 % 0.63 [ 0.37, 1.07 ]
Finazzi-Agr 2010 5/17 18/18 20.9 % 0.31 [ 0.16, 0.63 ]
Peters 2010 64/103 81/104 34.0 % 0.80 [ 0.66, 0.96 ]
Yamanishi 2000a 6/26 19/28 19.7 % 0.34 [ 0.16, 0.72 ]
Total (95% CI) 161 163 100.0 % 0.52 [ 0.32, 0.86 ]
Total events: 83 (Electrical stimulation), 129 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 11.92, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 2.56 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 10 Number of participants with no improvement in urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 10 Number of participants with no improvement in urgency urinary incontinence
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Percutaneous tibial nerve stimulation
Booth 2013 8/15 11/13 25.4 % 0.63 [ 0.37, 1.07 ]
Finazzi-Agr 2010 5/17 18/18 20.9 % 0.31 [ 0.16, 0.63 ]
Peters 2010 64/103 81/104 34.0 % 0.80 [ 0.66, 0.96 ]
Subtotal (95% CI) 135 135 80.3 % 0.59 [ 0.36, 0.97 ]
Total events: 77 (Electrical stimulation), 110 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 7.15, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 2.08 (P = 0.038)
2 Intravaginal
Yamanishi 2000a 6/26 19/28 19.7 % 0.34 [ 0.16, 0.72 ]
Subtotal (95% CI) 26 28 19.7 % 0.34 [ 0.16, 0.72 ]
Total events: 6 (Electrical stimulation), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
Total (95% CI) 161 163 100.0 % 0.52 [ 0.32, 0.86 ]
Total events: 83 (Electrical stimulation), 129 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 11.92, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 2.56 (P = 0.011)
Test for subgroup differences: Chi2 = 1.45, df = 1 (P = 0.23), I2 =31%
0.2 0.5 1 2 5
favours ES favours control
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Analysis 1.11. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 11 Number of participants with no improvement in ICIQ-SF score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 11 Number of participants with no improvement in ICIQ-SF score
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 5/15 7/13 0.62 [ 0.26, 1.48 ]
0.2 0.5 1 2 5
favours ES favours control
Analysis 1.12. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 12 OAB-Q total score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 12 OAB-Q total score
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Bellette 2009 21 -83.99 (16.99) 16 -66.63 (25.06) -17.36 [ -31.63, -3.09 ]
-50 -25 0 25 50
favours ES favours control
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Analysis 1.13. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 13 Change in OAB-Q total score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 13 Change in OAB-Q total score
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Bellette 2009 21 -31.73 (23.44) 16 -15.71 (19.46) -16.02 [ -29.86, -2.18 ]
-50 -25 0 25 50
favours ES favours control
Analysis 1.14. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 14 OAB-Q severity score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 14 OAB-Q severity score
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Bellette 2009 21 31.72 (18.25) 16 51.21 (32.11) -19.49 [ -37.05, -1.93 ]
-100 -50 0 50 100
favours ES favours control
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Analysis 1.15. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 15 Change in OAB-Q severity score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 15 Change in OAB-Q severity score
Study or subgroup Electrical stimulation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Bellette 2009 21 -36.06 (25.33) 16 -16.26 (26.24) 10.4 % -19.80 [ -36.61, -2.99 ]
Peters 2010 101 -36.7 (21.5) 102 -29.2 (20) 89.6 % -7.50 [ -13.21, -1.79 ]
Total (95% CI) 122 118 100.0 % -8.77 [ -14.18, -3.36 ]
Heterogeneity: Chi2 = 1.84, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
favours ES favours control
Analysis 1.16. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 16 Urgency score (non validated instrument).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 16 Urgency score (non validated instrument)
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Yamanishi 2000a 37 1.7 (0.7) 31 2 (0.8) -0.30 [ -0.66, 0.06 ]
-1 -0.5 0 0.5 1
favours ES favours control
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Analysis 1.17. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 17 Quality of life score (non validated instrument).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 17 Quality of life score (non validated instrument)
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Yamanishi 2000a 37 1.6 (0.7) 31 2.2 (0.9) -0.60 [ -0.99, -0.21 ]
-1 -0.5 0 0.5 1
favours ES favours control
Analysis 1.18. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 18 Change in SF-36 score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 18 Change in SF-36 score
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Peters 2010 103 -34.2 (21.3) 105 -20.6 (20.6) -13.60 [ -19.30, -7.90 ]
-20 -10 0 10 20
favours ES favours control
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Analysis 1.19. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 19 Number of incontinence episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 19 Number of incontinence episodes per 24 hours
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Barroso 2002 24 1.3 (1) 12 3 (0.9) -1.70 [ -2.35, -1.05 ]
2 ES versus placebo
Kosilov 2013 51 3.7 (1.3) 56 4.8 (2.4) -1.10 [ -1.82, -0.38 ]
-2 -1 0 1 2
favours ES favours control
Analysis 1.20. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 20 Number of micturitions per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 20 Number of micturitions per 24 hours
Study or subgroup Electrical stimulation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Amaro 2006 20 7 (1.78) 20 7.5 (1.78) 31.1 % -0.50 [ -1.60, 0.60 ]
Bellette 2009 21 8.29 (2.8) 16 10.55 (3.1) 10.1 % -2.26 [ -4.19, -0.33 ]
Peters 2010 103 9.8 (2.8) 105 11 (3.1) 58.8 % -1.20 [ -2.00, -0.40 ]
Total (95% CI) 144 141 100.0 % -1.09 [ -1.70, -0.47 ]
Heterogeneity: Chi2 = 2.58, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
favours ES favours control
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Analysis 1.21. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 21 Number of nocturia episodes.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 21 Number of nocturia episodes
Study or subgroup Electrical stimulation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Bellette 2009 21 1.14 (1) 16 2.06 (1.2) 24.0 % -0.92 [ -1.65, -0.19 ]
Peters 2010 103 2.4 (1.4) 105 2.6 (1.6) 76.0 % -0.20 [ -0.61, 0.21 ]
Total (95% CI) 124 121 100.0 % -0.37 [ -0.73, -0.02 ]
Heterogeneity: Chi2 = 2.86, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
favours ES favours control
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Analysis 1.22. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 22 Number of pads per day.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 22 Number of pads per day
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Yamanishi 2000a 37 0.8 (1.2) 31 1.1 (2) -0.30 [ -1.10, 0.50 ]
-10 -5 0 5 10
favours ES favours control
Analysis 1.23. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 23 Number of participants with no improvement in nocturia.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 23 Number of participants with no improvement in nocturia
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 8/15 10/13 0.69 [ 0.40, 1.21 ]
0.2 0.5 1 2 5
favours ES favours control
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Analysis 1.24. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 24 Number of participants with no improvement in incomplete bladder emptying.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 24 Number of participants with no improvement in incomplete bladder emptying
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 7/15 12/13 0.51 [ 0.29, 0.89 ]
0.2 0.5 1 2 5
favours ES favours control
Analysis 1.25. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 25 Number of participants with no improvement in weak urinary stream.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 25 Number of participants with no improvement in weak urinary stream
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 6/15 12/13 0.43 [ 0.23, 0.82 ]
0.2 0.5 1 2 5
favours ES favours control
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Analysis 1.26. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 26 Number of participants with no improvement in intermittency.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 26 Number of participants with no improvement in intermittency
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 10/15 11/13 0.79 [ 0.51, 1.21 ]
0.2 0.5 1 2 5
favours ES favours control
Analysis 1.27. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 27 Number of participants with no improvement in urinary straining.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 27 Number of participants with no improvement in urinary straining
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 9/15 12/13 0.65 [ 0.42, 1.01 ]
0.2 0.5 1 2 5
favours ES favours control
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Analysis 1.28. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 28 Number of participants with no improvement in urine leakage.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 28 Number of participants with no improvement in urine leakage
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 7/15 11/13 0.55 [ 0.31, 0.99 ]
0.2 0.5 1 2 5
favours ES favours control
Analysis 1.29. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 29 Number of participants with no improvement in interference in everyday life.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 29 Number of participants with no improvement in interference in everyday life
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Booth 2013 6/15 7/13 0.74 [ 0.33, 1.65 ]
0.2 0.5 1 2 5
favours ES favours control
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Analysis 1.30. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 30 Number of participants with detrusor overactivity (objective evaluation).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 30 Number of participants with detrusor overactivity (objective evaluation)
Study or subgroup Electrical stimulation Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Brubaker 1997 14/32 23/28 48.1 % 0.53 [ 0.35, 0.82 ]
Yamanishi 2000a 24/32 24/26 51.9 % 0.81 [ 0.65, 1.02 ]
Total (95% CI) 64 54 100.0 % 0.68 [ 0.54, 0.85 ]
Total events: 38 (Electrical stimulation), 47 (Control)
Heterogeneity: Chi2 = 3.62, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 3.40 (P = 0.00069)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
favours ES favours control
Analysis 1.31. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 31 Number of participants with no improvement in detrusor overactivity (objective evaluation).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 31 Number of participants with no improvement in detrusor overactivity (objective evaluation)
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Yamanishi 2000a 4/32 17/26 0.19 [ 0.07, 0.50 ]
0.001 0.01 0.1 1 10 100 1000
favours ES favours control
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Analysis 1.32. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 32 Number of participants with nocturnal enuresis.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 32 Number of participants with nocturnal enuresis
Study or subgroup Electrical stimulation Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus no active treatment
Monteiro 2014 1/12 6/12 0.17 [ 0.02, 1.18 ]
0.005 0.1 1 10 200
favours ES favours control
Analysis 1.33. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 33 Detrusor Activity Index Score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 33 Detrusor Activity Index Score
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus no treatment
Berghmans 2002 17 0.57 (0.33) 14 0.8 (0.26) -0.23 [ -0.44, -0.02 ]
-0.5 -0.25 0 0.25 0.5
favours ES favours control
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Analysis 1.34. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 34 Maximum cystometric capacity (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 34 Maximum cystometric capacity (mL)
Study or subgroup Electrical stimulation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Bower 1998 16 352 (144) 8 313.5 (81) 0.8 % 38.50 [ -51.66, 128.66 ]
Bower 1998 16 305 (146) 7 313.5 (81) 0.7 % -8.50 [ -101.87, 84.87 ]
Walsh 2001 74 404.2 (26.7) 72 315.9 (22.9) 96.9 % 88.30 [ 80.24, 96.36 ]
Yamanishi 2000a 32 285 (143.4) 26 182.9 (99) 1.6 % 102.10 [ 39.52, 164.68 ]
Total (95% CI) 138 113 100.0 % 87.44 [ 79.50, 95.37 ]
Heterogeneity: Chi2 = 5.44, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 21.60 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
favours control favours ES
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Analysis 1.35. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 35 Maximum bladder pressure (cmH20).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 35 Maximum bladder pressure (cmH20)
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus placebo: end of treatment
Kosilov 2013 51 35.4 (9.3) 56 31 (7.9) 4.40 [ 1.11, 7.69 ]
2 ES versus placebo: 12 months after baseline
Kosilov 2013 51 30.9 (4.9) 56 23.9 (5.4) 7.00 [ 5.05, 8.95 ]
-10 -5 0 5 10
favours control favours ES
Analysis 1.36. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 36 Volume voided per 24h (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 36 Volume voided per 24h (mL)
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Peters 2010 103 183 (75.6) 102 172.6 (90.6) 10.40 [ -12.45, 33.25 ]
-20 -10 0 10 20
favours control favours ES
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Analysis 1.37. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 37 Volume at first desire to void (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 37 Volume at first desire to void (mL)
Study or subgroup Electrical stimulation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Bower 1998 16 208.5 (132) 7 186 (77) 1.5 % 22.50 [ -63.74, 108.74 ]
Bower 1998 16 154 (61) 8 186 (77) 3.0 % -32.00 [ -93.16, 29.16 ]
Subtotal (95% CI) 32 15 4.6 % -13.76 [ -63.65, 36.12 ]
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.54 (P = 0.59)
2 ES versus placebo
Kosilov 2013 51 210.9 (28.7) 56 192.9 (28.9) 95.4 % 18.00 [ 7.08, 28.92 ]
Subtotal (95% CI) 51 56 95.4 % 18.00 [ 7.08, 28.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.23 (P = 0.0012)
Total (95% CI) 83 71 100.0 % 16.55 [ 5.88, 27.22 ]
Heterogeneity: Chi2 = 2.51, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 3.04 (P = 0.0024)
Test for subgroup differences: Chi2 = 1.49, df = 1 (P = 0.22), I2 =33%
-100 -50 0 50 100
favours control favours ES
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Analysis 1.38. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 38 Pelvic floor muscle strength (cmH2O).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 38 Pelvic floor muscle strength (cmH2O)
Study or subgroup Electrical stimulation Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus sham treatment
Amaro 2006 20 53.8 (18.6) 20 46.8 (12.5) 7.00 [ -2.82, 16.82 ]
-20 -10 0 10 20
favours control favours ES
Analysis 1.39. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 39 Number of participants with adverse effects.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation versus no active treatment, placebo or sham treatment
Outcome: 39 Number of participants with adverse effects
Study or subgroup Electrical stimulation Control
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus sham treatment
Kennelly 2011 30/80 29/82 26.9 % 0.97 [ 0.77, 1.22 ]
Peters 2010 6/110 0/110 56.8 % 0.95 [ 0.90, 0.99 ]
Yamanishi 2000a 2/37 2/31 16.2 % 1.01 [ 0.90, 1.14 ]
Total (95% CI) 227 223 100.0 % 0.96 [ 0.90, 1.03 ]
Total events: 38 (Electrical stimulation), 31 (Control)
Heterogeneity: Chi2 = 1.15, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
favours control favours ES
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Analysis 1.40. Comparison 1 Electrical stimulation versus no active treatment, placebo or sham treatment,
Outcome 40 Other data.
Other data
Study Intervention (N) Control (N) Outcome Result favours Data
Amaro 2006 ES (20) sham ES (20) Reduction in ana-
logue discomfort sen-
sation
ES 39.7% v 24.5%
Amaro 2006 ES (20) sham ES (20) Reduction in ana-
logue wetness sensa-
tion
ES 31.5% v 26.8%
Bellette 2009 ES (21) sham ES (16) % change in fre-
quency and urgency
ES p < 0.05 (-62.5% v -42.8%)
Kennelly 2011 ES (80) sham ES (83) Change in UUI
episodes
ES p = 0.2191
Median (IQR):
A: -3.7 (-4.7 to -1.0). B: -1.
7 (-3.3 to -1.0).
Kennelly 2011 ES (80) sham ES (83) Change in frequency sham ES p = 0.2893
Median (IQR)
A: -1.0 (-2.7 to 0.3). B: -1.
3 (-3.0 to -0.3)
Kennelly 2011 ES (80) sham ES (83) Change in urgency
episodes
no difference p = 0.6557
Median (IQR)
A: -1.7 (-3.3 to 0.3). B: -1.
7 (-3.3 to 0.3).
Kennelly 2011 ES (80) sham ES (83) Change in volumeper
void (ml)
sham ES p = 0.3387
Median (IQR)
A: 1.0 (-26.6 to 23.5). B: 8.
8 (-24.3 to 33.3)
Kennelly 2011 ES (80) sham ES (83) Change in OAB-q
score
sham ES p = 0.9918
Median (IQR)
A: 8.8 (1.6 to 20.0). B: 9.2
(-0.8 to 27.2)
Marques 2008 ES (NR) unclear if sham or no
active treatment (NR)
Nocturia ES p = 0.0186
Marques 2008 ES (NR) unclear if sham or no
active treatment (NR)
Daytime frequency ES p = 0.0001
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Other data (Continued)
Oldham 2013 ES (64) no active treatment
(60)
ICI-Q score ES median, range: A: 6 (0-17),
B: 9 (3-18)
Analysis 2.1. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 1 Number of
participants with OAB symptoms.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 1 Number of participants with OAB symptoms
Study or subgroup Electrical stimulation
Conservative
treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 10/21 9/21 1.11 [ 0.57, 2.17 ]
0.01 0.1 1 10 100
favours ES favours conservative
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Analysis 2.2. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 2 Number of
participants with no improvement in OAB symptoms.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 2 Number of participants with no improvement in OAB symptoms
Study or subgroup Electrical stimulation
Conservative
treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus PFMT
Wang 2004 17/35 21/34 0.79 [ 0.51, 1.21 ]
2 ES versus PFMT + biofeedback
Wang 2004 17/35 17/34 0.97 [ 0.60, 1.57 ]
0.5 0.7 1 1.5 2
favours ES favours conservative
Analysis 2.3. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 3 Number of
participants with urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 3 Number of participants with urgency urinary incontinence
Study or subgroup Electrical stimulation
Conservative
treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus PFMT
Wang 2004 17/35 21/34 0.79 [ 0.51, 1.21 ]
2 ES versus PFMT + biofeedback
Wang 2004 17/35 17/34 0.97 [ 0.60, 1.57 ]
0.05 0.2 1 5 20
favours ES favours conservative
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Analysis 2.4. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 4 Number of
participants not satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 4 Number of participants not satisfied
Study or subgroup Electrical stimulation
Conservative
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 10/21 5/21 57.6 % 2.00 [ 0.82, 4.86 ]
Boaretto 2011 5/16 2/22 19.4 % 3.44 [ 0.76, 15.53 ]
Boaretto 2011 5/22 2/22 23.0 % 2.50 [ 0.54, 11.54 ]
Total (95% CI) 59 65 100.0 % 2.39 [ 1.21, 4.75 ]
Total events: 20 (Electrical stimulation), 9 (Conservative treatment)
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
favours ES favours conservative
Analysis 2.5. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 5 King’s Health
Questionnaire score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 5 King’s Health Questionnaire score
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Wang 2004 35 180.08 (176.03) 34 50.27 (171.42) 129.81 [ 47.83, 211.79 ]
2 ES versus PFMT + biofeedback
Wang 2004 35 180.08 (176.03) 34 185.86 (176.57) -5.78 [ -88.99, 77.43 ]
-200 -100 0 100 200
favours ES favours conservative
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Analysis 2.6. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 6 Number of
micturitions per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 6 Number of micturitions per 24 hours
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 21 7.9 (2.3) 21 7.1 (2.1) 0.80 [ -0.53, 2.13 ]
-1 -0.5 0 0.5 1
favours ES favours conservative
Analysis 2.7. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 7 Number of
nocturia episodes.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 7 Number of nocturia episodes
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 21 1.2 (1.3) 21 1 (1.1) 0.20 [ -0.53, 0.93 ]
-2 -1 0 1 2
favours ES favours conservative
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Analysis 2.8. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 8 Number of
incontinence episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 8 Number of incontinence episodes per 24 hours
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 21 7.9 (13.7) 21 7.8 (15.3) 0.10 [ -8.68, 8.88 ]
2 ES versus laseropuncture
Kosilov 2013 51 3.7 (1.3) 63 5.5 (1.4) -1.80 [ -2.30, -1.30 ]
-20 -10 0 10 20
favours ES favours conservative
Analysis 2.9. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 9 Number of
pads per day.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 9 Number of pads per day
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 21 0.9 (1.7) 21 0.8 (1.3) 0.10 [ -0.82, 1.02 ]
-1 -0.5 0 0.5 1
favours ES favours conservative
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Analysis 2.10. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 10 Number of
participants with OAB (objective evaluation).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 10 Number of participants with OAB (objective evaluation)
Study or subgroup Electrical stimulation
Conservative
treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 9/21 10/21 0.90 [ 0.46, 1.75 ]
0.01 0.1 1 10 100
favours ES favours conservative
Analysis 2.11. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 11 Number of
participants with detrusor overactivity.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 11 Number of participants with detrusor overactivity
Study or subgroup Electrical stimulation
Conservative
treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus magnetic stimulation
Yamanishi 2000b 17/17 12/15 1.24 [ 0.95, 1.63 ]
0.01 0.1 1 10 100
favours ES favours conservative
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Analysis 2.12. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 12 Detrusor
Activity Index Score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 12 Detrusor Activity Index Score
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT+BT
Berghmans 2002 17 0.57 (0.33) 18 0.62 (0.33) -0.05 [ -0.27, 0.17 ]
-0.5 -0.25 0 0.25 0.5
favours ES favours conservative
Analysis 2.13. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 13 Maximum
cystometric capacity (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 13 Maximum cystometric capacity (mL)
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus magnetic stimulation
Yamanishi 2000b 17 266.9 (151) 15 290.5 (146.3) -23.60 [ -126.72, 79.52 ]
2 ES versus PFMT
Arruda 2008 21 436.7 (178.7) 21 489 (141.3) -52.30 [ -149.74, 45.14 ]
-200 -100 0 100 200
favours conservative favours ES
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Analysis 2.14. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 14 Post
micturition residual volume.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 14 Post micturition residual volume
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 21 1.1 (2.5) 21 2.1 (3.5) -1.00 [ -2.84, 0.84 ]
-2 -1 0 1 2
favours conservative favours ES
Analysis 2.15. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 15 Bladder
capacity at first desire to void.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 15 Bladder capacity at first desire to void
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus magnetic stimulation
Yamanishi 2000b 17 220.4 (110.9) 15 225.1 (123.7) 2.7 % -4.70 [ -86.54, 77.14 ]
Subtotal (95% CI) 17 15 2.7 % -4.70 [ -86.54, 77.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
2 ES versus PFMT
Arruda 2008 21 123.8 (59) 21 137.6 (76.7) 10.7 % -13.80 [ -55.19, 27.59 ]
Subtotal (95% CI) 21 21 10.7 % -13.80 [ -55.19, 27.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
3 ES versus laseropuncture
Kosilov 2013 51 210.9 (28.7) 63 199.3 (49.4) 86.6 % 11.60 [ -2.92, 26.12 ]
-100 -50 0 50 100
favours conservative favours ES
(Continued . . . )
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(. . . Continued)
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 51 63 86.6 % 11.60 [ -2.92, 26.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 89 99 100.0 % 8.45 [ -5.07, 21.96 ]
Heterogeneity: Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 1.39, df = 2 (P = 0.50), I2 =0.0%
-100 -50 0 50 100
favours conservative favours ES
Analysis 2.16. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 16 Volume at
maximum desire to void.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 16 Volume at maximum desire to void
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus laseropuncture: end of treatment
Kosilov 2013 51 297 (45.3) 63 254.5 (49.1) 42.50 [ 25.13, 59.87 ]
2 ES versus laseropuncture: 12 months after baseline
Kosilov 2013 51 251.9 (42.9) 63 178.9 (29) 73.00 [ 59.22, 86.78 ]
-100 -50 0 50 100
favours conservative favours ES
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Analysis 2.17. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 17 Maximum
bladder pressure (cmH20).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 17 Maximum bladder pressure (cmH20)
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus laseropuncture: end of treatment
Kosilov 2013 51 35.4 (9.3) 63 30.9 (4.9) 4.50 [ 1.68, 7.32 ]
2 ES versus laseropuncture: 12 months after baseline
Kosilov 2013 51 30.9 (4.9) 63 29.8 (6.3) 1.10 [ -0.96, 3.16 ]
-20 -10 0 10 20
favours conservative favours ES
Analysis 2.18. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 18 Involuntary
detrusor contraction volume.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 18 Involuntary detrusor contraction volume
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 21 73.3 (112.4) 21 114.3 (154.2) -41.00 [ -122.61, 40.61 ]
-200 -100 0 100 200
favours ES favours conservative
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Analysis 2.19. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 19 Involuntary
detrusor contraction maximal pressure.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 19 Involuntary detrusor contraction maximal pressure
Study or subgroup Electrical stimulation
Conservative
treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus PFMT
Arruda 2008 21 22.4 (6.6) 21 17.2 (25.5) 5.20 [ -6.07, 16.47 ]
-10 -5 0 5 10
favours ES favours conservative
Analysis 2.20. Comparison 2 Electrical stimulation versus conservative treatment, Outcome 20 Number of
participants with adverse effects.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation versus conservative treatment
Outcome: 20 Number of participants with adverse effects
Study or subgroup Electrical stimulation
Conservative
treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus magnetic stimulation
Yamanishi 2000b 0/17 0/15 Not estimable
0.05 0.2 1 5 20
favours ES favours conservative
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Analysis 3.1. Comparison 3 Electrical stimulation versus drugs, Outcome 1 Number of participants with
OAB symptoms.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 1 Number of participants with OAB symptoms
Study or subgroup Electrical stimulation Drugs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus tolterodine
Franz n 2010 10/33 12/31 31.2 % 0.78 [ 0.40, 1.55 ]
Peters 2009 9/44 19/42 49.1 % 0.45 [ 0.23, 0.88 ]
Subtotal (95% CI) 77 73 80.3 % 0.58 [ 0.36, 0.93 ]
Total events: 19 (Electrical stimulation), 31 (Drugs)
Heterogeneity: Chi2 = 1.27, df = 1 (P = 0.26); I2 =21%
Test for overall effect: Z = 2.24 (P = 0.025)
2 ES versus oxybutynin
Arruda 2008 10/21 8/22 19.7 % 1.31 [ 0.64, 2.67 ]
Subtotal (95% CI) 21 22 19.7 % 1.31 [ 0.64, 2.67 ]
Total events: 10 (Electrical stimulation), 8 (Drugs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 98 95 100.0 % 0.72 [ 0.49, 1.07 ]
Total events: 29 (Electrical stimulation), 39 (Drugs)
Heterogeneity: Chi2 = 4.60, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Chi2 = 3.47, df = 1 (P = 0.06), I2 =71%
0.2 0.5 1 2 5
favours ES favours drugs
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Analysis 3.2. Comparison 3 Electrical stimulation versus drugs, Outcome 2 Number of participants with no
improvement in OAB symptoms.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 2 Number of participants with no improvement in OAB symptoms
Study or subgroup Electrical stimulation Drugs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus propantheline bromide
Smith 1996 5/18 10/20 16.4 % 0.56 [ 0.23, 1.32 ]
Subtotal (95% CI) 18 20 16.4 % 0.56 [ 0.23, 1.32 ]
Total events: 5 (Electrical stimulation), 10 (Drugs)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
2 ES versus tolterodine
Franz n 2010 9/33 9/31 16.0 % 0.94 [ 0.43, 2.06 ]
Subtotal (95% CI) 33 31 16.0 % 0.94 [ 0.43, 2.06 ]
Total events: 9 (Electrical stimulation), 9 (Drugs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
3 ES versus oxybutynin
Boaretto 2011 5/16 5/13 9.5 % 0.81 [ 0.30, 2.21 ]
Boaretto 2011 2/22 5/13 10.9 % 0.24 [ 0.05, 1.05 ]
Wang 2006 10/26 14/23 25.7 % 0.63 [ 0.35, 1.14 ]
Wang 2009 9/26 12/24 21.6 % 0.69 [ 0.36, 1.34 ]
Subtotal (95% CI) 90 73 67.6 % 0.61 [ 0.42, 0.90 ]
Total events: 26 (Electrical stimulation), 36 (Drugs)
Heterogeneity: Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 141 124 100.0 % 0.66 [ 0.48, 0.90 ]
Total events: 40 (Electrical stimulation), 55 (Drugs)
Heterogeneity: Chi2 = 2.97, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Chi2 = 1.06, df = 2 (P = 0.59), I2 =0.0%
0.05 0.2 1 5 20
favours ES favours drugs
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Analysis 3.3. Comparison 3 Electrical stimulation versus drugs, Outcome 3 Number of participants with no
improvement in OAB symptoms: routes of ES.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 3 Number of participants with no improvement in OAB symptoms: routes of ES
Study or subgroup Electrical stimulation Drugs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Transcutaneous posterior tibial nerve stimulation
Boaretto 2011 5/16 5/13 9.5 % 0.81 [ 0.30, 2.21 ]
Boaretto 2011 2/22 5/13 10.9 % 0.24 [ 0.05, 1.05 ]
Subtotal (95% CI) 38 26 20.4 % 0.51 [ 0.23, 1.13 ]
Total events: 7 (Electrical stimulation), 10 (Drugs)
Heterogeneity: Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 1.66 (P = 0.096)
2 Intravaginal/transanal
Franz n 2010 9/33 9/31 16.0 % 0.94 [ 0.43, 2.06 ]
Smith 1996 5/18 10/20 16.4 % 0.56 [ 0.23, 1.32 ]
Wang 2006 10/26 14/23 25.7 % 0.63 [ 0.35, 1.14 ]
Wang 2009 9/26 12/24 21.6 % 0.69 [ 0.36, 1.34 ]
Subtotal (95% CI) 103 98 79.6 % 0.69 [ 0.49, 0.99 ]
Total events: 33 (Electrical stimulation), 45 (Drugs)
Heterogeneity: Chi2 = 0.93, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
Total (95% CI) 141 124 100.0 % 0.66 [ 0.48, 0.90 ]
Total events: 40 (Electrical stimulation), 55 (Drugs)
Heterogeneity: Chi2 = 2.97, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Chi2 = 0.50, df = 1 (P = 0.48), I2 =0.0%
0.05 0.2 1 5 20
favours ES favours drugs
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Analysis 3.4. Comparison 3 Electrical stimulation versus drugs, Outcome 4 Number of participants not
satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 4 Number of participants not satisfied
Study or subgroup Electrical stimulation Drugs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus trospium hydrochloride
Ozdedeli 2010 1/15 2/16 10.4 % 0.53 [ 0.05, 5.29 ]
Subtotal (95% CI) 15 16 10.4 % 0.53 [ 0.05, 5.29 ]
Total events: 1 (Electrical stimulation), 2 (Drugs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 ES versus oxybutynin
Arruda 2008 10/21 5/22 26.2 % 2.10 [ 0.86, 5.11 ]
Boaretto 2011 5/16 5/13 29.6 % 0.81 [ 0.30, 2.21 ]
Boaretto 2011 5/22 5/13 33.8 % 0.59 [ 0.21, 1.66 ]
Subtotal (95% CI) 59 48 89.6 % 1.10 [ 0.64, 1.89 ]
Total events: 20 (Electrical stimulation), 15 (Drugs)
Heterogeneity: Chi2 = 3.75, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 74 64 100.0 % 1.05 [ 0.62, 1.77 ]
Total events: 21 (Electrical stimulation), 17 (Drugs)
Heterogeneity: Chi2 = 4.08, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.55), I2 =0.0%
0.01 0.1 1 10 100
favours ES favours drugs
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Analysis 3.5. Comparison 3 Electrical stimulation versus drugs, Outcome 5 Number of participants with
urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 5 Number of participants with urinary incontinence
Study or subgroup Electrical stimulation Drugs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus oxybutynin after 12 weeks
Souto 2014 2/18 6/19 0.35 [ 0.08, 1.52 ]
2 ES versus oxybutynin after 24 weeks
Souto 2014 3/18 6/19 0.53 [ 0.15, 1.80 ]
0.05 0.2 1 5 20
favours ES favours drugs
Analysis 3.6. Comparison 3 Electrical stimulation versus drugs, Outcome 6 Number of participants with no
improvement in urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 6 Number of participants with no improvement in urgency urinary incontinence
Study or subgroup Electrical stimulation Drugs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus tolterodine
Franz n 2010 9/33 9/31 0.94 [ 0.43, 2.06 ]
0.01 0.1 1 10 100
favours ES favours drugs
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Analysis 3.7. Comparison 3 Electrical stimulation versus drugs, Outcome 7 OABq-SF score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 7 OABq-SF score
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 2.9 (1.1) 14 3.1 (1.1) -0.20 [ -0.99, 0.59 ]
-2 -1 0 1 2
favours ES favours drugs
Analysis 3.8. Comparison 3 Electrical stimulation versus drugs, Outcome 8 Patient Global Impression of
Improvement questionnaire (PGI-I) score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 8 Patient Global Impression of Improvement questionnaire (PGI-I) score
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 2.3 (0.7) 14 2.9 (1.1) -0.60 [ -1.27, 0.07 ]
-2 -1 0 1 2
favours ES favours drugs
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Analysis 3.9. Comparison 3 Electrical stimulation versus drugs, Outcome 9 Urgency score (Patient
Perception of Intensity of Urgency (PPIUS)).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 9 Urgency score (Patient Perception of Intensity of Urgency (PPIUS))
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 2.2 (1.1) 14 2.7 (1.2) -0.50 [ -1.33, 0.33 ]
-2 -1 0 1 2
favours ES favours drugs
Analysis 3.10. Comparison 3 Electrical stimulation versus drugs, Outcome 10 Number of incontinence
episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 10 Number of incontinence episodes per 24 hours
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ES versus tolterodine
Peters 2009 41 1.2 (1.6) 43 1.8 (2.5) 44.2 % -0.60 [ -1.49, 0.29 ]
Subtotal (95% CI) 41 43 44.2 % -0.60 [ -1.49, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 ES versus oxybutynin
Arruda 2008 21 7.9 (13.7) 22 7 (10.6) 9.6 % 0.90 [ -6.45, 8.25 ]
Subtotal (95% CI) 21 22 9.6 % 0.90 [ -6.45, 8.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 ES versus trospium + solifenacin
Kosilov 2013 51 3.7 (1.3) 59 1.5 (0.9) 46.2 % 2.20 [ 1.78, 2.62 ]
-10 -5 0 5 10
favours ES favours drugs
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(. . . Continued)
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 51 59 46.2 % 2.20 [ 1.78, 2.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.16 (P < 0.00001)
Total (95% CI) 113 124 100.0 % 0.84 [ -1.71, 3.39 ]
Heterogeneity: Tau2 = 3.62; Chi2 = 30.83, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 30.83, df = 2 (P = 0.00), I2 =94%
-10 -5 0 5 10
favours ES favours drugs
Analysis 3.11. Comparison 3 Electrical stimulation versus drugs, Outcome 11 Change in number of
incontinence episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 11 Change in number of incontinence episodes per 24 hours
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 -1 (2.2) 43 -1.7 (3.8) 82.8 % 0.70 [ -0.62, 2.02 ]
Preyer 2007 16 -1.3 (2.7) 15 -2.6 (5.1) 17.2 % 1.30 [ -1.60, 4.20 ]
Subtotal (95% CI) 57 58 100.0 % 0.80 [ -0.40, 2.00 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
-10 -5 0 5 10
favours ES favours drugs
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Analysis 3.12. Comparison 3 Electrical stimulation versus drugs, Outcome 12 Number of urgency episodes
per 24h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 12 Number of urgency episodes per 24h
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 3.9 (2.8) 43 4.5 (3.6) -0.60 [ -1.98, 0.78 ]
-4 -2 0 2 4
favours ES favours drugs
Analysis 3.13. Comparison 3 Electrical stimulation versus drugs, Outcome 13 Change in number of urgency
episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 13 Change in number of urgency episodes per 24 hours
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 -2.2 (4.3) 43 -2.9 (4.8) 80.5 % 0.70 [ -1.25, 2.65 ]
Preyer 2007 16 -9.3 (4.8) 15 -9.5 (6.3) 19.5 % 0.20 [ -3.76, 4.16 ]
Subtotal (95% CI) 57 58 100.0 % 0.60 [ -1.14, 2.35 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
-4 -2 0 2 4
favours ES favours drugs
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Analysis 3.14. Comparison 3 Electrical stimulation versus drugs, Outcome 14 Number of urgency
incontinence episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 14 Number of urgency incontinence episodes per 24 hours
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 1.7 (1.5) 14 2.6 (1.6) -0.90 [ -2.01, 0.21 ]
-4 -2 0 2 4
favours ES favours drugs
Analysis 3.15. Comparison 3 Electrical stimulation versus drugs, Outcome 15 Number of micturitions per
24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 15 Number of micturitions per 24 hours
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 9.8 (3) 43 9.9 (3.8) 25.2 % -0.10 [ -1.56, 1.36 ]
Subtotal (95% CI) 41 43 25.2 % -0.10 [ -1.56, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
2 ES versus oxybutynin
Arruda 2008 21 7.9 (2.3) 22 6.4 (1.6) 37.9 % 1.50 [ 0.31, 2.69 ]
Souto 2014 18 7.9 (3) 19 9.2 (3.8) 11.1 % -1.30 [ -3.50, 0.90 ]
Subtotal (95% CI) 39 41 49.0 % 0.87 [ -0.18, 1.91 ]
Heterogeneity: Chi2 = 4.81, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.62 (P = 0.10)
3 ES versus solifenacin succinate
-10 -5 0 5 10
favours ES favours drugs
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(. . . Continued)
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vecchioli-Scaldazza 2013 16 9.4 (1.9) 14 10 (2.1) 25.8 % -0.60 [ -2.04, 0.84 ]
Subtotal (95% CI) 16 14 25.8 % -0.60 [ -2.04, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 96 98 100.0 % 0.24 [ -0.49, 0.98 ]
Heterogeneity: Chi2 = 7.71, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Chi2 = 2.89, df = 2 (P = 0.24), I2 =31%
-10 -5 0 5 10
favours ES favours drugs
Analysis 3.16. Comparison 3 Electrical stimulation versus drugs, Outcome 16 Change in number of
micturitions per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 16 Change in number of micturitions per 24 hours
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Franz n 2010 30 -2.8 (1.61) 31 -3.2 (2.18) 73.2 % 0.40 [ -0.56, 1.36 ]
Peters 2009 41 -2.4 (4) 43 -2.5 (3.9) 23.6 % 0.10 [ -1.59, 1.79 ]
Preyer 2007 16 -0.1 (7.04) 15 -0.7 (5.93) 3.2 % 0.60 [ -3.97, 5.17 ]
Total (95% CI) 87 89 100.0 % 0.34 [ -0.49, 1.16 ]
Heterogeneity: Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
favours ES favours drugs
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Analysis 3.17. Comparison 3 Electrical stimulation versus drugs, Outcome 17 Number of nocturia episodes
per night.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 17 Number of nocturia episodes per night
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 1.7 (1.1) 43 1.9 (1.6) 43.9 % -0.20 [ -0.78, 0.38 ]
Subtotal (95% CI) 41 43 43.9 % -0.20 [ -0.78, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 ES versus oxybutynin
Arruda 2008 21 1.2 (1.3) 22 0.9 (0.8) 35.6 % 0.30 [ -0.35, 0.95 ]
Subtotal (95% CI) 21 22 35.6 % 0.30 [ -0.35, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 1.7 (0.9) 14 1.9 (1.4) 20.5 % -0.20 [ -1.06, 0.66 ]
Subtotal (95% CI) 16 14 20.5 % -0.20 [ -1.06, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI) 78 79 100.0 % -0.02 [ -0.41, 0.37 ]
Heterogeneity: Chi2 = 1.47, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 1.47, df = 2 (P = 0.48), I2 =0.0%
-4 -2 0 2 4
favours ES favours drugs
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Analysis 3.18. Comparison 3 Electrical stimulation versus drugs, Outcome 18 Change in number of
nocturia episodes per night.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 18 Change in number of nocturia episodes per night
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 -0.7 (1) 43 -0.6 (1.7) -0.10 [ -0.69, 0.49 ]
-4 -2 0 2 4
favours ES favours drugs
Analysis 3.19. Comparison 3 Electrical stimulation versus drugs, Outcome 19 Number of participants with
nocturia.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 19 Number of participants with nocturia
Study or subgroup Electrical stimulation Drugs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus oxybutynin
Souto 2014 2/18 3/19 0.70 [ 0.13, 3.73 ]
0.02 0.1 1 10 50
favours ES favours drugs
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Analysis 3.20. Comparison 3 Electrical stimulation versus drugs, Outcome 20 Number of pads per day.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 20 Number of pads per day
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 21 0.9 (1.7) 22 0.9 (1.5) 0.0 [ -0.96, 0.96 ]
-0.1 -0.05 0 0.05 0.1
favours ES favours drugs
Analysis 3.21. Comparison 3 Electrical stimulation versus drugs, Outcome 21 Number of participants with
OAB (objective evaluation).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 21 Number of participants with OAB (objective evaluation)
Study or subgroup Electrical stimulation Drugs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 9/21 14/22 0.67 [ 0.37, 1.21 ]
0.2 0.5 1 2 5
favours ES favours drugs
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Analysis 3.22. Comparison 3 Electrical stimulation versus drugs, Outcome 22 Maximum cystometric
capacity (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 22 Maximum cystometric capacity (mL)
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 21 436.7 (178.7) 22 517.3 (191.7) -80.60 [ -191.32, 30.12 ]
-200 -100 0 100 200
favours drugs favours ES
Analysis 3.23. Comparison 3 Electrical stimulation versus drugs, Outcome 23 Volume voided per 24h (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 23 Volume voided per 24h (mL)
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 185.5 (81.1) 43 158.7 (99.8) 16.1 % 26.80 [ -12.01, 65.61 ]
Subtotal (95% CI) 41 43 16.1 % 26.80 [ -12.01, 65.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
2 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 156.1 (18.4) 14 147.4 (27.5) 83.9 % 8.70 [ -8.29, 25.69 ]
Subtotal (95% CI) 16 14 83.9 % 8.70 [ -8.29, 25.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 57 57 100.0 % 11.61 [ -3.95, 27.18 ]
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Chi2 = 0.70, df = 1 (P = 0.40), I2 =0.0%
-100 -50 0 50 100
favours drugs favours ES
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Analysis 3.24. Comparison 3 Electrical stimulation versus drugs, Outcome 24 Change in voided volume per
24h (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 24 Change in voided volume per 24h (mL)
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Franz n 2010 30 -54 (72.66) 31 -55 (53.97) 38.8 % 1.00 [ -31.20, 33.20 ]
Peters 2009 41 -32.8 (61.3) 43 -17.6 (58.4) 61.2 % -15.20 [ -40.83, 10.43 ]
Subtotal (95% CI) 71 74 100.0 % -8.92 [ -28.97, 11.13 ]
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
-50 -25 0 25 50
favours ES favours drugs
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Analysis 3.25. Comparison 3 Electrical stimulation versus drugs, Outcome 25 Volume at first desire to void
(mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 25 Volume at first desire to void (mL)
Study or subgroup Electrical stimulation Drugs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 21 128.8 (59) 22 157.3 (63.8) 12.5 % -28.50 [ -65.21, 8.21 ]
Subtotal (95% CI) 21 22 12.5 % -28.50 [ -65.21, 8.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 ES versus trospium + solifenacin
Kosilov 2013 51 210.9 (42.9) 59 257.5 (28.9) 87.5 % -46.60 [ -60.49, -32.71 ]
Subtotal (95% CI) 51 59 87.5 % -46.60 [ -60.49, -32.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.57 (P < 0.00001)
Total (95% CI) 72 81 100.0 % -44.33 [ -57.33, -31.34 ]
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 6.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.82, df = 1 (P = 0.37), I2 =0.0%
-100 -50 0 50 100
favours drugs favours ES
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Analysis 3.26. Comparison 3 Electrical stimulation versus drugs, Outcome 26 Volume at maximum desire
to void (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 26 Volume at maximum desire to void (mL)
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus trospium + solifenacin: end of treatment
Kosilov 2013 51 334.8 (38.3) 59 313.7 (47.1) 21.10 [ 5.13, 37.07 ]
2 ES versus trospium + solifenacin: 12 months after baseline
Kosilov 2013 51 251.9 (42.9) 59 279.9 (33.8) -28.00 [ -42.59, -13.41 ]
-100 -50 0 50 100
favours drugs favours ES
Analysis 3.27. Comparison 3 Electrical stimulation versus drugs, Outcome 27 Maximum bladder pressure
(cmH2O).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 27 Maximum bladder pressure (cmH2O)
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus trospium + solifenacin: end of treatment
Kosilov 2013 51 35.4 (9.3) 59 32.8 (6) 2.60 [ -0.38, 5.58 ]
2 ES versus trospium + solifenacin: 12 months after baseline
Kosilov 2013 51 30.9 (4.9) 59 28.8 (4.7) 2.10 [ 0.30, 3.90 ]
-4 -2 0 2 4
favours drugs favours ES
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Analysis 3.28. Comparison 3 Electrical stimulation versus drugs, Outcome 28 Post micturition residual
volume (mL).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 28 Post micturition residual volume (mL)
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 21 1.1 (2.5) 22 4.8 (9.4) -3.70 [ -7.77, 0.37 ]
-10 -5 0 5 10
favours ES favours drugs
Analysis 3.29. Comparison 3 Electrical stimulation versus drugs, Outcome 29 Involuntary detrusor
contraction volume.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 29 Involuntary detrusor contraction volume
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 9 73.3 (112.4) 13 188.6 (183.2) -115.30 [ -239.03, 8.43 ]
-200 -100 0 100 200
favours ES favours drugs
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Analysis 3.30. Comparison 3 Electrical stimulation versus drugs, Outcome 30 Involuntary detrusor
contraction maximal pressure.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 30 Involuntary detrusor contraction maximal pressure
Study or subgroup Electrical stimulation Drugs
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 21 22.4 (6.6) 22 19.6 (20.9) 2.80 [ -6.38, 11.98 ]
-10 -5 0 5 10
favours ES favours drugs
Analysis 3.31. Comparison 3 Electrical stimulation versus drugs, Outcome 31 Number of participants with
adverse effects.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation versus drugs
Outcome: 31 Number of participants with adverse effects
Study or subgroup Electrical stimulation Drugs
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus oxybutynin
Svihra 2002 0/9 2/10 25.3 % 1.23 [ 0.87, 1.75 ]
Wise 1993 0/28 7/32 74.7 % 1.27 [ 1.05, 1.54 ]
Subtotal (95% CI) 37 42 100.0 % 1.26 [ 1.07, 1.49 ]
Total events: 0 (Electrical stimulation), 9 (Drugs)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0068)
2 ES versus tolterodine
Franz n 2010 0/33 10/30 69.8 % 1.49 [ 1.15, 1.92 ]
Preyer 2007 1/16 6/15 30.2 % 1.56 [ 1.01, 2.41 ]
Subtotal (95% CI) 49 45 100.0 % 1.51 [ 1.21, 1.89 ]
0.5 0.7 1 1.5 2
favours drugs favours ES
(Continued . . . )
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(. . . Continued)
Study or subgroup Electrical stimulation Drugs
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1 (Electrical stimulation), 16 (Drugs)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.66 (P = 0.00025)
3 ES versus trospium hydrochloride
Ozdedeli 2010 8/17 5/18 100.0 % 0.73 [ 0.43, 1.25 ]
Subtotal (95% CI) 17 18 100.0 % 0.73 [ 0.43, 1.25 ]
Total events: 8 (Electrical stimulation), 5 (Drugs)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Chi2 = 6.37, df = 2 (P = 0.04), I2 =69%
0.5 0.7 1 1.5 2
favours drugs favours ES
Analysis 3.32. Comparison 3 Electrical stimulation versus drugs, Outcome 32 Other data.
Other data
Study Intervention (n) Comparator (n) Outcome Result Data
Aaronson 1995 ES (NR) Probanthine (NR) Cured or improved ES 69% v 50%
Firra 2013 ES + PFMT (7) no active treatment
(7)
% change in pelvic
floor muscle strength
ES + PFMT 8.9% v 1.2%
Firra 2013 ES + PFMT (7) no active treatment
(7)
% change in inconti-
nence episodes
ES + PFMT -78.1% v -4.0%
Firra 2013 ES + PFMT (7) no active treatment
(7)
% change in YIPS
score
ES + PFMT 38.7% v -2.4%
Firra 2013 ES + PFMT (7) no active treatment
(7)
% change in fre-
quency
ES + PFMT -19.2% v 27.4%
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Analysis 4.1. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 1 Number of participants not satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 1 Number of participants not satisfied
Study or subgroup ES + other treatment
Other
treatment
alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES + PFMT versus PFMT
Gaspard 2014 4/15 1/16 5.5 % 4.27 [ 0.54, 33.98 ]
Schreiner 2010 8/25 17/26 94.5 % 0.49 [ 0.26, 0.92 ]
Total (95% CI) 40 42 100.0 % 0.70 [ 0.39, 1.24 ]
Total events: 12 (ES + other treatment), 18 (Other treatment alone)
Heterogeneity: Chi2 = 4.11, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
favours ES + other favours other
Analysis 4.2. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 2 Number of participants with urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 2 Number of participants with urgency urinary incontinence
Study or subgroup ES + other treatment
Other
treatment
alone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES + PFMT versus PFMT alone
Schreiner 2010 11/25 20/26 0.57 [ 0.35, 0.93 ]
0.05 0.2 1 5 20
favours ES + other favours other
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Analysis 4.3. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 3 Number of participants with no improvement in urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 3 Number of participants with no improvement in urgency urinary incontinence
Study or subgroup ES + other treatment
Other
treatment
alone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES + PFMT versus PFMT alone
Schreiner 2010 6/25 19/26 0.33 [ 0.16, 0.69 ]
0.01 0.1 1 10 100
favours ES + other favours other
Analysis 4.4. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 4 Incontinence Impact Questionnaire score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 4 Incontinence Impact Questionnaire score
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + drugs versus drugs alone
Sancaktar 2010 20 9 (0.8) 18 11.2 (2.7) -2.20 [ -3.50, -0.90 ]
-4 -2 0 2 4
favours ES + other favours other
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Analysis 4.5. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 5 International Consultation on Incontinence Questionnaire (short form) score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 5 International Consultation on Incontinence Questionnaire (short form) score
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus PFMT alone
Schreiner 2010 25 7.9 (4.5) 26 10.6 (4.4) -2.70 [ -5.14, -0.26 ]
-4 -2 0 2 4
favours ES + other favours other
Analysis 4.6. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 6 I-QOL score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 6 I-QOL score
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT + drugs versus drugs
Kaya 2011 16 10.1 (12.2) 14 26.3 (19.5) -16.20 [ -28.04, -4.36 ]
-50 -25 0 25 50
favours ES + other favours other
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Analysis 4.7. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 7 SF-Qualiveen score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 7 SF-Qualiveen score
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT + biofeedback versus PFMT + biofeedback
Gaspard 2014 16 1.21 (0.74) 15 1.39 (0.91) -0.18 [ -0.77, 0.41 ]
-4 -2 0 2 4
favours ES + other favours other
Analysis 4.8. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 8 York Incontinence Perception Scale score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 8 York Incontinence Perception Scale score
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus PFMT
Firra 2013 6 -41.2 (10.2) 6 -47 (5.5) 5.80 [ -3.47, 15.07 ]
-20 -10 0 10 20
favours ES + other favours other
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Analysis 4.9. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 9 Number of incontinence episodes per 24h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 9 Number of incontinence episodes per 24h
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + drugs versus drugs
Sancaktar 2010 20 0.9 (0.2) 18 1.8 (0.3) 100.0 % -0.90 [ -1.06, -0.74 ]
Subtotal (95% CI) 20 18 100.0 % -0.90 [ -1.06, -0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.76 (P < 0.00001)
2 ES + PFMT versus PFMT
Firra 2013 6 1 (1.47) 6 0.8 (0.97) 20.8 % 0.20 [ -1.21, 1.61 ]
Gaspard 2014 51 3.7 (1.3) 56 4.8 (2.4) 79.2 % -1.10 [ -1.82, -0.38 ]
Subtotal (95% CI) 57 62 100.0 % -0.83 [ -1.47, -0.19 ]
Heterogeneity: Chi2 = 2.59, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 2.53 (P = 0.011)
3 ES + PFMT + drugs versus drugs
Kaya 2011 16 0.5 (0.8) 14 1.5 (2) 100.0 % -1.00 [ -2.12, 0.12 ]
Subtotal (95% CI) 16 14 100.0 % -1.00 [ -2.12, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
-1 -0.5 0 0.5 1
favours ES + other favours other
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Analysis 4.10. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 10 Number of urgency episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 10 Number of urgency episodes per 24 hours
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + drugs versus drugs alone
Sancaktar 2010 20 5.7 (0.6) 18 7.6 (0.9) 100.0 % -1.90 [ -2.39, -1.41 ]
Subtotal (95% CI) 20 18 100.0 % -1.90 [ -2.39, -1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.57 (P < 0.00001)
2 ES + PFMT versus PFMT alone
Schreiner 2010 25 1.8 (2.7) 26 4.6 (3.7) 100.0 % -2.80 [ -4.57, -1.03 ]
Subtotal (95% CI) 25 26 100.0 % -2.80 [ -4.57, -1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.0020)
3 ES + PFMT + biofeedback versus PFMT + biofeedback
Gaspard 2014 16 2.25 (2.53) 15 1.67 (1.64) 100.0 % 0.58 [ -0.91, 2.07 ]
Subtotal (95% CI) 16 15 100.0 % 0.58 [ -0.91, 2.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 11.07, df = 2 (P = 0.00), I2 =82%
-4 -2 0 2 4
favours ES + other favours other
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Analysis 4.11. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 11 Change in number of nocturia episodes.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 11 Change in number of nocturia episodes
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus PFMT alone
Schreiner 2010 25 -1.6 (1.1) 26 -0.4 (1.1) -1.20 [ -1.80, -0.60 ]
-4 -2 0 2 4
favours ES + other favours other
Analysis 4.12. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 12 Number of micturitions per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 12 Number of micturitions per 24 hours
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus PFMT
Firra 2013 6 8.6 (3.13) 6 7.8 (1.97) 8.7 % 0.80 [ -2.16, 3.76 ]
Schreiner 2010 25 5.9 (1.4) 26 6.8 (1.9) 91.3 % -0.90 [ -1.81, 0.01 ]
Subtotal (95% CI) 31 32 100.0 % -0.75 [ -1.62, 0.12 ]
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 1.69 (P = 0.091)
2 ES + drugs versus drugs
Souto 2014 21 7.8 (5.43) 19 9.2 (3.41) 100.0 % -1.40 [ -4.18, 1.38 ]
Subtotal (95% CI) 21 19 100.0 % -1.40 [ -4.18, 1.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
-4 -2 0 2 4
favours ES + other favours other
(Continued . . . )
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(. . . Continued)
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
3 ES + PFMT + drugs versus drugs
Kaya 2011 16 6.9 (2.4) 15 8.9 (2.8) 100.0 % -2.00 [ -3.84, -0.16 ]
Subtotal (95% CI) 16 15 100.0 % -2.00 [ -3.84, -0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 1.52, df = 2 (P = 0.47), I2 =0.0%
-4 -2 0 2 4
favours ES + other favours other
Analysis 4.13. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 13 Change in number of micturitions per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 13 Change in number of micturitions per 24 hours
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus PFMT alone
Schreiner 2010 25 -1.4 (2) 26 -0.8 (0.9) -0.60 [ -1.46, 0.26 ]
-4 -2 0 2 4
favours ES + other favours other
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Analysis 4.14. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 14 Number of nocturia episodes.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 14 Number of nocturia episodes
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus PFMT alone
Schreiner 2010 25 1.3 (1.5) 26 2.4 (1.3) 100.0 % -1.10 [ -1.87, -0.33 ]
Subtotal (95% CI) 25 26 100.0 % -1.10 [ -1.87, -0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
2 ES + PFMT + drugs versus drugs
Kaya 2011 16 1.1 (0.9) 14 2.1 (1.8) 100.0 % -1.00 [ -2.04, 0.04 ]
Subtotal (95% CI) 16 14 100.0 % -1.00 [ -2.04, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
-4 -2 0 2 4
favours ES + other favours other
Analysis 4.15. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 15 Detrusor Activity Index Score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 15 Detrusor Activity Index Score
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES+PFMT+BT versus PFMT+BT alone
Berghmans 2002 19 0.84 (0.27) 18 0.62 (0.33) 0.22 [ 0.03, 0.41 ]
-0.5 -0.25 0 0.25 0.5
favours ES + other favours other
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Analysis 4.16. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 16 Bladder hyperactivity score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 16 Bladder hyperactivity score
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT + biofeedback versus PFMT + biofeedback
Gaspard 2014 16 6.42 (3.9) 15 6.5 (3.45) -0.08 [ -2.67, 2.51 ]
-4 -2 0 2 4
favours ES + other favours other
Analysis 4.17. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 17 Pelvic floor muscle strength (cmH2O).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 17 Pelvic floor muscle strength (cmH2O)
Study or subgroup ES + other treatment
Other
treatment
alone
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus PFMT
Firra 2013 6 27 (16) 6 47.2 (22.7) -20.20 [ -42.42, 2.02 ]
-50 -25 0 25 50
favours other favours ES + other
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Analysis 4.18. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 18 Number of participants with adverse effects.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation plus another treatment versus other treatment alone
Outcome: 18 Number of participants with adverse effects
Study or subgroup ES + other treatment
Other
treatment
alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES + drugs versus drugs
Sancaktar 2010 1/20 2/18 100.0 % 0.45 [ 0.04, 4.55 ]
Subtotal (95% CI) 20 18 100.0 % 0.45 [ 0.04, 4.55 ]
Total events: 1 (ES + other treatment), 2 (Other treatment alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 ES + PFMT versus PFMT
Schreiner 2010 0/25 0/26 Not estimable
Subtotal (95% CI) 25 26 Not estimable
Total events: 0 (ES + other treatment), 0 (Other treatment alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 ES + PFMT + drugs versus drugs
Kaya 2011 0/16 1/15 100.0 % 0.31 [ 0.01, 7.15 ]
Subtotal (95% CI) 16 15 100.0 % 0.31 [ 0.01, 7.15 ]
Total events: 0 (ES + other treatment), 1 (Other treatment alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.005 0.1 1 10 200
favours ES + other favours other
Analysis 4.19. Comparison 4 Electrical stimulation plus another treatment versus other treatment alone,
Outcome 19 Other data.
Other data
Study Intervention (n) Comparator (n) Outcome Result favours Data
Firra 2013 ES + PFMT (7) PFMT (8) % change in pelvic floor
muscle strength
PFMT 155.1% v 8.9%
Firra 2013 ES + PFMT (7) PFMT (8) % change in frequency ES -19.2% v -16.7%
Firra 2013 ES + PFMT (7) PFMT (8) % change in inconti-
nence episodes
PFMT -70.5% v -78.1%
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Other data (Continued)
Firra 2013 ES + PFMT (7) PFMT (8) % change in YIPS score PFMT 78.7% v 38.7%
Analysis 5.1. Comparison 5 Electrical stimulation plus another treatment versus no active treatment,
placebo or sham treatment, Outcome 1 York Incontinence Perception Scale score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation plus another treatment versus no active treatment, placebo or sham treatment
Outcome: 1 York Incontinence Perception Scale score
Study or subgroup ES + other treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus no active treatment
Firra 2013 6 -41.2 (10.2) 6 -28.8 (2.9) -12.40 [ -20.89, -3.91 ]
-50 -25 0 25 50
favours ES + other favours control
Analysis 5.2. Comparison 5 Electrical stimulation plus another treatment versus no active treatment,
placebo or sham treatment, Outcome 2 Number of incontinence episodes per 24h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation plus another treatment versus no active treatment, placebo or sham treatment
Outcome: 2 Number of incontinence episodes per 24h
Study or subgroup ES + other treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus no active treatment
Firra 2013 6 1 (1.47) 6 2.6 (1.97) -1.60 [ -3.57, 0.37 ]
-4 -2 0 2 4
favours ES + other favours control
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Analysis 5.3. Comparison 5 Electrical stimulation plus another treatment versus no active treatment,
placebo or sham treatment, Outcome 3 Number of micturitions per 24h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation plus another treatment versus no active treatment, placebo or sham treatment
Outcome: 3 Number of micturitions per 24h
Study or subgroup ES + other treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus no active treatment
Firra 2013 6 8.6 (3.13) 6 8.1 (3.47) 0.50 [ -3.24, 4.24 ]
-4 -2 0 2 4
favours ES + other favours control
Analysis 5.4. Comparison 5 Electrical stimulation plus another treatment versus no active treatment,
placebo or sham treatment, Outcome 4 Detrusor Activity Index score.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation plus another treatment versus no active treatment, placebo or sham treatment
Outcome: 4 Detrusor Activity Index score
Study or subgroup ES + other treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus no active treatment
Berghmans 2002 19 0.84 (0.27) 14 0.8 (0.26) 0.04 [ -0.14, 0.22 ]
-0.2 -0.1 0 0.1 0.2
favours ES + other favours control
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Analysis 5.5. Comparison 5 Electrical stimulation plus another treatment versus no active treatment,
placebo or sham treatment, Outcome 5 Pelvic floor muscle strength (cmH2O).
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation plus another treatment versus no active treatment, placebo or sham treatment
Outcome: 5 Pelvic floor muscle strength (cmH2O)
Study or subgroup ES + other treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES + PFMT versus no active treatment
Firra 2013 6 27 (16) 6 34.3 (25.5) -7.30 [ -31.39, 16.79 ]
-100 -50 0 50 100
favours control favours ES + other
Analysis 6.1. Comparison 6 One type of electrical stimulation versus another, Outcome 1 Number of
participants not satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 6 One type of electrical stimulation versus another
Outcome: 1 Number of participants not satisfied
Study or subgroup ES type A ES type B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 200 s pulse width versus 500 s pulse width
Boaretto 2011 5/22 5/16 0.73 [ 0.25, 2.10 ]
0.01 0.1 1 10 100
favours A favours B
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Analysis 6.2. Comparison 6 One type of electrical stimulation versus another, Outcome 2 Maximum
cystometric capacity.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 6 One type of electrical stimulation versus another
Outcome: 2 Maximum cystometric capacity
Study or subgroup ES type A ES type B
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 150Hz versus 10Hz
Bower 1998 16 351 (144) 16 305 (146) 46.00 [ -54.48, 146.48 ]
-200 -100 0 100 200
favours B favours A
Analysis 6.3. Comparison 6 One type of electrical stimulation versus another, Outcome 3 Volume at first
desire to void.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 6 One type of electrical stimulation versus another
Outcome: 3 Volume at first desire to void
Study or subgroup ES type A ES type B
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 150Hz versus 10Hz
Bower 1998 16 208.5 (132) 16 154 (61) 54.50 [ -16.75, 125.75 ]
-200 -100 0 100 200
favours B favours A
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A D D I T I O N A L T A B L E S
Table 1. Description of electrical stimulation interventions
Study Current Current
intensity
Pulse shape&
duration
Frequency
(Hz)
Duty cycle Electrodes Treatment
duration/
supervision
Aaronson
1995
Unclear Unclear Unclear Unclear Unclear Intravaginal Unclear
Amaro 2006 Bipolar 0-100 mA ac-
cording to pa-
tient tolerance
Bipolar square
wave 0.1 µs
4 2 s on - 4 s off Intravaginal Three 20-min
sessions per
week on alter-
nate days for 7
weeks
Arruda 2008 Biphasic 10-100mAac-
cording to pa-
tient tolerance
1 ms intermit-
tent
10 Unclear Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
Barroso 2002 Biphasic 0-100mA Asymmetric, 1
s rise time, sus-
tained for 5 s
and resting for
5 s
20 1 s rise time,
sustained
for 5s and rest-
ing for 5 s
Intravaginal Home
use: two 20-
min sessions
per day for 12
weeks
Bellette 2009 Unclear Unclear Unclear Unclear Unclear Transcuta-
neous
posterior tibial
nerve
Two 30-min
sessions
per week for 4
weeks
Berghmans
2002
Biphasic 0-100 mA Rect-
angular 200 µs
stochastic vari-
ation
4-10 Unclear Intravaginal Unclear
Boaretto 2011 Unclear Unclear 200 µs 10 Unclear Transcuta-
neous
posterior tibial
nerve
Twelve-30
min sessions
Boaretto 2011 Unclear Unclear 500 µs 10 Unclear Intravaginal Twelve-30
min sessions
Booth 2013 Unclear 0-50 mA 200 µs 10 Unclear Per-
cutaneous tib-
ial nerve stim-
ulation
Two 30-min
sessions
per week for 6
weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Bower 1998 Unclear Unclear 200 µs 150 Unclear Transcuta-
neous electri-
cal nerve stim-
ula-
tion - suprapu-
bic placement
Unclear
Bower 1998 Unclear Unclear 200 µs 10 Unclear Transcuta-
neous electri-
cal nerve stim-
ulation - sacral
placement
Unclear
Brubaker
1997
Bipolar 0-100 mA Bipolar square
wave 0.1 µs
20 2 s on - 4 s off Intravaginal 20 min-
utes daily for 8
weeks
Finazzi-Agrò
2010
Unclear 0-10 mA, ac-
cording to pa-
tient tolerance
200 µs 20 Unclear Per-
cutaneous tib-
ial nerve stim-
ulation
Three 30-min
sessions
per week for 4
weeks
Firra 2013 Unclear Unclear
current, inten-
sity according
to patient tol-
erance
Unclear 12.5 5 s on - 10 s off Intravaginal Fourteen 30-
min sessions
Franzén 2010 Unclear According to
patient toler-
ance
Unclear 5-10 Intravaginal/
transanal
Ten sessions: 1
to
2 20-min ses-
sions per week
for 5-7 weeks
Gaspard 2014 Biphasic Unclear Biphasic rect-
angular 220 µs
10 20 s on - 4 s off Transcu-
taneous poste-
rior tib-
ial nerve stim-
ulation: exter-
nal electrode 5
cm above me-
dial malleolus,
1 cm behind
the tibia. The
other electrode
on dorsum of
foot
One 30-min
session
per week for 9
weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Kaya 2011 Unclear Unclear Unclear 0-10, 0-100 0-10
Hz 10 mins;
0-100 Hz 10
mins
Interfer-
ential current
therapy. Two
vacuum elec-
trodes placed
in suprapu-
bic region, two
placed cross-
wise on medial
side of ischial
tuberosity
Five 20-min
sessions
per week for 8
weeks
Kennelly
2011
Unclear Unclear Unclear Unclear Unclear VERV elec-
trode patches,
placed by the
par-
ticipant - exact
placement un-
clear
One patch per
week for 12
weeks
Kosilov 2013 Diadynamic 20-40 mA, 50-
75% intensity
Unclear 20 Unclear Ac-
tive electrode
(50 cm to 70
cm2) above the
pubis,
and a passive
electrode (150
cm2) in lum-
bosacral area
15
procedures ev-
ery other day
Lima 2011 Unclear Unclear Unclear Unclear Unclear Intravaginal Twelve 30-
min sessions
Lima 2011 Unclear Unclear Unclear Unclear Unclear Transcu-
taneous poste-
rior tib-
ial nerve stim-
ulation.
Twelve 30-
min sessions
Lo 2003 Unclear According to
patient toler-
ance
Unclear 0-100 Unclear Inter-
ferential ther-
apy. Two an-
terior flat elec-
trodes placed
over obturator
foramen
1.5 cm to 2 cm
lateral to sym-
12 sessions:
first session 15
min, all others
30 min
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Table 1. Description of electrical stimulation interventions (Continued)
physis, two
posterior elec-
trodes placed
medial to is-
chial tuberosi-
ties either side
of anus
Lobel 1998 Unclear Unclear Unclear Unclear Unclear Intravaginal/
transanal
Once per week
Lobel 1998 Unclear Unclear Unclear Unclear Unclear Intravaginal/
transanal
Twice per
week
Marques 2008 Biphasic Imme-
diately below
motor thresh-
old
200 µs 10 Unclear Transcuta-
neous electri-
cal nerve stim-
u-
lation through
one channel
and two elec-
trodes
Two 30-min
sessions
per week for 4
weeks
Monga 2011 Unclear Unclear Unclear Unclear Unclear Transdermal
amplitude-
modulated sig-
nal through a
patch applied
to the skin,
controlled by
wireless hand-
held remote
control
Patch worn for
4 weeks
Monteiro
2014
Unclear Below the
threshold that
causes motor
contraction
200 µs 10 Unclear Posterior tibial
nerve stimula-
tion with sur-
face
electrodes.
Negative elec-
trode on me-
dial malleolus,
and the pos-
itive electrode
10 cm
above negative
electrode, also
on the medial
side. Rrhyth-
30-min twice
weekly over 12
sessions (45
days)
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Table 1. Description of electrical stimulation interventions (Continued)
mic flexion of
the second toe
dur-
ing the stim-
ulation deter-
mined the cor-
rect position
of the negative
electrode
Oldham 2013 Unclear Pre-
programmed
to increase in-
tensity over 24
s to reach ther-
apeutic level
and switch off
automat-
ically after 30
mins. All de-
vices same
level of stimu-
lation (average
in-
tensity consid-
ered comfort-
able and capa-
ble of produc-
ing contrac-
tions of pelvic
floor muscles)
Unclear During the 10
s “on time” the
device delivers
10 repeats of a
short high in-
tensity burst of
50Hz stimula-
tion immedi-
ately preceded
by a doublet
(125 Hz), su-
perimposed
on continuous
low frequency
2 Hz stimula-
tion
10 s on - 10 s
off
Intravaginal -
single use tam-
pon-like
Pelviva device
One
disposable de-
vice per day
for 12 weeks
except during
menstruation
Ozdedeli
2010
Biphasic 0-80 mA, ac-
cording to pa-
tient tolerance
100 µs Symmetri-
cal rectangular
5 Hz
Unclear Intravaginal:
two-ring vagi-
nal probe
Three 20-min
ses-
sions per week
for 6 weeks,
except during
menstruation
Peters 2009 Unclear Unclear Unclear Unclear Unclear Percu-
taneous tibial
nerve stimula-
tion: 34-gauge
needle slightly
cephalad to
medial malleo-
lus
One 30-min
ses-
sion per week
for 12 weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Peters 2010 Unclear 0.5-9 mA Unclear 20 Unclear Percu-
taneous tibial
nerve stimula-
tion: 34-gauge
needle
inserted at 60
degree angle 5
cmcephalad to
medial malleo-
lus, slightly
posterior
to tibia. Sur-
face electrode
placed on ip-
silateral calca-
neous
One 30-min
ses-
sion per week
for 12 weeks
Preyer 2007 Unclear Unclear Unclear Unclear Unclear Peripheral tib-
ial neurostim-
ulation
One 30-min
ses-
sion per week
for 12 weeks
Sancaktar
2010
Unclear 0.5-10mA, ac-
cording to pa-
tient tolerance
200 µs 20 Unclear Stoller afferent
neurostimula-
tion: 34-gauge
needle in-
serted at 30de-
gree angle 2cm
to 3 cm supe-
rior-medial as-
pect of tibial
medial malleo-
lus along
posterior tibial
nerve trace
One 30-min
ses-
sion per week
for 12 weeks
Schmidt 2009 Biphasic Controlled
by patient ac-
cording to tol-
erance
300 µs Asymmetrical,
50
Unclear Intrav-
aginal: probe
with two 26
mm rings 40
mm apart
Unclear
Schreiner
2010
Unclear Unclear 200 µs 10 Unclear Transcu-
taneous tibial
nerve stimula-
tion
One 30 min
ses-
sion per week
for 12 weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Seth 2014 Unclear Unclear Unclear Unclear Unclear Transcuta-
neous: discrete
[sic], self-con-
tained,
portable de-
vice adhesive
to the skin
One 30 min
session per day
for 12 weeks
Seth 2014 Unclear Unclear Unclear Unclear Unclear Transcuta-
neous: discrete
[sic], self-con-
tained,
portable de-
vice adhesive
to the skin
One 30-min
ses-
sion per week
for 12 weeks
Shepherd
1984
Unclear Up to 40 v Unclear 10-50 Unclear Max-
imum perineal
stimulation:
Scott electrode
in vagina, large
indifferent
electrode un-
der buttocks
Single 20-min
session
Shepherd
1985
Unclear Unclear Unclear 10 Unclear Intravagi-
nal cushion at-
tached to stim-
ulator worn
around waist
Cushion worn
for 8 out of 24
hours, day or
night accord-
ing to patient
preference
Smith 1996 Unclear 5-25 mA Unclear Device
uses two pro-
grammes
simultane-
ously: 12.5 Hz
and 50 Hz
5 s impulse Intravaginal Twice daily for
4 months.
Length of ses-
sion increased
monthly:
15, 30, 45, 60
minutes
Soomro 2001 Unclear Pa-
tients asked to
control stimu-
lation
to achieve tick-
ling sensation
200 µs 20 Continuous Transcu-
taneous. Two
self-
adhesive pads
applied bilat-
erally over the
perianal region
(S2-S3
dermatome)
Up to 6
hours daily for
6 weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Sotelo 2011 Unclear Unclear Unclear Unclear Unclear Transdermal.
Carrier signal
and pulse en-
ve-
lope through
patch applied
on skin over
spinal nerves
in lower back
Horizon-
tal placement
of electrode
patch near
sacral nerve
Patch
worn contin-
uously for 7
days
Sotelo 2011 Unclear Unclear Unclear Unclear Unclear Transdermal.
Carrier signal
and pulse en-
ve-
lope through
patch applied
on skin over
spinal nerves
in lower back
30 degree an-
gle placement
of electrode
patch near
sacral nerve
Patch
worn contin-
uously for 7
days
Souto 2014 Unclear According to
patient toler-
ance
250 µs 10 Unclear Posterior tibial
nerve stimula-
tion. Sur-
face electrode
placed behind
media malleo-
lus and
another placed
10 cm above
first electrode
Two 30 min
ses-
sions per week
for 12 weeks
Spruijt 2003 Biphasic 0-100 mA, ac-
cording to pa-
tient tolerance
100 µs 20 2 s contraction
time, duty cy-
cle 1-2 s
Intravaginal Three 30-min
ses-
sions per week
for 8 weeks. 5
min rest be-
tween each 15
min
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Table 1. Description of electrical stimulation interventions (Continued)
Svihra 2002 Square 25 mA. 70%
of intensity of
maximal am-
plitude of reg-
istered
response from
abductor hal-
lucis muscle
Square im-
pulse 100 µs
1 Unclear Stoller afferent
neurostim-
ulation. Elec-
trodes placed
behind medial
ankle of left
lower extrem-
ity, cathode
placed proxi-
mally and an-
ode distally
One
30 min session
per week for 5
weeks
Vahtera 1997 Unclear According to
patient toler-
ance
Unclear 10 min of each
frequency, 3
min: 5-10 Hz,
10-50 Hz, 50
Hz
7 s on, 25 s off Intravaginal/
transanal
Six ses-
sions over two
weeks
Vecchioli-
Scaldazza
2013
Unclear Unclear Unclear Unclear Unclear Per-
cutaneous tib-
ial nerve stim-
ulation
Two 30-min
sessions
per week for 6
weeks
Vohra 2002 Unclear 0-10 mA Unclear Unclear Unclear Percutaneous
posterior tibial
nerve stimula-
tion
One 30-min
ses-
sion per week
for 12 weeks
Walsh 2001 Unclear Unclear 200 ms 10 Unclear Transcuta-
neous neu-
rostimulation.
Electrode pads
affixed bilater-
ally to the skin
overlying S3
dermatomes
(junction
of buttock and
upper thigh)
Single session
Wang 2004 Biphasic Minimum 20-
63 mA, maxi-
mum
40-72 mA, ac-
cording to pa-
tient tolerance
Biphasic sym-
metrical 400
µs
10 10 s on, 5 s off Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Wang 2006 Biphasic Minimum 20-
63 mA, maxi-
mum
40-72 mA, ac-
cording to pa-
tient tolerance
Biphasic sym-
metrical 400
µs
10 10 s on, 5 s off Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
Wang 2009 Biphasic Minimum 20-
63 mA, maxi-
mum
40-72 mA, ac-
cording to pa-
tient tolerance
Biphasic sym-
metrical 400
µs
10 10 s on, 5 s off Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
Wise 1992 Unclear Unclear Unclear Unclear Unclear Intravaginal One
session per day
(at home) for 6
weeks
Wise 1993 Unclear 0-90 mA, ac-
cording to pa-
tient tolerance
Unclear 20 Unclear Intravaginal One
session per day
(at home) for 6
weeks
Yamanishi
2000
Square 0-60 mA, ac-
cording to pa-
tient tolerance
Square, 1 ms 10 Unclear Intravaginal
(women), sur-
face electrode
or anal plug
(men)
Sur-
face electrode
placed on dor-
sal part of pe-
nis. Anal elec-
trode bullet-
shaped, vagi-
nal plug cylin-
der-formed
with ring-
formed
electrodes
Two 15-min
sessions per
day for 4weeks
Yamanishi
2000
Square 0-60 mA, ac-
cording to pa-
tient tolerance
Square, 1 ms 10 Unclear Intravaginal
(women), sur-
face electrode
or anal plug
(men)
Sur-
face electrode
Single session
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Table 1. Description of electrical stimulation interventions (Continued)
placed on dor-
sal part of pe-
nis. Anal elec-
trode bullet-
shaped, vagi-
nal plug cylin-
der-formed
with ring-
formed
electrodes
A P P E N D I C E S
Appendix 1. Search strategies
Incontinence Group Specialised Register
The terms that were used to search the Incontinence Group Specialised Register are given below:
(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND ({INTVENT.PHYS.ELECTSTIM*}) AND ({TOPIC.URINE.INCON*} OR
{TOPIC.URINE.OVERACTIVE*})
All searches were of the keyword field of Reference Manager 2012. Date of last search 10 December 2014.
A further updated search of the Cochrane Incontinence Group Specialised Trials Register was performed on 10 December 2015, the
results of which were screened and the potentially eligible studies were added to Studies Awaiting Classification. These studies will be
fully incorporated at the first update of this review.
Other searches
Some of the review authors (OLFG, RE, MOG, AK, JLA) also searched the following databases, details of the searches are below:
PubMed (inception to December 2013) andCENTRAL (2013, Issue 12 ) were searched on 12 December 2013 using the following
search terms:
((Overactive Bladder)OR (OveractiveUrinary Bladder)OR (OveractiveDetrusor)OR (OveractiveDetrusor Function)ORbladderOR
(urinary bladder) OR (unstable bladder) OR (urge incontinence) OR (inhibits bladder) OR (Urinary Reflex Incontinence) OR (Urinary
Urge Incontinence) OR (Urge Incontinence) OR (Urinary Bladder Disease) OR (Urinary Bladder Diseases) OR (Bladder Diseases) OR
(Bladder Disease)) AND ((Electrical Stimulation) OR (Electrical Stimulations) OR (Electric Stimulations) OR (Electric Stimulation)
OR (Electric Stimulation Therapy)OR (Therapeutic Electrical Stimulation) OR ElectrotherapyOR (Therapeutic Electric Stimulation)
OR (Electrical Stimulation Therapy) OR (Transcutaneous Electrical Stimulation) OR (Percutaneous Electric Nerve Stimulation) OR
(Percutaneous Electrical Nerve Stimulation) OR (Transdermal Electrostimulation) OR (Transcutaneous Electrical Nerve Stimulation)
OR (Transcutaneous Nerve Stimulation) OR (Transcutaneous Electric Stimulation) OR TENS OR Electroanalgesia OR (Analgesic
Cutaneous Electrostimulation))
Embase on OVID SP (from 1980 onwards) (searched on 12 December 2013)
The search strategy that was be used in Embase is given below. The RCT terms (lines 1 and 2) are those recommended by Lefebvre 2011.
The search was limited to those records added to Embase from January 2010 onwards as earlier trials are included in the Specialised
Register search of CENTRAL.
1. (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$
or allocat$ or volunteer$).tw.
2. (crossover-procedure or double-blind procedure or randomised controlled trial or single-blind procedure).sh.
3. 1 or 2
4. urine incontinence/ or mixed incontinence/ or stress incontinence/ or urge incontinence/
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5. overactive bladder/
6. (Detrusor$ or bladder$ or incontinen$ or continen$).tw.
7. 4 or 5 or 6
8. (Electric$ Stimulation$ or Electric Stimulation or Electrotherap$ or TENS or Electroanalgesia or electrostimulation$ or nerve
stimulation$).tw.
9. electrostimulation/
10. electrostimulation therapy/
11. transcutaneous nerve stimulation/
12. 8 or 9 or 10 or 11
13. 3 and 7 and 12
14. 2010$.em.
15. 2011$.em.
16. 2012$.em.
17. 2013$.em.
18. 14 or 15 or 16 or 17
19. 13 and 18
LILACS (on the Virtual Health Library/Bireme) (from 1982 to December 2013) (searched on 12 December 2013).
The terms that were used to search LILACS are given below. The RCT terms are those developed by Castro and colleagues (Castro
1997; Castro 1999).
(Detrusor$ OR bladder$ OR incontinen$ OR continen$) [Words]
AND
((Electric$ Stimulation$) OR (Electric Stimulation) OR Electrotherap$ OR TENS OR Electroanalgesia OR electrostimulation$ OR
(nerve stimulation$)) [Words]
(nb for some reason if remove (electric stimulation) it retrieves less articles!!!)
((Pt randomised controlled trial OR Pt controlled clinical trial OR Mh randomised controlled trials OR Mh random allocation OR
Mh
double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical
trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$))
OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR
Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) ORMh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR
Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) ORMh research design) ANDNOT (Ct animal ANDNOT (Ct human and
Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR
Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal))) [Words]
Field = words
Ongoing clinical trials were sought by searching the clinical trials registration sites ClinicalTrials.gov and WHO ICTRP using the
search term: overactive bladder. The date of the most recent search was 12 December 2013.
H I S T O R Y
Protocol first published: Issue 9, 2012
Review first published: Issue 4, 2016
Date Event Description
9 September 2015 Amended The protocol has been amended.
9 September 2015 New citation required and minor changes The protocol has been amended.
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